EP3349837B1 - Wedge dissectors for a medical ballon - Google Patents
Wedge dissectors for a medical ballon Download PDFInfo
- Publication number
- EP3349837B1 EP3349837B1 EP16847495.5A EP16847495A EP3349837B1 EP 3349837 B1 EP3349837 B1 EP 3349837B1 EP 16847495 A EP16847495 A EP 16847495A EP 3349837 B1 EP3349837 B1 EP 3349837B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- balloon
- strips
- strip
- cage
- rings
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000463 material Substances 0.000 claims description 103
- 239000000853 adhesive Substances 0.000 claims description 26
- 230000001070 adhesive effect Effects 0.000 claims description 26
- 230000014759 maintenance of location Effects 0.000 claims description 26
- 229920000642 polymer Polymers 0.000 claims description 19
- 239000010410 layer Substances 0.000 description 107
- 238000000034 method Methods 0.000 description 69
- 238000002399 angioplasty Methods 0.000 description 59
- 239000003814 drug Substances 0.000 description 46
- 229940079593 drug Drugs 0.000 description 41
- 238000004519 manufacturing process Methods 0.000 description 31
- 238000005520 cutting process Methods 0.000 description 23
- 238000000576 coating method Methods 0.000 description 20
- 229910052751 metal Inorganic materials 0.000 description 18
- 239000002184 metal Substances 0.000 description 18
- 239000011248 coating agent Substances 0.000 description 17
- 230000008569 process Effects 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- 210000004204 blood vessel Anatomy 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 11
- 210000001367 artery Anatomy 0.000 description 10
- -1 polytetrafluoroethylene Polymers 0.000 description 10
- 230000008901 benefit Effects 0.000 description 9
- 238000013461 design Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000007373 indentation Methods 0.000 description 9
- 230000007423 decrease Effects 0.000 description 8
- 229920001971 elastomer Polymers 0.000 description 8
- 230000033001 locomotion Effects 0.000 description 8
- 238000012377 drug delivery Methods 0.000 description 7
- 239000000806 elastomer Substances 0.000 description 7
- 229960002930 sirolimus Drugs 0.000 description 7
- 238000003698 laser cutting Methods 0.000 description 6
- 229920002635 polyurethane Polymers 0.000 description 6
- 239000004814 polyurethane Substances 0.000 description 6
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 6
- 238000007514 turning Methods 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 5
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 5
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 239000012790 adhesive layer Substances 0.000 description 5
- 229920002313 fluoropolymer Polymers 0.000 description 5
- 239000004811 fluoropolymer Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 230000007704 transition Effects 0.000 description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 4
- 239000004812 Fluorinated ethylene propylene Substances 0.000 description 4
- 239000002033 PVDF binder Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 239000013013 elastic material Substances 0.000 description 4
- 239000000017 hydrogel Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 229920009441 perflouroethylene propylene Polymers 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 4
- 239000004810 polytetrafluoroethylene Substances 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
- 229920002449 FKM Polymers 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 240000007643 Phytolacca americana Species 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000003484 anatomy Anatomy 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000009760 electrical discharge machining Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 229920000098 polyolefin Polymers 0.000 description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000009420 retrofitting Methods 0.000 description 3
- 238000007790 scraping Methods 0.000 description 3
- 238000001338 self-assembly Methods 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 229920003051 synthetic elastomer Polymers 0.000 description 3
- 239000005061 synthetic rubber Substances 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- BQCIDUSAKPWEOX-UHFFFAOYSA-N 1,1-Difluoroethene Chemical compound FC(F)=C BQCIDUSAKPWEOX-UHFFFAOYSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- XUXUHDYTLNCYQQ-UHFFFAOYSA-N 4-amino-TEMPO Chemical group CC1(C)CC(N)CC(C)(C)N1[O] XUXUHDYTLNCYQQ-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 229920001651 Cyanoacrylate Polymers 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 229920006370 Kynar Polymers 0.000 description 2
- 108010007859 Lisinopril Proteins 0.000 description 2
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- 229910045601 alloy Inorganic materials 0.000 description 2
- 239000000956 alloy Substances 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000002927 anti-mitotic effect Effects 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000004019 antithrombin Substances 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 108010055460 bivalirudin Proteins 0.000 description 2
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 229960000830 captopril Drugs 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000002788 crimping Methods 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 229960001123 epoprostenol Drugs 0.000 description 2
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229960002394 lisinopril Drugs 0.000 description 2
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 229910001105 martensitic stainless steel Inorganic materials 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- YDKNBNOOCSNPNS-UHFFFAOYSA-N methyl 1,3-benzoxazole-2-carboxylate Chemical group C1=CC=C2OC(C(=O)OC)=NC2=C1 YDKNBNOOCSNPNS-UHFFFAOYSA-N 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- 229960002460 nitroprusside Drugs 0.000 description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 2
- 229960005330 pimecrolimus Drugs 0.000 description 2
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 description 2
- 229960003073 pirfenidone Drugs 0.000 description 2
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 229920001084 poly(chloroprene) Polymers 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000002089 prostaglandin antagonist Substances 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- OLTAWOVKGWWERU-UHFFFAOYSA-N proxazole Chemical compound C=1C=CC=CC=1C(CC)C1=NOC(CCN(CC)CC)=N1 OLTAWOVKGWWERU-UHFFFAOYSA-N 0.000 description 2
- 229960001801 proxazole Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960005314 suramin Drugs 0.000 description 2
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 2
- 230000003746 surface roughness Effects 0.000 description 2
- 229960001967 tacrolimus Drugs 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- 229960003676 tenidap Drugs 0.000 description 2
- LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- YWBFPKPWMSWWEA-UHFFFAOYSA-O triazolopyrimidine Chemical compound BrC1=CC=CC(C=2N=C3N=CN[N+]3=C(NCC=3C=CN=CC=3)C=2)=C1 YWBFPKPWMSWWEA-UHFFFAOYSA-O 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- RJNRORZRFGUAKL-ADMBVFOFSA-N (1r)-1-[(3ar,5r,6s,6ar)-6-[3-(dimethylamino)propoxy]-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-5-yl]ethane-1,2-diol;hydrochloride Chemical compound Cl.O1C(C)(C)O[C@@H]2[C@@H](OCCCN(C)C)[C@@H]([C@H](O)CO)O[C@@H]21 RJNRORZRFGUAKL-ADMBVFOFSA-N 0.000 description 1
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 1
- VYPKEODFNOEZGS-VIFPVBQESA-N (2r)-2-acetamido-3-(2-hydroxybenzoyl)sulfanylpropanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CSC(=O)C1=CC=CC=C1O VYPKEODFNOEZGS-VIFPVBQESA-N 0.000 description 1
- KWPACVJPAFGBEQ-IKGGRYGDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(3s)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]pyrrolidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)CCl)C1=CC=CC=C1 KWPACVJPAFGBEQ-IKGGRYGDSA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- AUDFHJLSHQWFQQ-SFHVURJKSA-N (2s)-2-[[2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetyl]amino]-3-hydroxypropanoic acid Chemical compound CC1=C(CC(=O)N[C@@H](CO)C(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 AUDFHJLSHQWFQQ-SFHVURJKSA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- XYRIRLDHOQSNLW-UHFFFAOYSA-N (3-oxo-1h-2-benzofuran-1-yl) 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetate Chemical compound CC1=C(CC(=O)OC2C3=CC=CC=C3C(=O)O2)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 XYRIRLDHOQSNLW-UHFFFAOYSA-N 0.000 description 1
- SHCYQUDTKWHARF-UHFFFAOYSA-N (3-oxo-1h-2-benzofuran-1-yl) 2-acetyloxybenzoate Chemical compound CC(=O)OC1=CC=CC=C1C(=O)OC1C2=CC=CC=C2C(=O)O1 SHCYQUDTKWHARF-UHFFFAOYSA-N 0.000 description 1
- BVNJBATUHVXZKP-QXMHVHEDSA-N (3z)-6-chloro-5-fluoro-3-[hydroxy(thiophen-2-yl)methylidene]-2-oxoindole-1-carboxamide Chemical compound C12=CC(F)=C(Cl)C=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 BVNJBATUHVXZKP-QXMHVHEDSA-N 0.000 description 1
- ZDHHGGFQZRPUSN-UHFFFAOYSA-N (4-chlorophenyl)-[3-(2h-tetrazol-5-ylmethyl)indol-1-yl]methanone Chemical compound C1=CC(Cl)=CC=C1C(=O)N1C2=CC=CC=C2C(CC2=NNN=N2)=C1 ZDHHGGFQZRPUSN-UHFFFAOYSA-N 0.000 description 1
- PPQZABOURJVKNI-UHFFFAOYSA-N (4-fluorophenyl)-[4-(4-fluorophenyl)-4-hydroxy-1-methylpiperidin-3-yl]methanone Chemical compound C1N(C)CCC(O)(C=2C=CC(F)=CC=2)C1C(=O)C1=CC=C(F)C=C1 PPQZABOURJVKNI-UHFFFAOYSA-N 0.000 description 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- JFTOCKFCHJCDDX-UVTDQMKNSA-N (4z)-4-benzylidene-5,6,7,8-tetrahydroisoquinoline-1,3-dione Chemical compound C1CCCC2=C1C(=O)NC(=O)\C2=C/C1=CC=CC=C1 JFTOCKFCHJCDDX-UVTDQMKNSA-N 0.000 description 1
- VDNZZIYSCXESNI-ILSZZQPISA-N (6s,8s,9s,10r,11s,13s,14s,17s)-17-acetyl-11-hydroxy-6,10,13-trimethyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@H](C(C)=O)CC[C@H]21 VDNZZIYSCXESNI-ILSZZQPISA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- GQGRDYWMOPRROR-ZIFKCHSBSA-N (e)-7-[(1r,2r,3s,5s)-3-hydroxy-5-[(4-phenylphenyl)methoxy]-2-piperidin-1-ylcyclopentyl]hept-4-enoic acid Chemical compound O([C@H]1C[C@@H]([C@@H]([C@H]1CC\C=C\CCC(O)=O)N1CCCCC1)O)CC(C=C1)=CC=C1C1=CC=CC=C1 GQGRDYWMOPRROR-ZIFKCHSBSA-N 0.000 description 1
- ZHXUEUKVDMWSKV-UHFFFAOYSA-N 1-(3,5-ditert-butyl-4-hydroxyphenyl)hex-5-yn-1-one Chemical compound CC(C)(C)C1=CC(C(=O)CCCC#C)=CC(C(C)(C)C)=C1O ZHXUEUKVDMWSKV-UHFFFAOYSA-N 0.000 description 1
- YETULFFXNIHQLK-UHFFFAOYSA-N 1-ethynyl-4-(2-fluorophenyl)benzene Chemical compound FC1=CC=CC=C1C1=CC=C(C#C)C=C1 YETULFFXNIHQLK-UHFFFAOYSA-N 0.000 description 1
- ULIDRMKBVYYVIQ-UHFFFAOYSA-N 1-phenyltetrazol-5-amine Chemical compound NC1=NN=NN1C1=CC=CC=C1 ULIDRMKBVYYVIQ-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- SRETXDDCKMOQNE-UHFFFAOYSA-N 2,3-bis(4-methoxyphenyl)-1h-indole Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC(OC)=CC=2)C2=CC=CC=C2N1 SRETXDDCKMOQNE-UHFFFAOYSA-N 0.000 description 1
- IZGMROSLQHXRDZ-UHFFFAOYSA-N 2-(1-propyl-4,9-dihydro-3h-pyrano[3,4-b]indol-1-yl)acetic acid Chemical compound N1C2=CC=CC=C2C2=C1C(CCC)(CC(O)=O)OCC2 IZGMROSLQHXRDZ-UHFFFAOYSA-N 0.000 description 1
- KLIVRBFRQSOGQI-UHFFFAOYSA-N 2-(11-oxo-6h-benzo[c][1]benzothiepin-3-yl)acetic acid Chemical compound S1CC2=CC=CC=C2C(=O)C2=CC=C(CC(=O)O)C=C12 KLIVRBFRQSOGQI-UHFFFAOYSA-N 0.000 description 1
- ODZUWQAFWMLWCF-UHFFFAOYSA-N 2-(3-phenyl-1-benzofuran-7-yl)propanoic acid Chemical compound C=1OC=2C(C(C(O)=O)C)=CC=CC=2C=1C1=CC=CC=C1 ODZUWQAFWMLWCF-UHFFFAOYSA-N 0.000 description 1
- LRXFKKPEBXIPMW-UHFFFAOYSA-N 2-(9h-fluoren-2-yl)propanoic acid Chemical compound C1=CC=C2C3=CC=C(C(C(O)=O)C)C=C3CC2=C1 LRXFKKPEBXIPMW-UHFFFAOYSA-N 0.000 description 1
- DCXHLPGLBYHNMU-UHFFFAOYSA-N 2-[1-(4-azidobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(N=[N+]=[N-])C=C1 DCXHLPGLBYHNMU-UHFFFAOYSA-N 0.000 description 1
- IDCAZKFFVIMCCS-UHFFFAOYSA-N 2-[3-(4-chlorophenyl)-4-imino-2-oxoimidazolidin-1-yl]acetonitrile Chemical compound C1=CC(Cl)=CC=C1N1C(=O)N(CC#N)CC1=N IDCAZKFFVIMCCS-UHFFFAOYSA-N 0.000 description 1
- ANMLJLFWUCQGKZ-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]-3-pyridinecarboxylic acid (3-oxo-1H-isobenzofuran-1-yl) ester Chemical compound FC(F)(F)C1=CC=CC(NC=2C(=CC=CN=2)C(=O)OC2C3=CC=CC=C3C(=O)O2)=C1 ANMLJLFWUCQGKZ-UHFFFAOYSA-N 0.000 description 1
- XILVEPYQJIOVNB-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]benzoic acid 2-(2-hydroxyethoxy)ethyl ester Chemical compound OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 XILVEPYQJIOVNB-UHFFFAOYSA-N 0.000 description 1
- NLGUJWNOGYWZBI-UHFFFAOYSA-N 2-[3-chloro-4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 NLGUJWNOGYWZBI-UHFFFAOYSA-N 0.000 description 1
- JIEKMACRVQTPRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenyl-5-thiazolyl]acetic acid Chemical compound OC(=O)CC=1SC(C=2C=CC=CC=2)=NC=1C1=CC=C(Cl)C=C1 JIEKMACRVQTPRC-UHFFFAOYSA-N 0.000 description 1
- QKKLKGVIECOSRM-CODXZCKSSA-N 2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol;4-[2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]-4-oxobutanoic acid Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21.O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC(O)=O)[C@@H]4[C@@H]3CCC2=C1 QKKLKGVIECOSRM-CODXZCKSSA-N 0.000 description 1
- LNXXSBRGLBOASF-UHFFFAOYSA-N 2-[[2-(4-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methoxy]-2-methylpropanoic acid Chemical compound O1C(COC(C)(C)C(O)=O)=C(C)N=C1C1=CC=C(Cl)C=C1 LNXXSBRGLBOASF-UHFFFAOYSA-N 0.000 description 1
- GXEUNRBWEAIPCN-UHFFFAOYSA-N 2-chloro-2-(3-chloro-4-cyclohexylphenyl)acetic acid Chemical compound ClC1=CC(C(Cl)C(=O)O)=CC=C1C1CCCCC1 GXEUNRBWEAIPCN-UHFFFAOYSA-N 0.000 description 1
- PYSICVOJSJMFKP-UHFFFAOYSA-N 3,5-dibromo-2-chloropyridine Chemical compound ClC1=NC=C(Br)C=C1Br PYSICVOJSJMFKP-UHFFFAOYSA-N 0.000 description 1
- PLZMRGRLCWCLFW-UHFFFAOYSA-N 3-[5-(3-bromophenyl)tetrazol-2-yl]-1-piperidin-1-ylpropan-1-one Chemical compound BrC1=CC=CC(C2=NN(CCC(=O)N3CCCCC3)N=N2)=C1 PLZMRGRLCWCLFW-UHFFFAOYSA-N 0.000 description 1
- YLJRTDTWWRXOFG-UHFFFAOYSA-N 3-[5-(4-chlorophenyl)furan-2-yl]-3-hydroxypropanoic acid Chemical compound O1C(C(CC(O)=O)O)=CC=C1C1=CC=C(Cl)C=C1 YLJRTDTWWRXOFG-UHFFFAOYSA-N 0.000 description 1
- YUORBURTMIUPMW-UHFFFAOYSA-N 3-methyl-5-[2-(4-phenyl-3,6-dihydro-2h-pyridin-1-yl)ethyl]-1,3-oxazolidin-2-one Chemical compound O1C(=O)N(C)CC1CCN1CC=C(C=2C=CC=CC=2)CC1 YUORBURTMIUPMW-UHFFFAOYSA-N 0.000 description 1
- 238000010146 3D printing Methods 0.000 description 1
- PIAMNHTVFPWVHG-UHFFFAOYSA-N 4-(4-chlorophenyl)-5-methyl-1h-imidazole;hydrochloride Chemical compound Cl.N1C=NC(C=2C=CC(Cl)=CC=2)=C1C PIAMNHTVFPWVHG-UHFFFAOYSA-N 0.000 description 1
- INDZCVYWKNWKIQ-UHFFFAOYSA-N 4-(fluoren-9-ylidenemethyl)benzenecarboximidamide;hydrochloride Chemical compound Cl.C1=CC(C(=N)N)=CC=C1C=C1C2=CC=CC=C2C2=CC=CC=C21 INDZCVYWKNWKIQ-UHFFFAOYSA-N 0.000 description 1
- LQVMQEYROPXMQH-UHFFFAOYSA-N 4-dibenzofuran-2-yl-4-oxobutanoic acid Chemical compound C1=CC=C2C3=CC(C(=O)CCC(=O)O)=CC=C3OC2=C1 LQVMQEYROPXMQH-UHFFFAOYSA-N 0.000 description 1
- SYCHUQUJURZQMO-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-n-(1,3-thiazol-2-yl)-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=CS1 SYCHUQUJURZQMO-UHFFFAOYSA-N 0.000 description 1
- CXSJGNHRBWJXEA-UHFFFAOYSA-N 5,12-dihydrophthalazino[3,2-b]phthalazine-7,14-dione Chemical compound C1C2=CC=CC=C2C(=O)N2N1C(=O)C1=CC=CC=C1C2 CXSJGNHRBWJXEA-UHFFFAOYSA-N 0.000 description 1
- HEOZYYOUKGGSBJ-UHFFFAOYSA-N 5-(4-methoxybenzoyl)-2,3-dihydro-1h-pyrrolizine-1-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C(=O)C1=CC=C2N1CCC2C(O)=O HEOZYYOUKGGSBJ-UHFFFAOYSA-N 0.000 description 1
- OAIZNWQBWDHNIH-UHFFFAOYSA-N 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)quinazolin-2-one Chemical compound N=1C(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 OAIZNWQBWDHNIH-UHFFFAOYSA-N 0.000 description 1
- XWXVKXXKKLBDDJ-UHFFFAOYSA-N 7-chloro-3,3a-dihydro-2h-[1,2]oxazolo[3,2-b][1,3]benzoxazin-9-one Chemical compound O1C2CCON2C(=O)C2=CC(Cl)=CC=C21 XWXVKXXKKLBDDJ-UHFFFAOYSA-N 0.000 description 1
- HCKFPALGXKOOBK-NRYMJLQJSA-N 7332-27-6 Chemical compound C1([C@]2(O[C@]3([C@@]4(C)C[C@H](O)[C@]5(F)[C@@]6(C)C=CC(=O)C=C6CC[C@H]5[C@@H]4C[C@H]3O2)C(=O)CO)C)=CC=CC=C1 HCKFPALGXKOOBK-NRYMJLQJSA-N 0.000 description 1
- ZOCUOMKMBMEYQV-GSLJADNHSA-N 9alpha-Fluoro-11beta,17alpha,21-trihydroxypregna-1,4-diene-3,20-dione 21-acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ZOCUOMKMBMEYQV-GSLJADNHSA-N 0.000 description 1
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 206010003162 Arterial injury Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- HNNIWKQLJSNAEQ-UHFFFAOYSA-N Benzydamine hydrochloride Chemical compound Cl.C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 HNNIWKQLJSNAEQ-UHFFFAOYSA-N 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- KATBVKFXGKGUFE-UHFFFAOYSA-N Cintazone Chemical compound C12=CC=CC=C2N2C(=O)C(CCCCC)C(=O)N2C=C1C1=CC=CC=C1 KATBVKFXGKGUFE-UHFFFAOYSA-N 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- YXKFATPOEMHNMJ-KJEYTGHBSA-N Cormethasone acetate Chemical compound C1C(F)(F)C2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O YXKFATPOEMHNMJ-KJEYTGHBSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- 241000256113 Culicidae Species 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- RHAXSHUQNIEUEY-UHFFFAOYSA-N Epirizole Chemical compound COC1=CC(C)=NN1C1=NC(C)=CC(OC)=N1 RHAXSHUQNIEUEY-UHFFFAOYSA-N 0.000 description 1
- 241001481760 Erethizon dorsatum Species 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 1
- YCISZOVUHXIOFY-HKXOFBAYSA-N Halopredone acetate Chemical compound C1([C@H](F)C2)=CC(=O)C(Br)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@](OC(C)=O)(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O YCISZOVUHXIOFY-HKXOFBAYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229920001499 Heparinoid Polymers 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- ACEWLPOYLGNNHV-UHFFFAOYSA-N Ibuprofen piconol Chemical compound C1=CC(CC(C)C)=CC=C1C(C)C(=O)OCC1=CC=CC=N1 ACEWLPOYLGNNHV-UHFFFAOYSA-N 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- HUXCOHMTWUSXGY-GAPIFECDSA-N Meclorisone dibutyrate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CCC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2Cl HUXCOHMTWUSXGY-GAPIFECDSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- INVGWHRKADIJHF-UHFFFAOYSA-N Sanguinarin Chemical compound C1=C2OCOC2=CC2=C3[N+](C)=CC4=C(OCO5)C5=CC=C4C3=CC=C21 INVGWHRKADIJHF-UHFFFAOYSA-N 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- MVLBCBPGBUAVJQ-CENSZEJFSA-N [(6s,8s,9r,10s,11s,13s,14s,16r,17r)-17-(chloromethylsulfanylcarbonyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCCl)(OC(=O)CC)[C@@]2(C)C[C@@H]1O MVLBCBPGBUAVJQ-CENSZEJFSA-N 0.000 description 1
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 1
- FBRAWBYQGRLCEK-UHFFFAOYSA-N [17-(2-chloroacetyl)-9-fluoro-10,13,16-trimethyl-3,11-dioxo-7,8,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)C=CC2(C)C2(F)C1C1CC(C)C(C(=O)CCl)(OC(=O)CCC)C1(C)CC2=O FBRAWBYQGRLCEK-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229960005142 alclofenac Drugs 0.000 description 1
- ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 1
- 229960004229 alclometasone dipropionate Drugs 0.000 description 1
- DJHCCTTVDRAMEH-DUUJBDRPSA-N alclometasone dipropionate Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O DJHCCTTVDRAMEH-DUUJBDRPSA-N 0.000 description 1
- LSWBQIAZNGURQV-WTBIUSKOSA-N algestone acetonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)C)[C@@]1(C)CC2 LSWBQIAZNGURQV-WTBIUSKOSA-N 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 229950004850 amcinafal Drugs 0.000 description 1
- NSZFBGIRFCHKOE-LFZVSNMSSA-N amcinafal Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(CC)(CC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O NSZFBGIRFCHKOE-LFZVSNMSSA-N 0.000 description 1
- 229950003408 amcinafide Drugs 0.000 description 1
- QZNJPJDUBTYMRS-UHFFFAOYSA-M amfenac sodium hydrate Chemical compound O.[Na+].NC1=C(CC([O-])=O)C=CC=C1C(=O)C1=CC=CC=C1 QZNJPJDUBTYMRS-UHFFFAOYSA-M 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 229940003354 angiomax Drugs 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229950004699 anirolac Drugs 0.000 description 1
- 229950002412 anitrazafen Drugs 0.000 description 1
- HDNJXZZJFPCFHG-UHFFFAOYSA-N anitrazafen Chemical compound C1=CC(OC)=CC=C1C1=NN=C(C)N=C1C1=CC=C(OC)C=C1 HDNJXZZJFPCFHG-UHFFFAOYSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001399 anti-metabolic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229960003856 argatroban Drugs 0.000 description 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 229960000560 balsalazide disodium Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 229960005149 bendazac Drugs 0.000 description 1
- BYFMCKSPFYVMOU-UHFFFAOYSA-N bendazac Chemical compound C12=CC=CC=C2C(OCC(=O)O)=NN1CC1=CC=CC=C1 BYFMCKSPFYVMOU-UHFFFAOYSA-N 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 229960005430 benoxaprofen Drugs 0.000 description 1
- 229960001689 benzydamine hydrochloride Drugs 0.000 description 1
- WHRVRSCEWKLAHX-LQDWTQKMSA-N benzylpenicillin procaine Chemical compound [H+].CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 WHRVRSCEWKLAHX-LQDWTQKMSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- AKUJBENLRBOFTD-QZIXMDIESA-N betamethasone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O AKUJBENLRBOFTD-QZIXMDIESA-N 0.000 description 1
- 229960004648 betamethasone acetate Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- UIDLJTHRRPMIQP-UHFFFAOYSA-L bis[2-[4-(2-methylpropyl)phenyl]propanoyloxy]aluminum;hydrate Chemical compound O.C1=CC(CC(C)C)=CC=C1C(C)C(=O)O[Al]OC(=O)C(C)C1=CC=C(CC(C)C)C=C1 UIDLJTHRRPMIQP-UHFFFAOYSA-L 0.000 description 1
- 229960001500 bivalirudin Drugs 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 229960001780 bromelains Drugs 0.000 description 1
- 229950011622 broperamole Drugs 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000004656 cell transport Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- CKMOQBVBEGCJGW-UHFFFAOYSA-L chembl1200760 Chemical compound [Na+].[Na+].C1=C(C([O-])=O)C(O)=CC=C1N=NC1=CC=C(C(=O)NCCC([O-])=O)C=C1 CKMOQBVBEGCJGW-UHFFFAOYSA-L 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229950002545 cicloprofen Drugs 0.000 description 1
- 229960005025 cilazapril Drugs 0.000 description 1
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
- GPUVGQIASQNZET-CCEZHUSRSA-N cinnoxicam Chemical compound C=1C=CC=CC=1/C=C/C(=O)OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 GPUVGQIASQNZET-CCEZHUSRSA-N 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 229950005384 cliprofen Drugs 0.000 description 1
- 229960002842 clobetasol Drugs 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- 229960005465 clobetasone butyrate Drugs 0.000 description 1
- SJCRQMUYEQHNTC-UHFFFAOYSA-N clopirac Chemical compound CC1=CC(CC(O)=O)=C(C)N1C1=CC=C(Cl)C=C1 SJCRQMUYEQHNTC-UHFFFAOYSA-N 0.000 description 1
- 229950009185 clopirac Drugs 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- MOVRKLZUVNCBIP-RFZYENFJSA-N cortancyl Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O MOVRKLZUVNCBIP-RFZYENFJSA-N 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 229950002276 cortodoxone Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- ZHPBLHYKDKSZCQ-UHFFFAOYSA-N cyclooctylmethanol Chemical compound OCC1CCCCCCC1 ZHPBLHYKDKSZCQ-UHFFFAOYSA-N 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960001145 deflazacort Drugs 0.000 description 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- 229960002593 desoximetasone Drugs 0.000 description 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 1
- 229960003657 dexamethasone acetate Drugs 0.000 description 1
- 229950000250 dexamethasone dipropionate Drugs 0.000 description 1
- CIWBQSYVNNPZIQ-PKWREOPISA-N dexamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-PKWREOPISA-N 0.000 description 1
- 229960004515 diclofenac potassium Drugs 0.000 description 1
- KXZOIWWTXOCYKR-UHFFFAOYSA-M diclofenac potassium Chemical compound [K+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KXZOIWWTXOCYKR-UHFFFAOYSA-M 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229960002124 diflorasone diacetate Drugs 0.000 description 1
- BOBLHFUVNSFZPJ-JOYXJVLSSA-N diflorasone diacetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)COC(C)=O)(OC(C)=O)[C@@]2(C)C[C@@H]1O BOBLHFUVNSFZPJ-JOYXJVLSSA-N 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 229960004875 difluprednate Drugs 0.000 description 1
- 229950007956 diftalone Drugs 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- GZBONOYGBJSTHF-QLRNAMTQSA-N drocinonide Chemical compound C([C@@H]1CC2)C(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O GZBONOYGBJSTHF-QLRNAMTQSA-N 0.000 description 1
- 229950006082 drocinonide Drugs 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229950002798 enlimomab Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229950003801 epirizole Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- ULANGSAJTINEBA-UHFFFAOYSA-N ethyl n-(3-benzoylphenyl)-n-(trifluoromethylsulfonyl)carbamate Chemical compound CCOC(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 ULANGSAJTINEBA-UHFFFAOYSA-N 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960001493 etofenamate Drugs 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960000192 felbinac Drugs 0.000 description 1
- 229950003579 fenamole Drugs 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- IDKAXRLETRCXKS-UHFFFAOYSA-N fenclofenac Chemical compound OC(=O)CC1=CC=CC=C1OC1=CC=C(Cl)C=C1Cl IDKAXRLETRCXKS-UHFFFAOYSA-N 0.000 description 1
- 229950006236 fenclofenac Drugs 0.000 description 1
- 229950003537 fenclorac Drugs 0.000 description 1
- HAWWPSYXSLJRBO-UHFFFAOYSA-N fendosal Chemical compound C1=C(O)C(C(=O)O)=CC(N2C(=CC=3C4=CC=CC=C4CCC=32)C=2C=CC=CC=2)=C1 HAWWPSYXSLJRBO-UHFFFAOYSA-N 0.000 description 1
- 229950005416 fendosal Drugs 0.000 description 1
- 229950002296 fenpipalone Drugs 0.000 description 1
- 229960002679 fentiazac Drugs 0.000 description 1
- 229950004322 flazalone Drugs 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 229950002335 fluazacort Drugs 0.000 description 1
- BYZCJOHDXLROEC-RBWIMXSLSA-N fluazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O BYZCJOHDXLROEC-RBWIMXSLSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- OPYFPDBMMYUPME-UHFFFAOYSA-N flumizole Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC(OC)=CC=2)NC(C(F)(F)F)=N1 OPYFPDBMMYUPME-UHFFFAOYSA-N 0.000 description 1
- 229950005288 flumizole Drugs 0.000 description 1
- WEGNFRKBIKYVLC-XTLNBZDDSA-N flunisolide acetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WEGNFRKBIKYVLC-XTLNBZDDSA-N 0.000 description 1
- 229960000588 flunixin Drugs 0.000 description 1
- NOOCSNJCXJYGPE-UHFFFAOYSA-N flunixin Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O NOOCSNJCXJYGPE-UHFFFAOYSA-N 0.000 description 1
- 229960000469 flunixin meglumine Drugs 0.000 description 1
- MGCCHNLNRBULBU-WZTVWXICSA-N flunixin meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O MGCCHNLNRBULBU-WZTVWXICSA-N 0.000 description 1
- XWTIDFOGTCVGQB-FHIVUSPVSA-N fluocortin butyl Chemical group C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)C(=O)OCCCC)[C@@]2(C)C[C@@H]1O XWTIDFOGTCVGQB-FHIVUSPVSA-N 0.000 description 1
- 229950008509 fluocortin butyl Drugs 0.000 description 1
- 229960001629 fluorometholone acetate Drugs 0.000 description 1
- YRFXGQHBPBMFHW-SBTZIJSASA-N fluorometholone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 YRFXGQHBPBMFHW-SBTZIJSASA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229950007253 fluquazone Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229950003750 fluretofen Drugs 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 229950008156 furaprofen Drugs 0.000 description 1
- 229950006099 furobufen Drugs 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960002383 halcinonide Drugs 0.000 description 1
- 229950004611 halopredone acetate Drugs 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 239000002554 heparinoid Substances 0.000 description 1
- 229940025770 heparinoids Drugs 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- MSYBLBLAMDYKKZ-UHFFFAOYSA-N hydron;pyridine-3-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CN=C1 MSYBLBLAMDYKKZ-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- CYWFCPPBTWOZSF-UHFFFAOYSA-N ibufenac Chemical compound CC(C)CC1=CC=C(CC(O)=O)C=C1 CYWFCPPBTWOZSF-UHFFFAOYSA-N 0.000 description 1
- 229950009183 ibufenac Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229950005954 ibuprofen piconol Drugs 0.000 description 1
- 229950011445 ilonidap Drugs 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229960004260 indomethacin sodium Drugs 0.000 description 1
- 229960004187 indoprofen Drugs 0.000 description 1
- 229950008443 indoxole Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229950004204 intrazole Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960003317 isoflupredone acetate Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- QFGMXJOBTNZHEL-UHFFFAOYSA-N isoxepac Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC(CC(=O)O)=CC=C21 QFGMXJOBTNZHEL-UHFFFAOYSA-N 0.000 description 1
- 229950011455 isoxepac Drugs 0.000 description 1
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 1
- 229950002252 isoxicam Drugs 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 238000001182 laser chemical vapour deposition Methods 0.000 description 1
- 239000002346 layers by function Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 description 1
- 229960003744 loteprednol etabonate Drugs 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- GQVWFGYYMWLERN-UHFFFAOYSA-J magnesium;2-carboxyphenolate;2-hydroxyethyl(trimethyl)azanium;sulfate;tetrahydrate Chemical compound O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O.C[N+](C)(C)CCO.C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O GQVWFGYYMWLERN-UHFFFAOYSA-J 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- OJGJQQNLRVNIKE-UHFFFAOYSA-N meseclazone Chemical compound O1C2=CC=C(Cl)C=C2C(=O)N2C1CC(C)O2 OJGJQQNLRVNIKE-UHFFFAOYSA-N 0.000 description 1
- 229950000701 meseclazone Drugs 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- PSCNNGGPKIBAHB-WFVOKNHCSA-N methylprednisolone 21-suleptanic acid ester Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCCCCCC(=O)N(C)CCS(O)(=O)=O)CC[C@H]21 PSCNNGGPKIBAHB-WFVOKNHCSA-N 0.000 description 1
- 229950010796 methylprednisolone suleptanate Drugs 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229960005170 moexipril Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- NKDJNEGDJVXHKM-UHFFFAOYSA-N n,2-dimethyl-4,5,6,7-tetrahydroindazol-3-amine Chemical compound C1CCCC2=NN(C)C(NC)=C21 NKDJNEGDJVXHKM-UHFFFAOYSA-N 0.000 description 1
- HWCORKBTTGTRDY-UHFFFAOYSA-N n-(4-chlorophenyl)-1,3-dioxo-4h-isoquinoline-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1C2=CC=CC=C2C(=O)NC1=O HWCORKBTTGTRDY-UHFFFAOYSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960003940 naproxen sodium Drugs 0.000 description 1
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
- LTRANDSQVZFZDG-SNVBAGLBSA-N naproxol Chemical compound C1=C([C@H](C)CO)C=CC2=CC(OC)=CC=C21 LTRANDSQVZFZDG-SNVBAGLBSA-N 0.000 description 1
- 229950006890 naproxol Drugs 0.000 description 1
- 229950006046 nimazone Drugs 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 229960004364 olsalazine sodium Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960004534 orgotein Drugs 0.000 description 1
- 108010070915 orgotein Proteins 0.000 description 1
- 229950003655 orpanoxin Drugs 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229960003820 pentosan polysulfate sodium Drugs 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229960001369 piroxicam cinnamate Drugs 0.000 description 1
- 229960000851 pirprofen Drugs 0.000 description 1
- PIDSZXPFGCURGN-UHFFFAOYSA-N pirprofen Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1N1CC=CC1 PIDSZXPFGCURGN-UHFFFAOYSA-N 0.000 description 1
- 239000011295 pitch Substances 0.000 description 1
- 239000011527 polyurethane coating Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229950008421 prednazate Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- WAAVMZLJRXYRMA-UHFFFAOYSA-N prifelone Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C(=O)C=2SC=CC=2)=C1 WAAVMZLJRXYRMA-UHFFFAOYSA-N 0.000 description 1
- 229950004465 prifelone Drugs 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000003651 pro-proliferative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229950003795 prodolic acid Drugs 0.000 description 1
- 229960002466 proquazone Drugs 0.000 description 1
- JTIGKVIOEQASGT-UHFFFAOYSA-N proquazone Chemical compound N=1C(=O)N(C(C)C)C2=CC(C)=CC=C2C=1C1=CC=CC=C1 JTIGKVIOEQASGT-UHFFFAOYSA-N 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 229960001302 ridaforolimus Drugs 0.000 description 1
- 229960001487 rimexolone Drugs 0.000 description 1
- QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229950001166 romazarit Drugs 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 229950000125 salcolex Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229950009768 salnacedin Drugs 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 229950011197 sanguinarium chloride Drugs 0.000 description 1
- 229950002093 seclazone Drugs 0.000 description 1
- 238000000110 selective laser sintering Methods 0.000 description 1
- 229950006250 sermetacin Drugs 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- HVBBVDWXAWJQSV-UHFFFAOYSA-N sodium;(3-benzoylphenyl)-(difluoromethylsulfonyl)azanide Chemical compound [Na+].FC(F)S(=O)(=O)[N-]C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 HVBBVDWXAWJQSV-UHFFFAOYSA-N 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- JMHRGKDWGWORNU-UHFFFAOYSA-M sodium;2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetate Chemical compound [Na+].CC1=C(CC([O-])=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 JMHRGKDWGWORNU-UHFFFAOYSA-M 0.000 description 1
- SEEXPXUCHVGZGU-UHFFFAOYSA-M sodium;2-[5-(4-chlorobenzoyl)-1,4-dimethylpyrrol-2-yl]acetate Chemical compound [Na+].C1=C(CC([O-])=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C SEEXPXUCHVGZGU-UHFFFAOYSA-M 0.000 description 1
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 description 1
- NNFXVGOLTQESMQ-UHFFFAOYSA-M sodium;4-butyl-5-oxo-1,2-diphenylpyrazol-3-olate Chemical compound [Na+].C=1C=CC=CC=1N1C(=O)C(CCCC)=C([O-])N1C1=CC=CC=C1 NNFXVGOLTQESMQ-UHFFFAOYSA-M 0.000 description 1
- AVERBMQHYOZACV-UHFFFAOYSA-M sodium;7-chloro-4-[(3,4-dichlorophenyl)carbamoyl]-1,1-dioxo-2,3-dihydro-1$l^{6}-benzothiepin-5-olate;hydrate Chemical compound O.[Na+].C1CS(=O)(=O)C2=CC=C(Cl)C=C2C([O-])=C1C(=O)NC1=CC=C(Cl)C(Cl)=C1 AVERBMQHYOZACV-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229950005175 sudoxicam Drugs 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229940032362 superoxide dismutase Drugs 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229950005100 talmetacin Drugs 0.000 description 1
- 229960005262 talniflumate Drugs 0.000 description 1
- 229950005400 talosalate Drugs 0.000 description 1
- 229950003441 tebufelone Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- 229950007324 tesicam Drugs 0.000 description 1
- 229950000997 tesimide Drugs 0.000 description 1
- TUGDLVFMIQZYPA-UHFFFAOYSA-N tetracopper;tetrazinc Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2] TUGDLVFMIQZYPA-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229920002725 thermoplastic elastomer Polymers 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 229950002345 tiopinac Drugs 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 229960003114 tixocortol pivalate Drugs 0.000 description 1
- BISFDZNIUZIKJD-XDANTLIUSA-N tixocortol pivalate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CSC(=O)C(C)(C)C)(O)[C@@]1(C)C[C@@H]2O BISFDZNIUZIKJD-XDANTLIUSA-N 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 229960002044 tolmetin sodium Drugs 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- VSVSLEMVVAYTQW-VSXGLTOVSA-N triclonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]2(C)C[C@@H]1Cl VSVSLEMVVAYTQW-VSXGLTOVSA-N 0.000 description 1
- 229950008073 triclonide Drugs 0.000 description 1
- 229950000451 triflumidate Drugs 0.000 description 1
- 230000005641 tunneling Effects 0.000 description 1
- 229950008396 ulobetasol propionate Drugs 0.000 description 1
- BDSYKGHYMJNPAB-LICBFIPMSA-N ulobetasol propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]2(C)C[C@@H]1O BDSYKGHYMJNPAB-LICBFIPMSA-N 0.000 description 1
- YYSFXUWWPNHNAZ-PKJQJFMNSA-N umirolimus Chemical compound C1[C@@H](OC)[C@H](OCCOCC)CC[C@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 YYSFXUWWPNHNAZ-PKJQJFMNSA-N 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229950007952 vapiprost Drugs 0.000 description 1
- 238000007740 vapor deposition Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229950007802 zidometacin Drugs 0.000 description 1
- 229960003516 zomepirac sodium Drugs 0.000 description 1
- CGTADGCBEXYWNE-GTTQIJKGSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](\C(C)=C\C=C\C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-GTTQIJKGSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/104—Balloon catheters used for angioplasty
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
- A61B17/22031—Gripping instruments, e.g. forceps, for removing or smashing calculi
- A61B17/22032—Gripping instruments, e.g. forceps, for removing or smashing calculi having inflatable gripping elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1027—Making of balloon catheters
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D19/00—Pallets or like platforms, with or without side walls, for supporting loads to be lifted or lowered
- B65D19/38—Details or accessories
- B65D19/40—Elements for spacing platforms from supporting surface
- B65D19/42—Arrangements or applications of rollers or wheels
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D19/00—Pallets or like platforms, with or without side walls, for supporting loads to be lifted or lowered
- B65D19/38—Details or accessories
- B65D19/44—Elements or devices for locating articles on platforms
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
- B65D85/30—Containers, packaging elements or packages, specially adapted for particular articles or materials for articles particularly sensitive to damage by shock or pressure
- B65D85/48—Containers, packaging elements or packages, specially adapted for particular articles or materials for articles particularly sensitive to damage by shock or pressure for glass sheets
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65G—TRANSPORT OR STORAGE DEVICES, e.g. CONVEYORS FOR LOADING OR TIPPING, SHOP CONVEYOR SYSTEMS OR PNEUMATIC TUBE CONVEYORS
- B65G1/00—Storing articles, individually or in orderly arrangement, in warehouses or magazines
- B65G1/02—Storage devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
- A61B2017/22001—Angioplasty, e.g. PCTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
- A61B2017/22051—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for with an inflatable part, e.g. balloon, for positioning, blocking, or immobilisation
- A61B2017/22065—Functions of balloons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
- A61B2017/22094—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for for crossing total occlusions, i.e. piercing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1027—Making of balloon catheters
- A61M25/1029—Production methods of the balloon members, e.g. blow-moulding, extruding, deposition or by wrapping a plurality of layers of balloon material around a mandril
- A61M2025/1031—Surface processing of balloon members, e.g. coating or deposition; Mounting additional parts onto the balloon member's surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1086—Balloon catheters with special features or adapted for special applications having a special balloon surface topography, e.g. pores, protuberances, spikes or grooves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/109—Balloon catheters with special features or adapted for special applications having balloons for removing solid matters, e.g. by grasping or scraping plaque, thrombus or other matters that obstruct the flow
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D2519/00—Pallets or like platforms, with or without side walls, for supporting loads to be lifted or lowered
- B65D2519/00004—Details relating to pallets
- B65D2519/00009—Materials
- B65D2519/00014—Materials for the load supporting surface
- B65D2519/00024—Metal
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D2519/00—Pallets or like platforms, with or without side walls, for supporting loads to be lifted or lowered
- B65D2519/00004—Details relating to pallets
- B65D2519/00009—Materials
- B65D2519/00049—Materials for the base surface
- B65D2519/00059—Metal
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D2519/00—Pallets or like platforms, with or without side walls, for supporting loads to be lifted or lowered
- B65D2519/00004—Details relating to pallets
- B65D2519/00009—Materials
- B65D2519/00084—Materials for the non-integral separating spacer
- B65D2519/00094—Metal
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D2519/00—Pallets or like platforms, with or without side walls, for supporting loads to be lifted or lowered
- B65D2519/00004—Details relating to pallets
- B65D2519/00258—Overall construction
- B65D2519/00263—Overall construction of the pallet
- B65D2519/00273—Overall construction of the pallet made of more than one piece
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D2519/00—Pallets or like platforms, with or without side walls, for supporting loads to be lifted or lowered
- B65D2519/00004—Details relating to pallets
- B65D2519/00258—Overall construction
- B65D2519/00283—Overall construction of the load supporting surface
- B65D2519/00293—Overall construction of the load supporting surface made of more than one piece
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D2519/00—Pallets or like platforms, with or without side walls, for supporting loads to be lifted or lowered
- B65D2519/00004—Details relating to pallets
- B65D2519/00258—Overall construction
- B65D2519/00313—Overall construction of the base surface
- B65D2519/00323—Overall construction of the base surface made of more than one piece
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D2519/00—Pallets or like platforms, with or without side walls, for supporting loads to be lifted or lowered
- B65D2519/00004—Details relating to pallets
- B65D2519/00258—Overall construction
- B65D2519/00313—Overall construction of the base surface
- B65D2519/00328—Overall construction of the base surface shape of the contact surface of the base
- B65D2519/00333—Overall construction of the base surface shape of the contact surface of the base contact surface having a stringer-like shape
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D2519/00—Pallets or like platforms, with or without side walls, for supporting loads to be lifted or lowered
- B65D2519/00004—Details relating to pallets
- B65D2519/00258—Overall construction
- B65D2519/00368—Overall construction of the non-integral separating spacer
- B65D2519/00373—Overall construction of the non-integral separating spacer whereby at least one spacer is made of one piece
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D2519/00—Pallets or like platforms, with or without side walls, for supporting loads to be lifted or lowered
- B65D2519/00004—Details relating to pallets
- B65D2519/00547—Connections
- B65D2519/00552—Structures connecting the constitutive elements of the pallet to each other, i.e. load supporting surface, base surface and/or separate spacer
- B65D2519/00557—Structures connecting the constitutive elements of the pallet to each other, i.e. load supporting surface, base surface and/or separate spacer without separate auxiliary elements
- B65D2519/00562—Structures connecting the constitutive elements of the pallet to each other, i.e. load supporting surface, base surface and/or separate spacer without separate auxiliary elements chemical connection, e.g. glued, welded, sealed
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D2519/00—Pallets or like platforms, with or without side walls, for supporting loads to be lifted or lowered
- B65D2519/00004—Details relating to pallets
- B65D2519/00547—Connections
- B65D2519/00552—Structures connecting the constitutive elements of the pallet to each other, i.e. load supporting surface, base surface and/or separate spacer
- B65D2519/00572—Structures connecting the constitutive elements of the pallet to each other, i.e. load supporting surface, base surface and/or separate spacer with separate auxiliary element, e.g. screws, nails, bayonets
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D2519/00—Pallets or like platforms, with or without side walls, for supporting loads to be lifted or lowered
- B65D2519/00004—Details relating to pallets
- B65D2519/00736—Details
- B65D2519/00741—Dimensional aspects of the pallet
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D2519/00—Pallets or like platforms, with or without side walls, for supporting loads to be lifted or lowered
- B65D2519/00004—Details relating to pallets
- B65D2519/00736—Details
- B65D2519/00776—Accessories for manipulating the pallet
- B65D2519/00781—Accessories for manipulating the pallet for moving on a surface, e.g. wheels, pads
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D2519/00—Pallets or like platforms, with or without side walls, for supporting loads to be lifted or lowered
- B65D2519/00004—Details relating to pallets
- B65D2519/00736—Details
- B65D2519/00776—Accessories for manipulating the pallet
- B65D2519/00796—Guiding means for fork-lift
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D2519/00—Pallets or like platforms, with or without side walls, for supporting loads to be lifted or lowered
- B65D2519/00004—Details relating to pallets
- B65D2519/00736—Details
- B65D2519/00805—Means for facilitating the removal of the load
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D2519/00—Pallets or like platforms, with or without side walls, for supporting loads to be lifted or lowered
- B65D2519/00004—Details relating to pallets
- B65D2519/00736—Details
- B65D2519/0081—Elements or devices for locating articles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D2519/00—Pallets or like platforms, with or without side walls, for supporting loads to be lifted or lowered
- B65D2519/00004—Details relating to pallets
- B65D2519/00736—Details
- B65D2519/0081—Elements or devices for locating articles
- B65D2519/00815—Elements or devices for locating articles on the pallet
Definitions
- Certain embodiments disclosed herein relate generally to a cage for use with a medical balloon, such as an angioplasty balloon.
- Methods of manufacturing the cage and treatment methods involving the cage are also disclosed, as well as various wedge dissectors and features of splines that can be used with the cages.
- the wedge dissectors can be used to create perforations in plaque in a blood vessel in an effort to control crack propagation and to reduce flow limiting dissections.
- Atherosclerotic occlusive disease is the primary cause of stroke, heart attack, limb loss, and death in the United States and the industrialized world.
- Atherosclerotic plaque forms a hard layer along the wall of an artery and is comprised of calcium, cholesterol, compacted thrombus and cellular debris.
- the blood supply intended to pass through a specific blood vessel is diminished or even prevented by the occlusive process.
- One of the most widely utilized methods of treating clinically significant atherosclerotic plaque is balloon angioplasty.
- Balloon angioplasty is a method of opening blocked or narrowed blood vessels in the body.
- the balloon angioplasty catheter is placed into the artery from a remote access site that is created either percutaneously or through open exposure of the artery.
- the catheter is passed along the inside of the blood vessel over a wire that guides the way of the catheter.
- the portion of the catheter with the balloon attached is placed at the location of the atherosclerotic plaque that requires treatment.
- the balloon is generally inflated to a size that is consistent with the original diameter of the artery prior to developing occlusive disease.
- the plaque When the balloon is inflated, the plaque is stretched, compressed, fractured, or broken, depending on its composition, location, and the amount of pressure exerted by the balloon.
- the plaque is heterogeneous and may be soft in some areas or hard in others causing unpredictable cleavage planes to form under standard balloon angioplasty. Balloon angioplasty can cause plaque disruption and sometimes even arterial injury at the angioplasty site.
- EP 1,809,361A discloses a cutting balloon catheter and method of making and using the same.
- the cutting balloon catheter may include a catheter shaft having a balloon coupled thereto.
- One or more cutting members or blades may be coupled to the balloon.
- the cutting members may include two or more sections that are connected via a fracturable or yielding bridge section that increases flexibility when passing through or being utilized in tortuous anatomy.
- US 2012/172901 discloses a medical balloon catheter including a catheter shaft and an inflatable balloon secured to a distal portion of the catheter shaft.
- One or more cutting blades are secured to the inflatable balloon by a first polymeric adhesive material forming a mounting pad encasing a base portion of the cutting blade therein, and a second polymeric adhesive material adhesively bonding the mounting pad to a surface of the balloon.
- the first polymeric adhesive material has a first ductility and the second polymeric adhesive material has a second ductility greater than the first ductility.
- US 2002/010489 discloses a stiffened balloon which can be used in angioplasty, endovascular, and valvuloplasty procedures or as a delivery balloon to deliver a stent or a stent-graft.
- Longitudinally discontinuous stiffening members connected to the expandable balloon stiffen the balloon but allow it to be navigated through curved passages. Projections on the stiffening members may engage, incise, crush, fracture, or pierce occlusions or retain a stent or stent-graft. Radio-opaque portions may be referenced to determine orientation.
- Longitudinally continuous stiffening members bearing projections and connected to the balloon perform in a similar manner.
- US 2004/098014 discloses a balloon angioplasty device which provides a combination of cutting elements to enhance dilation of an artery together with controlled drug delivery directed towards the regions of cutting.
- the invention is preferably implemented using rows of hollow microneedles to serve both as the cutting elements and the drug delivery conduits.
- the invention also provides a corresponding method in which a drug is delivered via conduits located within cutting elements around the exterior of a balloon angioplasty device during and/or immediately subsequent to inflation of the balloon within a blood vessel.
- US 2005/149082 discloses a microsurgical balloon, with at least one incising component mounted to the surface of the balloon, including a protective pad to prevent the outer surface of the incising component from coming into contact with and damaging the balloon surface.
- the protective pad is positioned on the outer surface of the balloon substantially parallel to and juxtaposed with the incising component.
- the protective pad engages the outer surface of the incising component thereby protecting the balloon from being punctured or damaged by the incising component.
- the protective pad may be bonded to the outer surface of the balloon, or it may be an integral part of a homogeneous balloon structure.
- a cage can be positioned around a medical balloon, such as an angioplasty balloon, to assist in a medical procedure.
- the cage can include at least first and second rings and a plurality of strips. Each strip can extend longitudinally between the first and second rings. Moving the cage to an expanded position can move the first and second rings closer together while expanding the strips.
- the cage may further include spikes on the strips that can be used as wedge dissectors to dissect plaque in a vessel, among other things.
- a medical balloon catheter and wedge dissectors and strips that can be configured to be attached to a medical balloon catheter or other expandable member.
- the balloon catheter can include any number of the following: an elongate member having an inner lumen, the elongate member defining a longitudinal axis; an expandable balloon connected to the elongate member at a distal end of the elongate member; and a plurality of strips, each strip of the plurality of strips including a plurality of wedge dissectors spaced apart along a surface of each strip, each strip extending longitudinally along an outer surface of the balloon.
- the wedge dissectors can include a strip-facing base surface directly adjacent a surface of each of the strips and an unhoned radially outward facing surface having a length between a proximal edge of the radially outward facing surface and a distal edge of the radially outward facing surface and defining a height of each wedge dissector.
- the radially outward facing surface has a first width at the proximal edge, a second width smaller than the first width between the proximal edge and the distal edge, and a third width at the distal edge larger than the second width.
- the second width corresponds to a single point along the length of the radially outward facing surface.
- the second width can correspond to a central segment having a central length in between the proximal edge and the distal edge.
- the length of each strip can be less than a length of the outer surface of the balloon coaxial to the length of each strip.
- the length of each strip can also be between about 3% and about 6% less than the length of the outer surface of the balloon coaxial to the length of each strip.
- the total length of the radially outward facing surface of each wedge dissector can be less than a total length of the strip-facing base surface of each wedge dissector.
- the radially outward facing surface can be, for example, one or more curved and/or chamfered surfaces.
- the radially outward facing surface can have a first height at the proximal edge and a second height between the proximal edge and the distal edge, wherein the second height is greater than the first height.
- a maximal height of the radially outward facing surface is at a midpoint between the first unbounded edge and the second unbounded edge.
- a maximal height of the unbounded surface can be offset from a midpoint between the proximal edge and the distal edge.
- a lateral surface segment of the wedge dissector from the strip-facing base surface to the proximal edge has a first segment with a first slope and a second segment with a second slope different from the first slope.
- the strip can include a textured surface.
- the strip can include a plurality of tabs on an inferior-facing surface of the strip opposite the wedge dissectors.
- a plurality of reliefs on the strip can also be included.
- the strips can in some cases include an elongate length and first and second lateral edges. The first and second lateral edges of the plurality of strips can be circumscribed by an adhesive.
- a hydrophilic slip layer can surround the outer surface of the balloon, the strips, and the wedge dissectors.
- at least one polymer retention layer surrounds the outer surface of the balloon, the strips, and the wedge dissectors.
- the balloon can also include cones about the lateral ends of the balloon. The cones can have a maximal outer diameter that is greater than about 5% of the maximal outer diameter of the balloon. In some cases, the cones comprise rails oriented with longitudinal axes of the strips.
- the cage can be assembled and/or manufactured in many ways, including, in some examples, an extrusion process, material removal from a tube, or by splitting a wire to form the strips.
- the cage can assist a medical procedure in many ways.
- the cage may cover a drug coating on the balloon pre-deployment.
- the cage when the cage is expanded, the cage may allow access to the drug coating on the surface of the balloon. In this way, the cage can prevent or reduce the chances that the drug will become diluted during delivery or will treat areas of the body not intended for treatment.
- the cage can prevent or reduce dog boning of the balloon by increasing the resistance to expansion of the combined balloon and cage at the ends of the cage as compared to the center of the cage.
- a balloon catheter can comprise an elongate member, a balloon, and a cage.
- the elongate member can have an inner lumen, the elongate member defining a longitudinal axis.
- the balloon can be connected to the elongate member at a distal end of the elongate member.
- the cage can be for positioning about the balloon.
- the cage can comprise a plurality of strips and a plurality of rings.
- the plurality of rings can be configured to secure the plurality of strips to the balloon catheter.
- Each strip of the plurality of strips can have a first ring of the plurality of rings at a distal end, a second ring of the plurality of rings at a proximal end.
- the balloon and cage are configured to have an initial state and an expanded state, the plurality of strips configured to move with the balloon as it moves toward the expanded state.
- each strip of the plurality of strips can include a plurality of wedge dissectors spaced along a surface of the strip, each strip extending longitudinally along an outer surface of the balloon.
- the plurality of rings can secure the plurality of strips to distal and proximal ends of the balloon. At least some of the strips of the plurality of strips can be secured with rings at intermediate points of the balloon. The strip may be secured at intermediate points and/or at the ends.
- At least some of the rings of the plurality of rings comprise a part ring having a top layer of heat sink material and a bottom layer, an end of a strip of the plurality of strips sandwiched between the top layer and the bottom layer.
- Some embodiments can include hooks on the strips, grooves on the strips or rings, springs, and other features.
- a plurality of polyurethane coatings in combination with a series of strips collectively produce a cage.
- the cage is comprised as a full or partial single top layer or multiple layers of urethane, polyurethane, or other polymer material and a bottom layer of urethane, polyurethane, or other polymer material, and a plurality of strips sandwiched between the top layer/s and the bottom layer.
- Some embodiments can include hooks on the edges of strips, grooves on the strips or rings, springs, and other features.
- a method of retrofitting a balloon catheter with a cage can comprise any of the below steps. Positioning a plurality of strips around an inflated balloon of a balloon catheter, the strips being positioned equally spaced around the inflated balloon. Advancing rings of heat shrink material over the balloon so that each end of the strips of the plurality of strips is covered by a ring heat shrink material. Heating the rings of heat shrink material to shrink the rings of heat shrink material to thereby secure the plurality of strips to the balloon, at least a portion of each strip of the plurality of strip between distal and proximal ends of the strip remaining uncovered by and/or unconnected to any ring of heat shrink material.
- a method may further include positioning the strips to extend primarily longitudinally, and/or positioning the strips serially in rows around the balloon with 4 rows, each having between 2-6 strips per row.
- the strips can be attached either permanently or temporarily to the balloon with an adhesive.
- Advancing rings of heat shrink material over the balloon further may comprise covering a distal end of distal-most strips of the plurality of strips with a single ring of heat shrink material.
- advancing rings of heat shrink material may include covering a proximal end of proximal-most strips of the plurality of strips with a single ring of heat shrink material.
- it can include covering a proximal end of distal-most strips of the plurality of strips and a distal end of proximal-most strips with a single ring of heat shrink material.
- a cage can be positioned around an angioplasty balloon.
- the cage can include first and second rings and a plurality of strips. Each strip of the plurality of strips can extend longitudinally between the first and second rings.
- the cage can have a pre-expansion position and an expanded position, wherein moving to the expanded position moves the first and second rings closer together while expanding the strips.
- a method of making a cage for an angioplasty balloon can comprise extruding a plastic tube with a plurality of spaced apart splines positioned longitudinally along the tube; cutting at least one of the splines of the plurality of splines to form a plurality of spikes positioned circumferentially around the tube; and cutting the tube to form a plurality of longitudinally extending strips, each strip including at least one spike of the plurality of spikes.
- a method of making a cage for an angioplasty balloon can comprise splitting a wire into a plurality of longitudinally extending strips; cutting at least two longitudinally extending strips of the plurality of longitudinally extending strips to form a plurality of spikes spaced apart along the longitudinally extending strip; and connecting the at least two longitudinally extending strips to a first ring and a second ring such that each strip of the plurality of longitudinally extending strips extends between the first and second rings.
- a method of protecting an angioplasty balloon with a drug coating can comprise providing an angioplasty balloon with a drug coating; providing a cage having a pre-expansion position and an expanded position, the cage comprising: first and second rings; and a plurality of strips, each strip of the plurality of strips extending between the first and second rings; wherein the cage is positioned over the angioplasty balloon such that in the pre-expansion position the cage covers the angioplasty balloon radially such that none, or substantially none, of the surface of the angioplasty balloon with the drug coating is exposed, and moving to the expanded position moves the first and second rings closer together while expanding the strips and exposing the angioplasty balloon surface.
- a method of treating a diseased blood vessel can comprise advancing an angioplasty balloon, optionally with a drug coating, to a treatment site in a diseased blood vessel, the angioplasty balloon having a cage positioned over the angioplasty balloon, the cage having a pre-expansion position and an expanded position, the cage comprising: first and second rings; and a plurality of strips, each strip of the plurality of strips extending between the first and second rings; expanding the angioplasty balloon at the treatment site, where expanding the angioplasty balloon further comprises moving the first and second rings closer together while expanding the strips, the cage preventing or reducing dog boning of the angioplasty balloon by increasing the resistance to expansion of the combined angioplasty balloon and cage at the ends of the cage as compared to the center of the cage.
- a cage for positioning about an angioplasty balloon can include a plurality of rings and a plurality of strips.
- the plurality of rings can be non-expandable. At least one of the plurality of rings can be configured to be disposed about a first end of an angioplasty balloon, and at least one of the plurality of rings can be configured to be disposed about a second end of the angioplasty balloon.
- Each of the plurality of strips can include a plurality of protrusions positioned on the surface of each of the plurality of strips.
- Each of the plurality of rings can be configured to attach to each end of the plurality of strips.
- the plurality of strips can be attached to the plurality of rings through a coupling.
- the cage can have a first length and a second length. The second length is shorter than the first length, and the plurality of rings are closer in proximity with each other such that each of the plurality of strips bends away from each of the plurality of strips.
- FIGs 1A and 1B illustrate an embodiment of a cage 10 positioned on an angioplasty balloon 20.
- Figure 1A shows an expanded position and Figure 1B shows how the angioplasty balloon can be advanced into the cage.
- the cage 10 is described herein primarily with respect to an angioplasty balloon 20 and an angioplasty procedure. It is to be understood that the cage 10 can be used with other types of medical balloons and in other procedures.
- the cage 10 can include a first ring 12 and second ring 14, and a plurality of strips 16. Each strip can extend longitudinally between the first ring 12 and the second ring 14.
- the strips and rings can be made of a monolithic part formed from a single piece of material. Thus, the first and second rings can be the ends of a cut tube, for example.
- the strips and rings can also be made of separate materials and be connected together. As shown the illustrated cage of Figures 1A and 1B has five strips 16, though other numbers of strips can be used such as 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.
- Figure 2 shows a plan view of a cut tube embodiment of cage, though some embodiments of cage can alternatively be made of a single flat piece of material.
- the material can be elastic or semi-elastic and made from a polymer, copolymer, a metal, alloy or combination of these.
- the strips are typically designed to enable the balloon 20 to be inflated multiple times.
- the strips 16 can be configured such that the cage 10 can apply forces both longitudinally and axially or in orientations that enable the strips 16 to return to this original position.
- the cage 10 is prefabricated, packaged, and sterilized separately from the balloon 20, allowing the physician to position the cage 10 around a medical balloon 20, such as an angioplasty balloon, to assist in a medical procedure at the time of the procedure.
- Figure 1B shows the balloon 20 in a folded state prior to deployment and prior to placement within the cage 10.
- the folded balloon 20 can be advanced into the cage 10 without requiring expansion or change in shape of the cage 10.
- the cage 10 can completely surround and enclose the balloon 20 prior to balloon deployment or expansion.
- the cage 10 in the pre-expanded state can be longer than the balloon 20. This can allow for movement of one or both ends of the cage 10 towards each other while the device (e.g. balloon 20) expands.
- the cage 10 can be free floating over the balloon 20.
- One or both ends 12, 14 of the cage 10 may be fixed to the balloon 20 or another part of the delivery device.
- the cage 10 is not attached to any portion of the balloon 20 that expands. This can prevent the cage 10 from interfering with the balloon 20 as it expands.
- a cage 10 can be used with an angioplasty balloon 20 with a drug coating to can protect the drug coating.
- the cage 10 can prevent or reduce the premature exposure of the drug to the blood vessel.
- the cage 10 can be positioned over a drug coated angioplasty balloon 20 in the pre-expansion state to prevent premature exposure of the drug to the blood vessel.
- the cage 10 can cover the balloon 20 radially such that a minimal amount, or substantially none, of the surface of the angioplasty balloon 20 with the drug coating is exposed.
- the balloon 20 and cage 10 can be advanced to a treatment location in this configuration. Though not shown, the system may be advanced over a guidewire within the vasculature.
- the cage 10 can be moved to an expanded position.
- the first 12 and second rings 14 are closer together and the strips are expanded thereby exposing the angioplasty balloon surface.
- the drug can be placed into contact with diseased tissue in the blood vessel.
- the cage 10 can offer a physical barrier to protect the drug covering of the balloon 20 during advancement to the treatment location. In this way the cage 10 can be used such that balloon 20 and drug covering are exposed to blood flow in a vessel only during expansion of the balloon 20 as the space between the strips increases.
- the cage 10 can prevent or reduce the chances that the drug will become diluted or that the drug will treat areas of the body that are not meant for treatment. In some variants, this can allow for more controlled delivery of the drug with a reduction in the amount of drug necessary to be coated on the balloon 20.
- the folded balloon 20 can be positioned entirely within the cage 10.
- the cage 10 can have slits between each of the strips 16.
- the slits can be formed by cutting between each of the strips 16 to separate them from a single piece of material.
- the slits are really just the space between adjacent strips.
- the space between strips can be a minuscule amount, such as would formed by a laser cut, or much larger, such as equal to or greater than a width of the strip itself.
- the exposed surface of the balloon 20 in the pre-expansion position is not more than 50% and can be as low as 25%, 10%, 5%, 1%, or less.
- expansion of the balloon 20 moves the first 12 and second rings 14 closer together while moving the strips 16 further apart radially.
- the balloon 20 With the strips 16 in an expanded position, the balloon 20 is more exposed to and can interact with the vessel wall.
- the balloon 20 can deliver a drug, stem cells, or other treatment to the vessel wall or to a diseased area of the vessel wall.
- the exposed surface of the balloon 20 not covered by the strips 16 can be between 65% and 99%, 75% and 99%, more commonly 80% and 99%, or most commonly 90% and 99%, among other ranges.
- Drug delivery using the cage 10 can be employed before, during, or after an angioplasty procedure. At the same time, it is not required that the cage cover the entire balloon, or be used to control or assist with drug delivery.
- a cage 10 can be used to prevent or reduce dog boning of the balloon 20 in an angioplasty procedure. This may be in addition to, or instead of assisting with drug delivery.
- Figure 3 shows an angioplasty balloon 20 within a blood vessel 2 at a treatment site. As illustrated, the angioplasty balloon 20 is experiencing dog boning as it is expanding. The plaque buildup 4 resists expansion of the balloon 20, forcing both ends of the balloon 20 to expand first, rather than focusing the expansion energy in the center of the balloon 20 at the plaque 4 where it is needed most.
- the cage 10 as shown in Figure 1A can constrain the balloon 20 upon expansion to encourage the middle of balloon 20 to expand first. This is because the middle area of the cage 10 can be designed to have the least resistance to expansion, being farthest away from the ends where the strips are confined by rings. This can prevent or reduce dog boning of the balloon 20 independent of the disease morphology or arterial topography the balloon 20 is expanding within.
- Dog boning usually occurs where a balloon 20 expands in a vessel with plaque where the plaque resists expansion, forcing the ends of the balloon 20 to expand first (due to lack of resistance) such that the balloon 20 takes the shape of a dog bone.
- the ends of the balloon 20 can have the highest resistance and the center of the balloon 20 have the lowest resistance. Therefore, the cage 10 can help control and limit expansion of the balloon 20, as the balloon 20 will tend to expand more readily in the center which is typically the area of disease.
- the pattern and orientation of the strips 16 can influence expansion and dog boning.
- the short slits 22 positioned in the center of the strips 16 can reduce rigidity in the center of each of the strips 16. This can help reduce the likelihood of dog boning by further reducing resistance to expansion in the center of the cage 10.
- the cage may further include spikes or wedge dissectors on the strips.
- the spikes can be used as a vessel preparation tool before a secondary treatment, or during a primary treatment.
- the spikes can assist with cutting and/or perforating plaque before or during an angioplasty procedure. This may be in addition to, or instead of assisting with drug delivery and/or preventing dog boning. It will be understood that any of the embodiments described herein can provide any of these benefits and/or be used in any of these procedures, as well as the other benefits and procedures described herein.
- Spikes can be positioned on the strips in any number of different orientations and configurations as will be described further below.
- the spikes can be any of the spikes discussed in U.S. Patent No. 8,323,243 to Schneider et al. , issued 12/04/12.
- the spikes and cage can also be used in accordance with the plaque serration methods and other methods also described therein.
- the cage 10 can be made in many ways. For example, an extrusion process may be used, a tube may be cut, and/or a wire split as will be described in more detail below. Beginning with Figures 4A-5B , various embodiments of cages will be described. Figures 4A and 5A show embodiments of cages 10 during the manufacturing process.
- the cages 10 are each in the form of a tube with a plurality of splines 24 spaced apart on the tube.
- the tube can be pre-formed and then machined to the illustrated shape.
- the tube can be made of metal or plastic among other materials. In other embodiments, the tube is extruded to form the illustrated shape.
- a method of making the tube can include extruding a plastic tube with a plurality of spaced apart splines 24 positioned longitudinally along the tube.
- Cross-sections of the cages are shown in Figures 4B-D and 5A .
- the splines may be shaped to form different shaped spikes or wedge dissectors 26.
- the splines 24 illustrated in Figure 4B can be machined to form the sharp wedge dissectors 26 as shown in Figures 4C and 4D .
- the splines 24 can be manufactured with an additive process and shaped initially like the illustrated wedge dissectors 26 without requiring additional machining or other work.
- the strip 16 has been formed with a plurality of spikes or wedge dissectors 26.
- a slit can be cut in the tube to form adjacent strips.
- the wedge dissectors 26 can be shaped like a tent or axe head with an elongated tip and base, both of which extend longitudinally, along the longitudinal axis of the tube.
- the wedge dissectors 26 can assist with cutting and/or perforating plaque before or during an angioplasty procedure.
- the space between the wedge dissectors 26 can be machined or otherwise formed to remove material and increase the flexibility of the strip.
- the space between the wedge dissectors 26 is shown as being twice the length of the wedge dissector 26, though other spacing can also be used. Typically spacing length can be 4:1 to 3:1 space to length and more commonly 3:1 to 1:1 space to length.
- the splines 26 are fabricated from a tube of material, where the cage 10 is a plastic extruded tube with splines that are cut, ground, electrical discharge machined, or molded to form the wedge dissectors 26.
- the tube can be manufactured with slits along its length. In some examples, the ends of the tube remain intact in order to forming rings.
- the strips 16 are spaced apart with some or all the strips 16 having spikes or wedge dissectors 26. As will be understood from the above discussion, in the embodiments shown in Figures 4A-5B five slits would be made to form outward points.
- a method of making a cage 10 for an angioplasty balloon 20 can comprise first extruding a plastic tube with a plurality of spaced apart splines positioned longitudinally along the tube. In some examples, the method can then include cutting at least one of the splines of the plurality of splines to form a plurality of spikes or wedge dissectors 26 positioned circumferentially around the tube. In some variants, the method can further include cutting the tube to form a plurality of longitudinally extending strips 16, each strip including at least one spike of the plurality of wedge dissectors 26.
- a wire 28 can be split or cut to form three or more strips 16 that can be used as part of forming a cage 10.
- the wire 28 is constructed of an alloy, or polymeric material. Any number of different manufacturing methods can be used including laser cutting and electrical discharge machining.
- the wire 28 can be divided into sections, such as four quarters.
- square or other shaped holes 30 can be cut into the wire 28 to form spaces between the wedge dissectors 26. Each of the sections of wire can then be separated to form the strips 16 of the cage 10.
- a cage 10 can be assembled with a plurality of rings and include any number of strips 16.
- a cage 10 can be assembled from 1, 2, 3, 4, 5, 6, 7, 8 or more strips 16.
- Strips 16 can be attached in many ways to form the cage 10. In addition, to forming the strips from a wire, they can also be extruded and/or formed from a flat piece of material and/or a tube. For example, it will be understood that the embodiments described with reference to Figures 2 , 4A-5B can be modified to provide individual strips that can then be connected to form a cage.
- strips can be connected with two or more rings 12, 14 to form a cage 10.
- the individual strips of the cage 10 may be bonded to rings on either end.
- each individual strip 16 is secured on either end by rings 12, 14.
- the strips 16 can be attached to the rings 12, 14 first before positioning around a balloon, or the cage can be assembled around a balloon.
- one or more strips can be placed onto the surface of the balloon 20 before connecting to the rings.
- the cage 10 may be permanently fixed to one or both ends of the balloon 20 or to the balloon catheter.
- the rings 12, 14 can hold the strips against a portion of the balloon or the balloon catheter.
- the strips 16 can also help to keep the balloon 20 in a compressed state prior to deployment and can assist in deflating the balloon after expansion.
- the rings 12, 14 are typically circular bands, though they can be a band of any number of shapes including oval, square, elliptical, rectangular, etc.
- the rings can also be capable of producing a binding and/or restraining force.
- the rings 12, 14 can be any number of different materials including one or more of a metal, polymer, copolymer, elastomer, thermoplastic elastomer, glue, or hydrogel.
- the rings can be rigid or flexible.
- the rings 12, 14 can be composed of a heat shrink material or a material with elastic properties that binds, captures, or restrains the plurality of strips 16 and prevents or limits the strips 16 from moving, sliding, tilting or twisting at any point along the length of the strips but especially at either end of the balloon 20.
- the rings are elastic, super elastic, or thermally active, the rings can be placed about the strips and allowed to shrink onto the strips such that the strips 16 are retained against the outer diameter of the balloon 20.
- the rings and strips are positioned around a balloon in a fully expanded state and then heat is applied to the heat shrink type rings.
- the heat shrink types rings are applied with the balloon in a deflated state.
- the cage can be performed and slid onto the balloon. But, in some embodiments, assembling the cage around the balloon can allow for a smaller cage design.
- the rings can be advanced onto the balloon catheter from either side which may allow for a smaller ring inner dimension as compared to a cage with one ring that is advanced over a balloon.
- the rings 12, 14 of the cage 10 can be configured to accommodate the balloon 20 as it transitions from a deflated to an inflated shape.
- the strips 16 of the cage 10 can be in contact with the balloon 20 when the balloon 20 is in a deflated configuration. As the balloon 20 inflates, each strip 16 bows in a concave orientation with the balloon 20 ( Figure 1A ). In some examples, the strips 16 are free-floating and not bound to the balloon surface.
- the material properties of the strips 16 can allow it to begin to return to their original position. This may be a completely flat position. As the strips 16 return to their original position, this can provide an additional force to assist the deflation of the balloon 20. As the strips move from the concave position to a flat linear position, the strips 16 move from an expanded length ("L e ”) to a deflated length (“L d ”) where L d is longer than L e . The straightening of the strips 16 from L e to L d in the axial direction elongates the balloon 20 and assists in more complete balloon 20 deflation.
- the rings 12, 14 can come in a variety of shapes and sizes that can secure the plurality of strips 16. The following discussion of certain illustrated embodiments, are but a few such examples.
- each ring 12, 14 can be a two-part ring that can connect to one or more strips 16 of the cage 10 by rotating the rings in opposite directions (e.g. clockwise and counterclockwise).
- the rings 12, 14 can include holes 32, through which the strips 16 can be advanced to connect to the ring.
- the asymmetrical shape of the holes 32 can be configured to accommodate a strip 16 with periodically spaced wedge dissectors 26 such as that illustrated in Figure 6B .
- the holes 32 can have a narrowed portion 33 and a wider portion 34.
- the wider portion 34 can be configured to accommodate the wedge dissector 26 while the narrowed portion 33 can be configured to accommodate the width of the strip 16 (i.e. the space between wedge dissectors).
- the strips 16 can be advanced through the holes 32 by fitting a wedge dissector 26 through the wider portion 34.
- the strip 16 can then be secured by turning the rings 12, 14 such that the strip 16 is moved into the narrowed portion 33. This can secure the strips 16 to the rings 12, 14 as the wedge dissector 26 cannot move past the narrowed portion 33.
- both rings 12, 14 can be present at either end of the cage 10. Additionally, as illustrated in Figure 8 , because the holes 32 of the ring 12 and the holes 32 of the ring 14 are opposed, by rotating the two parts of the ring in opposite directions, this further prevents movement of the strips 16.
- the strips 16 can be secured by rings 12, 14 that are formed from a variety of shapes.
- Figure 9A illustrates an embodiment of the cage 10 where the strips 16 are secured with a conical ring 12 at the distal end.
- the conical end can be the distal end of the balloon catheter and can provide an atraumatic end of the device.
- Figure 9B shows a ring 12 with a tapered outer diameter with a screw feature 101 on its outer surface.
- This screw feature 101 can provide either a negative or positive impression about the outer surface of the distal ring.
- the ring 12 illustrated in Figure 9B can serve a treatment purpose as well.
- the tapered and screw features on the ring can assist the balloon 20 in navigating and entering a narrow lesion.
- the coiled outer surface 101 can be configured to provide a gripping or tunneling mechanism. This feature can allow the ring to aid the operator in navigating through occluded lesions (either totally or partially) and enable passage of the balloon 20 therein.
- the negative or positive impression 101 can be circumferential or patterned like a cork screw. In some embodiments, the negative or positive impression 101 can be macro in scale or have micro features that offer an enhanced surface to enable passage through a narrowing in a vessel.
- the function of the outer surface 101 of the ring can be described as acting like a lubricant although the feature is mechanical in nature. This function can be further enhanced with hydrophilic, hydrophobic coating.
- the surface texture can also be modified to aid in passages with less penetration energy. In some embodiments, this can be accomplished by adding micro scales (as seen in porcupine quills) or enhanced surface roughness (as used in nature by mosquitos).
- the ring 12 illustrated in Figure 9B can be secured to strips 16 that are disposed about the surface of the balloon circumferentially in a helical fashion.
- the strips 16 attached to the tapered ring 12 can be wound around the balloon.
- a tapered or untampered ring 14 can be used at the proximal end of the balloon.
- the configuration of the attached strips 16 can follow the same pattern as the negative or positive impression 101 on the ring 12.
- a ring with multiple layers can be used to hold the strips between the layers.
- the ring can have at least a base layer 122 and a top layer 121.
- the ring 12, 14 can have a non-compressible bottom layer 122 and a compressible, thermally or electrostatically compressible layer 121.
- the top layer 121 can be configured of a compressible material while the base layer 122 can be configured of a non-compressible material and the strips 16 can be captured between them.
- the top layer or the top and base layers can be made from a heat shrink material.
- the ring 12, 14 can be formed from lengths of materials that are wound around themselves to form a layer of ring.
- the rings can be made of a layer of composite materials where the base layer 122 is less compressible or elastic than the top layer 121. Energy can be added to the top layer 121 to produce a reduction in the top layer's diameter until the top layer compresses and captures the strips between the base layer 122.
- the top layer 121 can be a heat shrink material.
- the top layer 121, base layer 122 and strips 16 can form a cage 10 as seen in Figures 10 and 11 .
- the strips can be attached to the balloon and/or balloon catheter with the rings that are made of a single layer of heat shrink material positioned over the strips similar to just the top layer.
- the strips or rings can include indentations to facilitate attachment to the other.
- the strip 16 can include an indentation 171 on either side of the strip 16 (as illustrated in Figure 10 ) or an indentation 171 on one surface of the strip 16 that can form a groove (as illustrated in Figure 11 ).
- the top layer 121 is shown as a heat shrink material, it will be understood that in other embodiments a rigid ring could be press fit into the indentation 171. Such a rigid ring could be part of a single or multiple layer ring, thus there may or may not be a corresponding base layer 122.
- Figure 12 illustrates another embodiment of the ring 12, 14.
- the ring 12, 14 can include a plurality of indentations or grooves 17.
- the grooves 17 can have a width that can accommodate the width of the distal end of strip 16.
- An end of a strip can be attached to the ring 12, 14 in the grooves 17 through the use of adhesive, mechanical coupling, wrapping heat shrink material around the ring, etc.
- the strip 16 of Figure 11 can be placed in the ring 12, 14 of Figure 12 so that the indentations are engaged with each other.
- Figures 13A-C illustrate examples of a strip 16 that includes an securement feature 181 that improves the hold of the strips 16 to the rings 12, 14.
- the securement feature 181 forms a section of the strip 16 with a higher surface roughness. This can be in the form of the illustrated ridges or other teeth-like elements that aid in the imbedding of the strip 16 into or holding the strip on the ring.
- the securement feature 181 can be formed as narrow sections of the strip 16 at the ends (as illustrated in Figure 13A-B ), or placed strategically along the strip length (such as where three or more rings are used).
- the securement feature 181 can be aligned with the rings 12, 14.
- the securement feature 181 can be pressed into the polymeric material as illustrated in Figure 13A at a high temperature where the polymeric material is near or greater than the glass transition temperature of the material. In so doing the securement feature 181 can be used to engage or connect the strips 16 to the rings 12, 14 as illustrated in Figure 13C .
- Figure 13A the ring 12, 14 is shown to incorporate the securement feature 181 into the body of the ring material.
- Figure 13A shows the strip 16 with a ridged hook feature 181 before it is pressed into the ring material.
- Figure 13B shows a perspective view of another embodiment of securement feature 181.
- the securement feature 181 can be significantly longer than the ring 12, 14 is wide and be designed to provide tension on the cage 10.
- the ring 12, 14 When the ring 12, 14 is made from an elastic material, such as rubber or polymer, or metallic alloy or a design with elastic properties like a spring, the ring 12, 14 can be used to provide tension on the cage 10 to enable the cage 10 to return to the relaxed, deflated balloon 20 position. Furthermore, the portion of the strips 16 without a wedge dissector is the thinnest and the most flexible. This can allow the strip 16 to be the most flexible at the edge of the balloon 20 where the forces are the highest.
- an elastic material such as rubber or polymer, or metallic alloy or a design with elastic properties like a spring
- FIGS 13D-F illustrate an example where the elastic material of a ring can provide tension on a cage during expansion and to then assist in deflating the balloon as the tension is released.
- the cage 10 is disposed about the balloon 20.
- the cage 10 can be composed of a plurality of strips 16 that are secured to the balloon by rings 12, 14.
- the rings 12, 14 can be made from long elastic material that can aid in pulling the strips 16 down into a linear position such that the wedge dissectors are perpendicular to the surface of the balloon 20.
- Callout "A" provides a schematic, see-through view of the proximal end of ring 14. As shown, ring 14 is secured about the outer catheter shaft 22 by an adhesive 23.
- an inner guidewire shaft 21 can run concentric to the balloon 20.
- the guidewire shaft 21 can be secured with relationship to the catheter shaft 22.
- the guidewire shaft 21 and the catheter shaft 22 can both be connected to different ports on a hub, such as the illustrated bifurcated luer at the proximal end of the balloon catheter.
- the balloon can be inflated by injecting a fluid into the catheter shaft. It will be understood that in some embodiments the catheter shaft 22 open directly inside the balloon 20, rather than opening at the ring 14 as shown.
- the ring can be attached to the catheter shaft 22 and/or the balloon 20.
- Figures 13E-F illustrate a balloon 20 and cage 10 as the balloon 20 is inflated and subsequently deflated.
- the elastic material of the rings 12, 14 can stretch to allow the cage 10 to expand as the balloon 20 is inflated.
- the rings can be made of an elastic polymer and the strips can be made of metal or an inelastic polymer.
- the strips 16 of the cage 10 begin to move apart. In order to push each of the strips 16 outward, force is exerted radially outwards (as illustrated by the arrows) on the balloon 20 - and by extension the cage 10 - as the balloon 20 is inflated.
- the rings 12, 14 are under tension and able to stretch enough to allow the strips 16 to maintain alignment while expanding with the balloon 20.
- This tension can also help the balloon 20 to deflate.
- the tension on the strips 16 exerts a force radially inward as the strips 16 and the rings 12, 14 tend to want to return to a relaxed state. This force pulls on the strips 16 and allowing them to flatten, thereby providing a narrowed profile for catheter retraction.
- the ring can be fabricated from the lip on the neck of the balloon 20 and the portion of the catheter body used to bond the catheter to the balloon 20.
- the catheter can provide a pathway for gas or liquid inflation of the balloon 20. Additional components such as an over mold or heat shrink can be added to the bond joint, as can additive glue or polymeric material. In some examples, this can serve to prevent pressure from leaking out of the balloon 20 along the length of the strips 16 forming the cage 10.
- a hook 161 at the strip end can enable the strip to be easily aligned along the balloon surface and can aid in orienting the strip in a longitudinal orientation relative to the axis of the balloon 20.
- the hook 161 can be integrated into each end of the strip 16.
- the hook 161 can be wrapped around the lip of the neck of the balloon 20 from the outer diameter ("OD") of the balloon 20 neck around the opening and into the neck where the end of the hook 161 rests within the inner diameter (“ID”) of the balloon 20 neck.
- Both ends of the strip 16 can have a hook 161, or just one end can have the hook.
- the ends can be attached to the balloon catheter in the same or in different ways.
- heat shrink can be wrapped around the ends of the strips and balloon.
- heat shrink is wrapped around one end and a rigid ring, such as those discussed with respect to Figures 8-12 can be used at the other end, which may also include a heat shrink layer.
- the strip may or may not be attached to the balloon at other locations.
- the strip 16 can also have hinges or pre-bent regions that correspond with the shape of the balloon.
- the strip in the expanded state can have a main portion having wedge dissectors 26 that is parallel with the axis of the balloon.
- Angled sections can extend from the main portion to the hooks 161. The angled sections can form an angle when the balloon is expanded as shown, but can be flat when the balloon is deflated.
- hinges between the sections can be formed with thinner sections of material.
- the strip can attach to the balloon without a separate ring by use of the hooks 161.
- the balloon can be glued to a catheter (for example an elongated tube with one or more lumen) which can also secure the hook in place.
- Figure 14A shows one strip for simplicity, though it will be understood that 2, 3, 4 ( Figure 14B ), 5, or more strips could be used.
- Figure 14C shows a detail view of the hook 161 attaching to a balloon 20.
- the balloon can serve as a base layer 122 of the ring and a top layer 122 is also shown.
- Adhesive 123 is also shown securing the top layer 121 to the balloon.
- the top layer 121 can be the tube of the catheter.
- Figure 14D shows a two layer 121, 122 ring.
- the two-layer ring can include two layers of heat shrink material.
- the ring illustrated in Figure 14D can be a multi-layer ring where the base layer 122 is less compressible or elastic than the top layer 121 and where energy is added to the top layer producing a reduction in the top layer's diameter until the top layer compresses and captures the strips between the base layer 122 and the top layer 121 to produce the cage 10.
- Figure 14E illustrates another embodiment of the rings 12, 14 that secure the strips 16 on the surface of the balloon 20.
- the rings 12, 14 can be secured to the balloon 20 such that the wedge dissectors protrude through the surface of the rings 12, 14.
- Callout "A” includes a cut away of the ring 12, 14 in the center in order to show the strip 16 below.
- the wedge dissectors can protrude through the rings 12, 14 in a variety of ways.
- the shape of the wedge dissector can cut through the material of the rings 12, 14 as the rings 12, 14 are secured to the strips 16. This can form a hole 27.
- the rings 12, 14 can also have a plurality of holes 27 pre-cut into the rings 12, 14 to allow the wedge dissectors to extend through.
- the rings 12, 14 can be shaped to correspond with the taper of the balloon 20.
- cutouts 29 of material in the rings can help a ring made of heat shrink material to shrink to the shape of the balloon.
- each of the strips 16 can extend between one or two rings, though additional rings can be used as needed. For example, three, four, five, six, seven, eight, nine, or ten, or more rings can be used, especially with longer balloons.
- an angioplasty balloon 20 having a length of 300 mm can be fitted with a cage 10 having two rings 12 and 14 at either end.
- the cage 10 can include rings 13 or other similar controlling elements that can aid the strips 16 in maintaining alignment and orientation as the balloon 20 expands towards the artery wall.
- the rings 13 can be a fraction of the overall length of the balloon 20. Some ring 13 designs are less than one and a half times the length of the balloon 20. In other examples, the rings are between 1.0-0.5 times the balloon 20 length. More commonly the length of the rings 13 are between 2.5 and 1.5 times the balloon 20 diameter and typically between 1.5 and 0.5 times the balloon 20 diameter. Each ring 12, 13, 14 can be made from a different material so at to provide more than one advantage and function of the rings 12, 13, 14.
- the rings 13 can be placed on the outer surface of the body of the balloon 20.
- the rings 13 can be designed to retain the body of the strips 16 such that the position and orientation of the strips 16 are maintained. It can also be seen, that the strip 16 does not extend along the shoulders of the balloon. Thus, the strip can be elongated and can extend parallel with the axis of the balloon.
- Figure 15A shows one strip 16 for simplicity, though it will be understood that 2, 3, 4, 5, or more strips could be used.
- rings 13 can be positioned over the expanded balloon 20 area and may have different properties than the rings 12, 14 on either end of the balloon 20. As illustrated in Figure 15A , in some embodiments, the rings 13 positioned over the balloon 20 surface may be more elastic in property than those located on the ends of the balloon 20. This can allow the rings to accommodate the expansion and refolding of the balloon 20. In some examples, the rings used on the outer diameter of the balloon 20 are placed over the two ends of each separated strip. The strips 16 may also be glued, welded, restrained by friction fit, or otherwise attached to any of the rings described above.
- rows of strips and/or strip segments can be placed around the balloon 20. Some rows may extend over the entire length of the balloon 20 and other rows may not. In some examples, a row may include a plurality of strips in series that are separated by gaps. Placing strips in a series on the balloon can provide greater flexibility which can improve deliverability through tortuous anatomy.
- rings 12, 14, 13 can be used to retain the strip on the surface of the balloon 20.
- the rings can be connected to the strips in any number of different ways, as described in the various embodiments herein.
- the ends of the strips 16 with no wedge dissectors can be used to attach to the rings. In other embodiments, the ends with wedge dissectors can attach to the rings.
- FIG 15B illustrates another embodiment of balloon catheter.
- a balloon 20 is shown with a cage 10 with four equally spaced rows of strips 16. Each row has two strips 16 that are laid in series.
- a ring 13 attaches the adjacent strips 16 to properly secure and orient the strips 16 across the surface of the balloon 20. Rings 12, 14 hold down the other ends of the strips.
- the callout "A” provides an enlarged view of the distal end of the balloon 20 with cage 10.
- the hatching illustrated in callout “A” is provided to help visualize and delineate the different parts of the device.
- the end of the balloon 20 includes a ring 12 that secures a plurality of strips 16 to the surface of the balloon 20.
- the balloon 20 is disposed about a catheter 19.
- the ring 12 can be a heat shrink material.
- a wedge dissector is also shown extending through the ring.
- the placement of the strips is further clarified in Figure 15C which shows how a pair of strips 16 which are laid in series such that the strips 16 span the length of the balloon 20.
- the cage 10 can have rows that are made up of a greater number of strips 16 than illustrated in Figures 15B and 15C .
- Figures 15D-15E illustrate an example where five strips 16 are laid across the surface of the balloon 20 in series. As noted previously, each of these strips 16 can be secured on the surface of the balloon 20 by a plurality of rings 13. Callout "A" provides a cut away of the ring 13 to show the gap between the two strips 16 that are in series.
- the wedge dissector can protrude through the ring 13 in a variety of ways. For example, the shape of the wedge dissector can cause the wedge dissector to poke through the material of the ring 13. As well, the ring 13 can have a plurality of holes cut into the rings 13 to allow the wedge dissectors to poke through.
- the gap between the strips in a row can also be adjusted to increase flexibility.
- the linear alignment in the theta direction around the radius (angle drift) and the spacing alignment between the strips 16 (gap) can have a relatively broad tolerance creating greater options in developing the manufacturing process and choosing tools.
- the gap tolerance can be ⁇ 5 mm and the angle drift ⁇ 25 degrees; ⁇ 3 mm and the angle drift ⁇ 10 degrees; and ⁇ 2 mm and the angle drift ⁇ 5 degrees.
- Cage designs that require greater tortuosity can utilize the periodic strip placements in a linear sequence with spaced apart strips. This can enable the balloon to manage bends and turns in anatomical spaces with less stress on the strips and more effective pushability of the entire system.
- the strips 16 have a flat bottom. This can help the strips 16 sit on the surface of the balloon and to maintain the orientation of the wedge dissectors. This can prevent rotational movement of the strips 16 on the surface of the balloon 20.
- strips typically have a flat bottom, are bounding to the balloon with rings on either end of the strip, are folded to limit wedge dissector interaction with tissue on its journey, and when a ring lays over the wedge dissectors the wedge dissectors poke through the rings and the majority of the wedge dissector height is still available for penetration into the vessel.
- rings to produce forces on the balloon enabling more effective balloon deflation by either pulling on the strips end to end or by applying radial compression
- the rings can support the strips by limiting strip movement, aiding in wedge dissector orientation, and preventing the strips from separating from the balloon.
- Design features that contribute to these functional characteristics include: strips that have flat bottoms enabling stable orientation of the wedge dissectors but are thin enough to be laid down tangential to the balloon or contained in a fold of the balloon during folding, spacing between the wedge dissectors does not have a cutting edge enabling rings to lay in the spacing and support strip retention, and the ends of the strips can be thinnest with no wedge dissectors enabling greater surface area for rings to bond to the strip and enabling the strip to be most flexible at the edge of the balloon where forces are highest during catheter migration to and from site of deployment. It will be understood that other benefits and advantages can also be provided.
- the rings 12, 13, 14 can be attached to the strips 16 in a variety of ways.
- Figures 16A-C shows examples of the rings 12, 13, 14 secured to the strips 16.
- Figure 16A shows a material wrapped around the balloon to form rings 12, 13, 14 such that the material of the ring can be secured to more than one strip.
- the ring 12, 13, 14 can be wrapped about a portion of each strip. This can be accomplished in the same way as illustrated in Figure 10 , where each of the rings can have an upper layer and bottom layer that wraps around a portion of the strip 16.
- Figure 16C illustrates a solid ring 12, 13, 14 that can be attached to a portion of the balloon. A portion of the strip can be secured to the ring.
- Heat shrink material generally starts from an extruded tube that is cross-linked using a form of radiation.
- the tube can be stretched or otherwise formed to the desired thickness.
- it can be stretched to a flexible microscopically-thin-wall tubing, it can be made rigid from a heavy-wall tubing, or it can be somewhere in-between.
- Cross-linking can create a diameter memory and can be designed with a shrink ratio from 2:1 up to 10:1. Heat shrink typically shrinks only in the radial direction but can also shrink in length.
- Heat shrink material can be manufactured from a thermoplastic material, such as polyolefin, fluoropolymer (including fluorinated ethylene-propylene (FEP), polytetrafluoroethylene (PTFE) or polyvinylidene fluoride (PVDF)(e.g. KYNAR)), polyvinyl chloride (PVC), neoprene, silicone, elastomer or synthetic rubber and fluoropolymer elastomer (e.g. VITON).
- a thermoplastic material such as polyolefin, fluoropolymer (including fluorinated ethylene-propylene (FEP), polytetrafluoroethylene (PTFE) or polyvinylidene fluoride (PVDF)(e.g. KYNAR)), polyvinyl chloride (PVC), neoprene, silicone, elastomer or synthetic rubber and fluoropolymer elastomer (e.g. VITON).
- Heat shrink material in the form of a tube can be used to slide onto or over the strips 16.
- the tube can have a shrink ratio of 3:1 or higher (e.g. 3.5:1, 4:1, 4.5:1, 5:1, 6:1) and allow for gentle heat shrinking to prevent any balloon deformation or other changing of the balloon's properties.
- the material can be flexible enough to conform to the balloon through a range of balloon diameters (such as typical with semi-compliant balloon technology ⁇ .5mm diameter range), and may have an adhesive or other coating to support the bonding of the heat shrink material and balloon.
- the heat shrink material can be a thin film.
- the heat shrink material may also be in the form of a sheet or multiple sheets instead of a tube.
- a method of retrofitting a balloon catheter with a cage can include any of the following steps. Positioning strips around an inflated balloon.
- the strips may include wedge dissectors.
- the strips can be positioned equally spaced around the inflated balloon.
- the strips can extend primarily longitudinally.
- the strips may be positioned serially in rows, such as 2-6 rows, each with 2-6 strips.
- the strips can be attached either permanently or temporarily to the balloon with an adhesive.
- Heat shrink material can be positioned around the ends of the strips as a ring. Individual rings of heat shrink material can connect to or cover ends of multiple strips positioned circumferentially around the balloon. Individual rings of heat shrink material can also connect to or cover ends of adjacent strips positioned serially in a row. Heat can then be applied to shrink the heat shrink material.
- the balloon can be deflated and then sterilized in preparation for use.
- the strip 16 is shown having a section 34 composed of a spring zone.
- the spring section of the strip 16 can provide a plurality of benefits.
- the spring section 34 can increase the flexibility of the cage 10. Increasing the flexibility of the cage 10 can allow the cage 10 to more easily pass through the tortuous geometry of a blood vessel.
- the spring section 34 can also provide a wider base for the wedge dissectors 26, to help the wedge dissectors 26 remain in the desired orientation.
- the spring section 34 can interface with a surface of the balloon 20.
- the spring section can help the strip 16 to remain in the correct position with the wedge dissectors 26 in an outwardly projecting orientation.
- the spring section can counteract a sideways bending moment on the spike such that the wedge dissectors 26 do not bend, flex, or change position an undesirable amount.
- the spring section 34 can also provide the benefit of assisting the balloon 20 in refolding post inflation.
- the spring can add mechanical tension on the balloon 20 to return it to a compressed state and further aid the rings in compressing the balloon 20 during deflation cycles.
- the spring section 34 can have an undulating configuration and be connected to a straight section 36.
- the wedge dissectors 26 can be located on the straight section.
- the spring section can be sinusoidal. As illustrated in Figure 18 , the spring section is shown having a larger amplitude at the proximal end as compared to the distal end. The amplitude can decrease while the period increases along the spring section towards the straight section in a distal direction.
- one side of the spring section can have a larger amplitude than the opposite side.
- the spring section can be symmetrical.
- Figure 18 illustrates various embodiments of the cage 10 utilizing the spring section 34 and straight section 36. Any number of different patterns can be used.
- Figure 19 shows a detail of wedge dissectors 26 on straight sections 36.
- Systems and methods as disclosed herein can deploy the cages and wedge dissectors in any body lumen, including vascular lumens such as arteries and veins.
- the arteries could be coronary arteries, peripheral arteries, or carotid or other cerebral arteries, for example, or iliac, femoral, superficial femoral, iliac, or other peripheral vasculature, for example.
- the device may also be used in any lumen or transportation vessel found in any of the respiratory, digestive, urinary, reproductive, lymphatic, auditory, optical, or endocrine systems. It is understood that a device for generating serrations in any one, two, or more of these systems may take slightly different forms.
- some embodiments of devices include spikes (also herein referred to as wedge dissectors, or serrating elements on a spline and an expandable mechanism to increase and decrease the diameter of the spike features (such as a balloon) with both attached to a base catheter-like device.
- spikes also herein referred to as wedge dissectors, or serrating elements on a spline
- an expandable mechanism to increase and decrease the diameter of the spike features such as a balloon
- a wedge dissector 200 can include a strip-facing base surface 202 (which may also be referred to herein as a bounded surface).
- the strip-facing base surface 202 of the wedge dissector 200 can be defined by the base where the wedges 200 protrude outward and directly continuous with a surface of the strip at the interface between the wedge dissectors and the balloon.
- the strip could be a spline 300 or other strip-like structure.
- this strip-facing base surface 202 has a relatively narrow width made of a hard material capable of holding a sharp edge.
- the preferred material is martensitic stainless steel, with a hardness of 52 to 64 on the Rockwell C-scale (HRC) although other materials including a polymer or co-polymer including but not limited to polyolefin, fluoropolymer (including fluorinated ethylene-propylene (FEP), polytetrafluoroethylene (PTFE) or polyvinylidene fluoride (PVDF)(e.g. KYNAR)), polyvinyl chloride (PVC), neoprene, silicone, elastomer or synthetic rubber and fluoropolymer elastomer (e.g. VITON), or a combination thereof can be utilized.
- FEP fluorinated ethylene-propylene
- PTFE polytetrafluoroethylene
- PVDF polyvinylidene fluoride
- PVC polyvinyl chloride
- neoprene silicone
- the strip is about or no more than about .008", .010", or .012" (0.203mm, 2.54mm, 3.048mm) wide (oriented circumferentially).
- the width can be between about .006" and about .020" (0.152mm and about 0.508mm) or between about .004" and about .030" (0.102mm and about 0.762mm) .
- the strip 300 typically runs longitudinally the length of the working balloon edge, but can also be oriented in angles up to and including 90 degrees from the longitudinal axis of the balloon (or other expandable structure), or in a helical fashion at varying pitches.
- the height of the base strip 300 can be between about .004" and about .01 “ (0.102mm and about 0.254mm), or between about .002". and about .020" (0.051mm and about 0.508mm) in some embodiments.
- a wedge dissector 200 can also include a radially outwardly facing surface 204 (which may be referred to herein as an unbounded surface) that can define a top surface of the wedge dissector 200 from first (e.g., proximal) edge 206 to second (e.g., distal) edge 208 and be configured to contact tissue, plaques, or other structures within the body. Also shown are anterior surface 210, posterior surface 212, and opposing lateral surfaces 214 and 216.
- the lateral surfaces 214, 216 extend upward generally perpendicular to the longitudinal axes of the strips, and the radially outward facing surface extends between the lateral surfaces as a linear, curved, or other geometry as described elsewhere herein at an angle to the lateral surface/lateral surface axis.
- strips or splines 300 having an unbounded (e.g., superior-facing) surface 302 that can be coextensive with the strip-facing surface or boundary 202 of the wedge dissector 200, as well as side surfaces (e.g., 304), and inferior-facing surface 303.
- Figure 21 is a schematic illustrating several possible non-limiting embodiments of a wedge dissector.
- the length of the radially outwardly facing surface L U (e.g., radially outwardly facing surface 204 between first edge 206 and second edge 208 of Figure 20 ) is between about 30%, 20%, or 10% less than the total length of the strip-facing surface L B (of strip-facing surface 202 in Figure 20 ).
- the radially outwardly facing surface length L U can be from about 50% to about 20% less than the strip-facing surface length L B , and sometimes as large as the strip-facing surface length L B .
- the radially outwardly facing surface width W U is in some cases equal to or less than the strip-facing surface width W B, , and typically between or less than about 10%, 20%, 30%, 40%, or 50% of the strip-facing surface width W B , or between about 20% and about to 50% less than the strip-facing surface width W B , and sometimes about or up to about 50%, 60%, 70%, 75%, or 80% of the strip-facing surface width W B . Therefore, in some embodiments there is an angle ⁇ that is equal to or less than about 90 degrees that defines the slope from the strip-facing surface width W B to the radially outwardly facing surface width W U on at least one of the strip-facing surface width W B edges.
- the radially outwardly facing surface width W U is constant from edge to edge, in some embodiments the radially outwardly facing surface width W U varies along the radially outwardly facing surface length L U as described elsewhere herein, such as decreasing from a first lateral edge to a point or segment in between the first lateral edge and the second lateral edge of the radially outwardly facing surface segment, and then increasing, from the point or segment in between the proximal edge and the distal edge, to the distal edge.
- the relatively central segment in between the proximal edge and the distal edge has a constant width, while the lateral segments surrounding relatively central segment have variable, such as tapered widths.
- the radially outward facing width W U can come to a point, sloping from the strip-facing base width W B of the strip-facing base surface 202 to the radially outward facing width W U of the radially outward facing surface 204 in a single, constant sloped angle ⁇ or bevel such as shown in Figure 22A (end view resembling an isosceles triangle) and Figure 22B (isometric view), it can also in some embodiments include a plurality of different angles, such as more than a single slope angle such as a double, triple or more bevel (e.g., a first angle for a first segment of the height, a second angle for a second part of the height that can be less than or greater than the first angle, and in some cases a third angle for a third part of the height that can be less than or greater than the first angle, and less than or greater than the second angle).
- a single slope angle such as a double, triple or more bevel
- Figure 22C illustrates an end view
- Figure 22D illustrates an isometric view of a wedge dissector with a plurality of differing slopes and associated angles from the strip-facing base surface to the radially outward facing surface, where the angle ⁇ 2 between horizontal and an upward slope after a transition point is greater than an angle ⁇ 1 between the horizontal strip-facing base edge and the intersecting upward slope (in other words, the first slope S1 from the strip-facing base edge base is less steep than a second slope S2 higher up after a transition point).
- Figures 22E and 22F illustrate an embodiment similar to Figures 22C and 22D except the angle ⁇ 2 is less than the angle ⁇ 1 (in other words, the first slope S1 from the strip-facing base edge base is steeper than a second slope S2 higher up after a transition point).
- some embodiments may also include a series of steps at different heights where the width transitions to a narrower width and then continues to climb in height.
- a series of steps is used in place of the bevel it can sometimes be due to fabrication limitation when methods other than a reel of stainless steel is honed to an edge.
- the shapes of the radially outward facing edge or surface can in some embodiments be the same height from one edge 206 of the radially outward facing length or width to the other edge 208. In some embodiments, the height along the radially outward facing surface 204 can vary from one edge 206 to the other edge 208.
- the radially outward facing edge or surface 204 typically the radially outward facing edge has a series of raised features herein referred to as wedge dissectors, spikes, or serrating elements 200.
- the midpoint of these raised features along the radially outward facing length 204 between edges 206, 208 is the highest point of the radially outward facing surface.
- the highest point is offset from the midpoint, and there may be a plurality of highest points interspersed by lower point relative to the bounded/base surface 202.
- the maximal variation of height between edges 206, 208 of the radially outward facing surface 204 of the wedge dissectors 200 and the radially outward facing surface 302 of the base strip 300 between the wedge dissectors 200 can in some embodiments be less than about 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, or less than the total height of the wedge dissector 200.
- the base strip 300 has a roughened or otherwise textured inferior surface to aid in adhesion to an outer surface of the underlying balloon.
- the base strip can have any desired geometry such as square, rectangular, or in some embodiments trapezoidal with the bottom surface having a greater width, such as about or at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more of the top surface.
- between about 1/3 and 1 ⁇ 2 of the top surface of the strip 300 is covered by wedge dissectors 200, while between about 1 ⁇ 2 and 2/3 of the top surface are free of wedge dissectors 200.
- the radially outward facing surface viewed from the top can be seen as a line extending from one edge of the radially outward facing length to the other edge of the radially outward facing length (e.g., where Wu is a point assuming 210A is the radially outward facing surface of the device). This would be analogous to a honed or "razor-sharpened" edge with no apparent width.
- the top view appears as an unhoned surface that is slightly blunt resembling a rectangle (e.g., if 210B or 210C is the top of the device, and assuming everything above those lines were cut off) with the width of the radially outward facing surface Wu being less than the strip-facing base surface W B but directly correlated with the slope or slopes between the width edge and height from the strip-facing base surface to the radially outward facing surface.
- the top or the radially outward facing surface can be a line, a flat rectangle, a rounded or mounded surface (that might appear to be a rectangle or square in a 2-dimension point of view), or take a pyramidal, wedge, trapezoidal, or other polygonal shape.
- an unhoned width can be a width, for example, that is about or greater than about 1nm, 5nm, 10nm, 50nm, 100nm, 500nm, 1 ⁇ m, 2 ⁇ m, 5 ⁇ m, or 10 ⁇ m.
- unhoned radially outward facing surfaces of wedge dissectors can be advantageous as being slightly blunt/relatively less sharp than honed edges, in situations for example where creating serrations, indentations, and/or microperforations in a wedge dissector target, for example, is desirable rather than making cuts through the entire luminal wall.
- the entire radially outward facing wedge dissector surface has an unhoned width.
- FIG. 21A illustrates wedge dissectors 200 rising from a base strip 300 with a honed/sharp radially outward facing surface 204 from edge 206 to edge 208.
- Figure 21B-21C illustrates wedge dissectors with chamfered segments 780 of a radially outward facing surface on both lateral edges that slope or otherwise ramp upward to a honed central single point 782 or edge having a length 781. The slope could be a straight line ramp, or follow a curve as seen in Figure 21D below.
- the wedge dissector includes lateral segments 780 of radially outward facing surface that increases in height, but decreases in width from a first edge to a central mid-portion 781 having a length with minimal/negligible width, and then increases in width and decreases in width from the midpoint to the second edge.
- Figure 21C illustrates a wedge dissector similar to Figure 21B except that the mid-portion is a single honed apex point 782.
- Figure 21D illustrates a wedge dissector with a radiused radially outward facing surface 785 that increases in height from an edge along a first curved length but decreases in width from a first edge to a central zone such as a midpoint 786, then decreases in height and increases in width along a second curved length to another edge.
- Figures 21E-21G illustrate embodiments of wedge dissectors with an unhoned, radially outward facing surface that do not include a sharp honed point or edge (e.g., having a width that is larger than that of a honed edge).
- Figure 21E illustrates an embodiment of a wedge dissector somewhat similar to that of Figure 21B , except the radially outward facing surface is completely unhoned along its length.
- Figure 21F illustrates an embodiment of a wedge dissector somewhat similar to that of Figure 21C , except the radially outward facing surface is completely unhoned along its length.
- Figure 21G illustrates an embodiment of a wedge dissector somewhat similar to that of Figure 21D , except the radially outward facing surface is completely unhoned along its length.
- the widths of the radially outward facing surfaces are greater (wider) at the lateral edges, and narrower/less wide more centrally, either at a central point or longer central segment.
- the height of the radially outward facing surface from one edge to the other edge can be arched or otherwise variable, e.g., with a highest point more centrally and the shortest height at one or more edges when viewed from the side.
- the orientation of the narrowest or thinnest (least wide) section of the radially outward facing surface can be along the longitudinal axis of the strip, which may or may not be aligned with the longitudinal axis of the balloon.
- the narrower point or segment need not be symmetric about the midpoint of the length of the radially outward facing surface, but can be asymmetrical/offset from the midpoint of the length in some cases.
- some embodiments are characterized by having a bounded end 202 or base (e.g., the spikes have a base the spikes are "attached" to, whether it is a spline (or strip), a balloon, or a molded element of some sort) with a length and width and an radially outward facing surface 204, end or tip with a length and width.
- the width of the radially outward facing end is about, or less than about 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, or less than the width of the strip-facing base end, or ranges incorporating any of two of the foregoing values.
- the width of the strip-facing base end of the wedge dissector (as well as the spline/strip) can be fixed/constant, or alternatively variable in some embodiments.
- the wedge dissectors can be a number of different sizes and shapes.
- the wedge dissectors are about or less than about, for example, 0.10", 0.09", 0.08", 0.07", 0.06", 0.05", 0.04", 0.03", 0.02", or 0.01" (2.54mm, 2.286mm, 2.032mm, 1.78mm, 1.52mm, 1.27mm, 1.02mm, 0.762mm, 0.508mm or 0.254mm) in length at the strip-facing base end or ranges incorporating any of two of the foregoing values, or between about 0.01" and about 0.06", or between about 0.01" and about 0.04' (0.254mm and about 1.52mm, or between about 0.254mm and about 1.02mm) ' in length.
- the wedge dissectors can be about or less than about 0.05", 0.04", 0.03", 0.025", 0.02", 0.015", 0.01", or 0.005" (1.27mm, 1.02mm, 0.762mm, 0.52mm, 0.508mm, 0.284mm, 0.254mm or 0.127mm) in height as measured from the unbonded edge of the base strip, or between about 0.005" and about 0.025" or between about 0.01" and about 0.025", or between about 0.005" and about 0.015' (between about 0.127mm and about 0.52mm or between about 0.254mm and about 0.52mm or between about 0.127mm and about 0.284mm) ' in some embodiments.
- the wedge dissectors can, in some embodiments, have a wedge strip-facing base length of about, or less than about 25mm, 20mm, 15mm, 14mm, 13mm, 12mm, 11mm, 10mm, 9mm, 8mm, 7mm, 6mm, 5mm, 4mm, 3mm, 2mm, or 1mm long, or ranges incorporating any two or more of the foregoing values.
- the wedge dissectors have a wedge strip-facing base length of 2mm, 2.5mm, or 3mm long, or between about 1mm and about 5mm long, or between about 1.5mm and about 3.5mm long.
- the wedge dissectors can be spaced apart in a regular or irregular fashion to increase the flexibility of the device.
- the space between adjacent wedge dissectors can be, for example, between about 2 times to about 10 times the wedge strip-facing base length of the wedge dissectors, with the wedge dissectors positioned lengthwise.
- wedge dissectors with a wedge strip-facing base length about 2.5mm long can have about 5mm spaces between them, or about 25mm spaces between them.
- groups of wedge dissectors can be spaced apart with a first smaller ratio of, for example, about 1-4 times the strip-facing base length of the wedge dissectors and then a group can be spaced apart by a second larger ratio, for example, about 8-10 times the strip-facing base length of the wedge dissectors.
- a first group of wedge dissectors with a strip-facing base length of 2.5mm can have 5mm spaces between them and then a second group of wedge dissectors can be spaced 20mm from first group.
- the second group can have the same or a different size, shape, and or spacing as the first group.
- the location of the radially outward facing surface relative to the strip-facing base surface is not always centered or symmetric in some embodiments.
- the midpoint of the radially outward facing surface can be offset from the midpoint of the strip-facing base surface.
- Figures 23A-B and 24 illustrate an asymmetric radially outward facing surface as an alternate embodiment of the spikes.
- An asymmetric radially outward facing surface can be off center with respect to the alignment of a radially outward facing width edge directly over the strip-facing base width edge.
- the strip-facing base width edges has a tilted edge 440 climbing in height off of the radially outward facing surface while the other height edge 442 is perpendicular, at a 90 degree (right) angle RA to the strip-facing base surface 444, seen best in Figure 23A .
- the edges of the radially outward facing surface in one or both of the width ends and/or in one or both of the length ends can be chamfered or beveled or have a radius.
- the radially outward facing surface location is limited to the area projected upward over the strip-facing base surface.
- the radially outward facing surface can be a sharp line (e.g., honed edge) or any of the described unhoned edge variations for example.
- Figure 23C-D illustrates an embodiment where the total volume or substantially the total volume of the wedge dissector rises/is present over less than the entire width (or surface area) of the base of the strip, such as about or less than about 70%, 60%, 50%, 40%, or 30% of the width or surface area of the strip, for example, and are thus the wedge dissectors are asymmetrically offset either anteriorly or posteriorly from the longitudinal axis of the strip.
- Figure 24 illustrates an embodiment illustrating how the radially outward facing surface 204 may have a varying height (increasing from first height 24H1 at first edge 206 to second height 24H2 at second edge 208) from the strip-facing base surface 202 and may include edge profiles that are rounded with a radius of curvature of the radially outward facing length edges 206, 208.
- a wider radius of curvature at one edge 206 that has a shallow height 24H1 measured from the strip-facing base surface 202 while the radius of curvature of the opposite edge 208 is narrower and has a longer height 24H2 measured from the strip-facing base surface 202.
- the various wedge dissector features described herein can offer unique advantages to aid in delivery of the device, including but not limited to reducing vessel trauma if the radially outward facing surface is positioned outside of the delivery apparatus and/or can contact the luminal wall and has the potential to scrape the vessel wall during movement through the artery. This can be the case, for example, in embodiments with wedge dissectors with unhoned, radially outward facing surfaces.
- certain shapes may offer more effective penetration into the tissue.
- wedge dissectors that include chamfered or rounded radially outward facing edges can potentially enter the vessel wall with less force (requires less pressure to penetrate tissue) while still maintaining an effective micro channel to weaken the tissue and enable tissue expansion with minimal vessel trauma and cellular injury.
- Cutting or scoring a luminal wall such as, for example, the plaque during angioplasty can be performed at high pressures that can result in high injury to the blood vessel.
- the cutting blades, edges or scoring wire can be forced into the wall of the blood vessel at the same time that the angioplasty balloon is expanded to dilate the plaque. During this process the cutting blades, edges, or scoring wire can be forced into the vessel wall at oblique angles and can plow up the plaque potentially increasing the tendency for dissections.
- wedge dissectors employ can be expanded into the plaque at low pressures so as to form precise microperforations, serrations, and/or indentations in a radially outward direction that form precise indentations, cleavage lines or planes in the plaque or other location in the luminal wall, or other target.
- the radially outward facing surface of the wedge dissector can push into the plaque or other luminal surface in small surface areas, thereby being much less likely to plow up the plaque or luminal surface.
- Wedge dissectors can be designed, in some embodiments, to provide a series of oriented punctures or serrations into (but not completely through in some cases) a diseased vessel wall.
- the wedge dissectors produce a linear line of weakness or perforations that enable more effective and gentler vessel lumen expansion.
- the perforations can also serve as a pathway for pharmaceutical agents.
- the pharmaceutical agents could be delivered using a drug coated balloon, either incorporated with the device disclosed herein, or on a separate device that is used following the usage of the disclosed device.
- the wedge dissectors can be detachable from the base strip, and/or be coated or otherwise impregnated with one or more pharmaceutical agents for drug delivery.
- a series of reliefs on the spline can be added in some embodiments, as illustrated in Figures 25 and 26 .
- the relief elements can be produced in many different ways with the intent to have material removed and offer a more pliable spline for the wedges to be strip-facing base to.
- Relief can be made in the base of the spline opposite the wedge dissector strip-facing base surface, at the top of the spline directly adjacent the wedge dissector strip-facing base surface, or in both locations, e.g., a combination of top and bottom.
- the relief can also be made on the side of the spline, or apertures strip-facing base by other areas of the spline can be added to the spline. Any combination of top, bottom, side or through apertures can be added to the spline to offer relief.
- the strip 300 can have relief holes or slits located at the top, bottom, centered or off center that are either circular, rectangular, linear, triangular, or elliptical or combinations thereof (See figures 25 and 26 ).
- the strips offer a supporting base infrastructure, intended to be flexible and follow the movement of the balloon, for the wedges to be oriented correctly.
- Figures 25A-C illustrate embodiments of wedge dissectors with reliefs 502 on the inferior surface 500 of the strips 300 opposite the bounded surface of the wedge dissectors 200.
- Figure 25A illustrates an embodiment where the reliefs 502 are regularly spaced apart approximately a length of the bounded surface of each wedge dissector 200.
- Figure 25B illustrates an embodiment where the reliefs 502 are regularly spaced apart 50% or less of the length of the bounded surface of each wedge dissector 200.
- Figure 25C illustrates an embodiment where each relief 502 is spaced apart 50% or less of the length of the bounded surface of each wedge dissector 200, but the reliefs 502 are grouped only under the wedge dissectors and are not present under the strip sections in between the wedge dissectors. In other embodiments, the reliefs 502 are grouped only under the strip sections in between the wedge dissectors, but not under the strip sections directly below the wedge dissectors.
- Figures 25D-25E illustrates an embodiment where the reliefs 502' are present on the top (bounded or superior-facing surface 302) of the strip in between the wedge dissectors.
- the reliefs form depressions in the superior-facing surface 302 of the strips in between wedge dissectors with a generally curved based as illustrated in Figure 25D , and a relatively more square or rectangular base as illustrated in Figure 25E , with or without rounded edges.
- Figure 25F is an embodiment combining two different kinds of reliefs 502 found in the embodiments of Figures 25C and 25D . Other permutations of combinations are also possible, depending on the desired clinical result.
- Figures 25G and 25H illustrate other embodiments where the reliefs 502 are on an anterior 304 and/or posterior side surface of the strip 300.
- Figure 25G illustrates generally pyramidal-shaped reliefs 502, while Figure 25H illustrates generally arcuate reliefs 502.
- the reliefs can be spaced axially apart from the wedge dissectors as shown, and/or spaced axially aligned with wedge dissectors in other embodiments.
- Figures 25I and 25J illustrate embodiments where the reliefs 502 take the form of vertically ( Figure 25I ) or horizontally ( Figure 25J ) oriented through-channels, which can be spaced axially apart from the wedge dissectors as shown, or in another configuration.
- the reliefs can be oriented at an oblique angle to the longitudinal axis of the strip.
- Figure 25K illustrates an embodiment where the reliefs 502 take the form of slots on the anterior and/or posterior side surfaces, bounded base surface, and/or other locations.
- the strips can include tabs along the base or bonded surface in some embodiments.
- the tabs can aid in controlling long strips from vibration or movement during the material removal.
- the tabs are then removed.
- the tabs have an inset that they sit at the base of the strip.
- inset reliefs can serve as the tabs, and be advantageous during the manufacturing process, when several strips are, for example, laser cut from the same sheet of source material.
- a complementary protrusion e.g., a tab or related structure
- a complementary protrusion on or connected to an adjacent area of the source material to be laser cut can fit into an inset relief of a strip adjacent to the source material to maintain proper alignment of the strips during laser cutting/manufacturing. This can keep the strips in place during laser cutting, and prevent undesired migration and misalignment of a strip relative to an adjacent material area due to, for example, laser vibrations, which can decrease product yields.
- reliefs for manufacturing stability purposes need not be inset and can take the form of tabs that protrude outwardly from the base of the tab.
- these tabs are later removed by laser cutting or other methods prior to bonding or other attachment to the outer surface of the balloon, to prevent inadvertent puncture of the balloon.
- Figures 25L and 25M schematically illustrate strips 300 with wedge dissectors 200 during the strip and manufacturing process.
- tab 580 which can be laser cut out of the source material, and be connected with one end at an adjacent area of the source material 581 and the other end inset in an inset relief 502 in, for example, an inferior surface of the strip 300.
- the inset relief 502 can be any pattern as previously described, for example, in Figures 25A-25K or others, and in some embodiments are shown underneath the wedge dissector 200.
- Figure 25M illustrates the tab 580 which can be cut into segments 588, 589 following the manufacturing process when it is no longer required to hold the strip 300 in place with respect to adjacent source material 581, and the strip 300 can then be separated for attachment to a balloon or other device.
- the inset can allow for the tab to be removed while minimizing that amount of material that could potentially hang below the base of the strip which might interfere with the bonding of the strip to the balloon or other expansion device.
- balloons can be pleated and crimped down to the very narrow profile allowing the device to be delivered through and introducer sheath with a narrow diameter.
- the post-inflated balloon profile can be larger than its original pleated and crimped down diameter. This new profile may have strips that sit proud of the balloon profile potentially scraping the arterial wall or snagging on the opening of an accessory device such as an introducer sheath.
- the following elements, which are in general described as ramps, can address this potential issue, according to some embodiments.
- Figure 25N illustrates schematically an embodiment of a ramp 680 of adhesive or other material is placed at (e.g., over) one, as shown, or both lateral ends 333 of some or all of the strips 300.
- This can be, in some cases, in addition to adhesive placed at other locations such as under the strips (e.g., on the inferior surface of the strips 300) to attach the strips 300 to the balloon.
- the ramp 680 can offer an effective flexible interface between the edge of the flexible balloon (not shown) and the semi-rigid strip 300, as the ramp 680 can be made of a material (e.g., an adhesive) that is relatively more flexible than that of the strip 300.
- the ramp 680 can be designed in some embodiments to gently slope from the balloon surface (not shown) to the edge of strip.
- the adhesive ramps 680 can advantageously both retain strips and offer protection from undesired strip interaction 300 with ancillary devices during a procedure.
- a feature that can be incorporated into the balloon element is a cone ramp.
- the cone ramp feature can be implemented in several ways.
- the cone ramp is fabricated by taking a cone configuration for a larger balloon, for example taking a cone for a 6 mm balloon, or 5.5 mm balloon and incorporating it using known methods to be attached to a 5 mm balloon.
- One such embodiment is shown schematically in Figure 25O .
- the cone 970 can have in some cases an outer diameter that is larger than that of the outer diameter of the balloon 960, such as about or at least about 5%, 10%, 15%, 20%, or more than that of the outer diameter of the balloon 960, or between about 5% and about 20% larger than that of the outer diameter of the balloon 960 in some embodiments.
- the relatively larger cone 970 will sit proud of the balloon 960 generating a lip 972 at the intersection of the balloon body.
- the lip 972 can be beneficial in reducing the potential of the metal strip edges to be snagged or lifted off when the balloon is deflated and retracted through the introducer catheter.
- a series of rails 980 along the cone 970 to serve as support or stiffening structures, and assist in collapsing the balloon 960 as it enters an introducer catheter (not shown).
- the rails 980 are oriented/align with the longitudinal axes of the strips, furthering enhancing the function of pushing the strips toward the middle of the balloon as the cone is pulled through the introducer.
- balloons that can have depressions in the outer surface of the balloon for strip attachment.
- a series of depressions can be produced on the surface of the balloon.
- the depressions can, in some embodiments, configured to be wide enough and long enough to allow the strips to be placed within, such as entirely within the depression.
- the depths of the depressions can be sized to limit the likelihood that the strips could get caught on the distal opening of the introducer during balloon retraction.
- the use of the through-holes or microchannels either in the spline or on the spline sides can offer a mechanism for a therapeutic agent such as, for example, one or more drugs, nanoparticles, and/or stem cell transport from the balloon surface into the diseased luminal surface through capillary or diffusion action and/or utilization of the balloon pressure forcing the drug, nanoparticles, and/or stem cells through the micro channels on to the surface or into the diseased site.
- the microchannels or modified surfaces can provide a reservoir for drug, nanoparticles, or stem cells or other therapeutics to be placed and protected during transport to the diseased site.
- the drug may be any drug known in the art.
- examples of drugs that may be suitable for use in the methods and devices of this disclosure depending, on the specific disease being treated, and with consideration of the physical properties of the drug, include, without limitation, anti-restenosis, pro- or anti-proliferative, anti-inflammatory, antineoplastic, antimitotic, anti-platelet, anticoagulant, antifibrin, antithrombin, cytostatic, antibiotic, anti-enzymatic, anti-metabolic, angiogenic, cytoprotective, angiotensin converting enzyme (ACE) inhibiting, angiotensin II receptor antagonizing and/or cardioprotective drugs.
- ACE angiotensin converting enzyme
- antiproliferative drugs include, without limitation, actinomycins, taxol, docetaxel, paclitaxel, sirolimus (rapamycin), biolimus A9 (Biosensors International, Singapore), deforolimus, AP23572 (Ariad Pharmaceuticals), tacrolimus, temsirolimus, pimecrolimus, zotarolimus (ABT-578), 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-bydroxypropyl)rapamycin (a structural derivative of rapamycin), 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin (a structural derivative of rapamycin), 40-O-tetrazole-rapamycin (a structural derivative of rapamycin), 40-O-tetrazolylrapamycin, 40-epi-(N-1-tetrazole)-rapamycin, and pirfenidone.
- anti-inflammatory drugs include both steroidal and non-steroidal (NSAID) anti-inflammatories such as, without limitation, clobetasol, alclofenac, alclometasone dipropionate, algestone acetonide, alpha amylase, amcinafal, amcinafide, amfenac sodium, amiprilose hydrochloride, anakinra, anirolac, anitrazafen, apazone, balsalazide disodium, bendazac, benoxaprofen, benzydamine hydrochloride, bromelains, broperamole, budesonide, carprofen, cicloprofen, cintazone, cliprofen, clobetasol propionate, clobetasone butyrate, clopirac, cloticasone propionate, cormethasone acetate, cortodoxone, deflazacort, desonide, desoximetasone, dex
- antineoplastics and antimitotics include, without limitation, paclitaxel, docetaxel, methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride and mitomycin.
- anti-platelet, anticoagulant, antifibrin, and antithrombin drugs include, without limitation, heparin, sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin, prostacyclin dextran, D-phe-pro-arg-chloromethylketone, dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin and thrombin, thrombin inhibitors such as ANGIOMAX® (bivalirudin, from Biogen), calcium channel blockers such as nifedipine, colchicine, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin, monoclonal antibodies such as those specific for Platelet-Derived Growth Factor (PDGF) receptors, nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors
- cytostatic or antiproliferative drugs include, without limitation, angiopeptin, angiotensin converting enzyme inhibitors such as captopril, cilazapril or lisinopril, calcium channel blockers such as nifedipine; colchicine, fibroblast growth factor (FGF) antagonists; fish oil ( ⁇ -3-fatty acid); histamine antagonists; lovastatin, monoclonal antibodies such as, without limitation, those specific for Platelet-Derived Growth Factor (PDGF) receptors; nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist) and nitric oxide.
- angiopeptin angiotensin converting enzyme inhibitors such as captopril, cilazapril or lisinopril
- calcium channel blockers such as nifedipine
- colchicine
- ACE inhibitors include, without limitation, quinapril, perindopril, ramipril, captopril, benazepril, trandolapril, fosinopril, lisinopril, moexipril and enalapril.
- angiotensin II receptor antagonists include, without limitation, irbesartan and losartan.
- Other therapeutic drugs that may find beneficial use herein include, again without limitation, alpha-interferon, genetically engineered endothelial cells, dexamethasone, antisense molecules which bind to complementary DNA to inhibit transcription, and ribozymes, antibodies, receptor ligands such as the nuclear receptor ligands estradiol and the retinoids, thiazolidinediones (glitazones), enzymes, adhesion peptides, blood clotting factors, inhibitors or clot dissolving drugs such as streptokinase and tissue plasminogen activator, antigens for immunization, hormones and growth factors, oligonucleotides such as antisense oligonucleotides and ribozymes and retroviral vectors for use in gene therapy, antiviral drugs and diuretics.
- alpha-interferon genetically engineered endothelial cells
- dexamethasone antisense molecules which bind to complementary DNA to inhibit transcription
- a combination of any two, three, or other number of the foregoing drugs or other therapeutic agents can be utilized depending on the desired clinical result.
- MICRO-PENNING MICROPEN Technologies, Honeoye Falls, NY
- direct write describes a printing or patterning method that employs a computerized, motion-controlled stage with a motionless pattern generating device to dispense flowable materials in a designed pattern onto a surface.
- MICRO-PENNING is a flow-based micro-dispensing technique in which printed materials are extruded with a high degree of control through a syringe and a precision pen tip. The pen tip "rides” on the surface of the material, not touching the substrate surface and is capable of place precise amount of materials in precise locations.
- Figure 26 illustrates an embodiment of a strip 500 with reliefs 502 on the inferior surface of the strips 300 opposite the bounded surface of the wedge dissectors 200, with additional relatively larger apertures 503 in between wedge dissectors 200 which can be configured to facilitate bonding of the strip 300 to the underlying balloon, which can be as disclosed, for example in PCT Pub. No. WO 2016/073490 published on May 12, 2016 .
- the apertures 503 can be relatively oval shaped, circular, or any other shape depending on the desired clinical result.
- the longitudinal axis of the strips are longitudinally oriented along the balloon and spaced apart from each other. In some embodiments, the strips do not completely cover the length of the balloon. For example, in one embodiment an 80mm long balloon can have strips that measure 76.6mm. While the length of the strip can be the same as the defined working balloon length, in some embodiments the length of the strip is shorter than the defined working balloon length to allow for balloon contraction that is typically observed when a balloon goes to rated burst pressure.
- each strip can in some cases be no more than about 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1%, or between about 2% and about 8%, between about 3% and about 6%, or between about 4% and about 5% shorter than the overall working balloon length.
- the working balloon length does not include the lengths of the cones.
- part of the strip e.g., the base of the strip (e.g., the inferiormost surface configured to be attached to the outer surface of the balloon) can be roughened to aid in adhesion.
- Spikes e.g., serrating elements or wedge dissectors
- the devices may be fabricated using one or more additive or subtractive processes.
- Additive processes such as high energy vapor deposition, for instance laser chemical vapor deposition, self-assembly techniques, polymer/metal 3D printing, selective laser sintering, powder printers, or other stereo lithographic are a few such options but other additive processes may be used.
- subtractive processes such as etching, CNC milling, laser cutting, water jet, or electrical discharge machining are just a few examples but other subtractive processes may be used.
- a method of fabrication includes the use of a reel of martensitic stainless steel, such as for example a 300 or 400 series stainless steel with a hardness of about 52 to about 64 on the Rockwell C-scale (HRC) although other materials can be used.
- the reel is then honed on one or both edges of the steel.
- the steel is in the form of a thin reel strip about 0.007" to about 0.015" (0.178mm to about 0.381mm) thick and between about 0.25" to about 0.75" (6.35mm to about 19.05mm) wide, but can range between 0.005" (0.127mm) and about 0.005".
- the tolerance of the thickness and width of the reel is greater on the higher end and can have a thickness greater than about .020" (0.508mm) and a width greater than about 1" (25.4mm) .
- the honed edge can be a single hone or two or more honed angles (as illustrated, for example in Figures 21 and 22 ). In some embodiments, when the angle of the honed edges are measured as the slope from the bounded end to the height of the unbounded end shown in Figure 21 , the angle of the honed edge can be, for example, greater than about 75 degrees.
- the tip angle is can be less than, for example, about 75 degrees.
- the honed edge has an angle of about or at least about 70, 75, 80, 85, 90 degrees or greater as it moves toward the honed edge in a series of bevels.
- a separate and additional edge is generated at the very tip of the unbound edge of the strips. When added, the additional tip edge height from the honed edge to the unbounded edge is often very short and typically has a much larger angle than the overall honed edge.
- the unbounded tip width, W u can be described as the radius of the tip.
- the unbounded tip width, Wu is the penetrating edge into the lesion, when the width is, in some cases, less than about 0.01" or 0.005" (0.254mm or 0.127mm) , the surface area is minimized to have a less pronounced contact surface with the vessel enabling a reduced amount of energy requirement for penetration.
- the tip is configured for penetration into harder surfaces such as calcium beds, in some cases either a more obtuse angle or the removal of the unbound tip at a greater distance from the unbounded surface can produce a wider tip edge (see Figure 21 , Wu).
- this wider edge distributes the load across the larger surface area generating a more effective resistance to tip deformation when the tip is pressured into rigid tissue surfaces.
- the serrated elements are processed on the reel and then hardened and passivated.
- the tip of the blade that was produced during the reel sharpening step, is removed during the wedge dissector and strip manufacturing step.
- the material removal is design to start a distance, such as from about 0.0001" to about 0.003" (0.0025mm to about 0.076mm) below the honed edge, or from about .0001" to about .0005" (0.0025mm to about 0.0127mm) is removed from the honed edge, producing a flat top as illustrated in Figure 21 .
- the thinnest edge remaining (now a flat top in some cases) on the previously honed edge side is what will become the unbounded surface of the strip.
- the methods can include any number of processing steps that provides effective strip retention, perpendicular orientation, and structural stability during the fabrication and use.
- the bounded surface is typically coated with a base coat of an appropriate material, such as a polymer, e.g., polyurethane through a controlled dipping process producing a uniform layer of polyurethane.
- the coating is dried and typically 3 or 4 strips are aligned with a strip alignment mechanism or jig and glued with a medical grade cyanoacrylate into place at predetermined orientations.
- the number of strips and the periodicity can vary from, for example, 1 to 8 and is typically associated with the same number of balloon folds but can be less than the number of folds and the periodicity can be non-sequential.
- a single or series of multiple top coats or retention layers are placed over the metal interrupted scoring elements or wedge dissectors to retain the strips and protect the balloon from the thin tips of the scoring elements.
- these layers follow a similar process as the base or pre coat using a controlled dipping process producing one or more uniform layers of urethane or polyurethane.
- a layer of hydrophilic or other coating may be apply to decrease balloon friction and increase the balloons deliverability and retrievability.
- the outer slip coating as can increase the functionality of the balloon by reducing the force to insert and retract the device.
- Figure 27 illustrates a schematic cross-sectional view of a strip and wedge dissector operably attached to the outer surface of a balloon
- a polymer layer typically thin (e.g., from 0.0001" to 0.0009' (0.0025mm to 0.0229mm)), or about or less than about 0.001" (0.0254mm) in some embodiments, such as to limit increasing the balloon diameter profile, can be used as a base coat (layer 270A) covering the outer balloon surface.
- This base coat 270A offers an interface bonding layer for the interrupted scoring element to the balloon surface.
- This layer 270A can be made of the same or similar polymer chemistry as other layers while offering a chemical, mechanical, or electromagnetic bond to the balloon surface.
- This base coat layer 270A can be configured to and potentially capable of reducing the interface strain between the balloon outer surface and the bonding surface of the metal scoring element. Strain between the two surfaces is reduced by allowing an adhesive layer 270E and the scoring element 200 to be sandwiched within a polymer matrix independent and somewhat isolated from the balloon strain during balloon expansion and pressure.
- typical base coats 270A are polymers, e.g., urethane or polyurethane this layer can be a variety of other materials.
- the coating could include silicone and hydrophilic coatings involving hydrogel polymers or the like, such as polymer networks of a vinyl polymer and an uncrosslinked hydrogel, for example. Polyethylene oxide (PEO) is an example of a hydrogel.
- NPG neopentyl glycol diacrylate
- the deposition of the layer can be done by single or a series of dips of a balloon or matrix of balloons into a polymer bath under controlled insertion and extraction conditions at controlled rates in both or in one direction. Alternately, layers can be deposited at Angstrom layers through self-assembly of monolayers using known and practiced self-assembly techniques, typically employing surface ionic charging.
- a bonding layer 270E between the metal scoring element and the basecoat can typically be thin (0.0001" to 0.0005" (0.0025mm to 0.0127mm)) but can be as thick as 0.001" (0.0254mm) in some embodiments and thin enough such as to limit increasing the balloon diameter profile.
- the adhesive layer 270E can be a cyanoacrylate but can be made from other bonding materials that offer a chemical, mechanical, or electromagnetic bond between the basecoat 270A and the bonding surface of the metal scoring element. This layer 270E can be seen as the functional layer at joining the bonding surface of the metal scoring element to the balloon and sometimes is the only layer between the bonding surface of the metal scoring element and the outer balloon surface.
- This layer 270E can be one or more adhesive products.
- the adhesive layer 270E is a single adhesive with the low viscosity allowing a wicking of the adhesive along the interface of the bonded surface of the metal scoring element and the base coat.
- an adhesive dries quickly, allowing successive layers to be applied on the top of the adhesive layer with minimal curing delay.
- a more viscous adhesive layer can be placed at both ends of the bottom of the strips or periodically between the bonding surface of the metal scoring element and the base layer allowing non-glued sections to be free or unbonded.
- more than one adhesive can be used.
- a more viscous adhesive can be used on either end of the bonding surface of the metal interrupted scoring elements and then followed by wicking adhesive on some or all of the unbonded sections.
- one (e.g., a single layer) two, or more retention layers (two layers shown in Figure 27 ) 270B, 270C can be present over the base layer 270A as well as the scoring element.
- a polymer retention layer can in some embodiments be similar to, and have dimensions as described above for the base layer with enough properties such that the base 270A and retention 270B, 270C layers produce an effective bond between the layers.
- the retention layer(s) can be designed to offer a similar thickness as the base layer while other times it may be useful to have the retention layers slightly thicker than the base layer. Thicker base and/or retention layers can in some circumstances offer greater puncture resistance and increased durability of the balloon against potential puncturing from the metal interrupted scoring elements, any sharp edges from implants left in the body, or from sharp edges found in severely calcified disease vessels for example.
- an outer slip layer 270D can also be present, above the retention layer(s) over the balloon and/or scoring elements.
- hydrophilic coatings are commercially available to reduce friction and offer increased navigation of balloons through tortuous and narrow anatomical features.
- the balloon surface can be fully encased in a hydrophilic coating while in other embodiments the balloon can be coated after pleating or after pleating and crimping and therefore only surfaces that will typically be exposed during delivery are coated with the hydrophilic coat.
- Typical hydrophilic coats are a few microns thick and can be as thin as about 10 Angstroms in some embodiments.
- the adhesive can be applied separately to the balloon and to the strips and then both components are then bonded together.
- a template can be used to ensure proper positioning of the scoring elements along the surface of the balloon.
- a retention polymer layer 270B, 270C can be typically similar to the base layer with enough properties such that the base and retention layers produce an effective bond between the layers.
- the retention layer(s) can be designed to offer a similar thickness as the base layer while other times it may be useful to have the retention layers slightly thicker than the base layer, such as about or no more than about 20%, 15%, 10%, or 5% thicker in some cases.
- Thicker base and/or retention layers offer greater puncture resistance and increased durability of the balloon against potential puncturing from the metal interrupted scoring elements, any sharp edges from implants left in the body, or from sharp edges found in severely calcified disease vessels.
- the layers can be made of the same or differing materials.
- layer 270D of Figure 27 can be a hydrophilic slip layer.
- the balloon surface can be fully incased in a hydrophilic coating while in other embodiments the balloon can be coated after pleating or after pleating and crimping and therefore only surfaces that will typically be exposed during delivery are coated with the hydrophilic coat.
- Typical hydrophilic coats are a few microns thick and can be as thin as, for example 10 Angstroms.
- the height of the wedge dissectors, strips, and layers of the outer balloon encapsulation process can be viewed as a cage for use with an expandable member such as a medical balloon, such as an angioplasty balloon or as part of a medical procedure involving a medical balloon or other expandable member.
- an expandable member such as a medical balloon, such as an angioplasty balloon or as part of a medical procedure involving a medical balloon or other expandable member.
- the ability to fold the balloon to a fraction of the diameter of the intended inflation diameter can be of value. Therefore the balloon and in some cases the cage are typically folded where the profile of the folded balloon can be effectively used.
- the cage is folded in a manner that offers orientation of the spikes such as to avoid puncturing the balloon or scraping the intima of the lumen during delivery and removal, as illustrated in Figure 28.
- Figure 28 illustrates the balloon 1000 with a plurality of pleats 1002, and strips 300 and associated wedge dissectors 200 in between the pleats , thus allowing a single strip 300 with its plurality of wedge dissectors 200 to lie between two pleats 1002.
- a pleating tool was designed that offers effective orientation of the spikes and splines.
- the pleating tool can have a series of pleating wedges where each wedge offers the ability of the crimp the balloon between the wedges as the wedge elements are closed down onto the balloon. Due to the bulk of the spline elements and desire to minimize contact, and potential damage to the wedge heads, the wedges are designed with a series of pockets that run the length of the wedge heads.
- the pockets in the wedge heads offer the ability of the spline features to rest within said pockets and limits the spline to wedge contact.
- the pockets can also offer the ability to aid in orientation of the spline and spike features such that the orientation of the features limits contact with the balloon, such as over folding, and limits orientation, such as perpendicular orientation to the balloon, that might produce scraping of the intima of the vessel during transport of the device on said balloon.
- orientation of the spikes might be at a tangential orientation, an apparent lying down, to the balloon surface as illustrated in Figure 28 .
- actions such as “creating microperforations in an arterial plaque” includes “instructing the creating of microperforations in an arterial plaque.”
- the ranges disclosed herein also encompass any and all overlap, sub-ranges, and combinations thereof.
- the terms “approximately”, “about”, and “substantially” may refer to an amount that is within less than 10% of, within less than 5% of, within less than 1% of, within less than 0.1% of, and within less than 0.01% of the stated amount.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Biophysics (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Mechanical Engineering (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Materials For Medical Uses (AREA)
- Surgical Instruments (AREA)
Description
- Certain embodiments disclosed herein relate generally to a cage for use with a medical balloon, such as an angioplasty balloon. Methods of manufacturing the cage and treatment methods involving the cage are also disclosed, as well as various wedge dissectors and features of splines that can be used with the cages. Among other things, the wedge dissectors can be used to create perforations in plaque in a blood vessel in an effort to control crack propagation and to reduce flow limiting dissections.
- Atherosclerotic occlusive disease is the primary cause of stroke, heart attack, limb loss, and death in the United States and the industrialized world. Atherosclerotic plaque forms a hard layer along the wall of an artery and is comprised of calcium, cholesterol, compacted thrombus and cellular debris. As the atherosclerotic disease progresses, the blood supply intended to pass through a specific blood vessel is diminished or even prevented by the occlusive process. One of the most widely utilized methods of treating clinically significant atherosclerotic plaque is balloon angioplasty.
- Balloon angioplasty is a method of opening blocked or narrowed blood vessels in the body. The balloon angioplasty catheter is placed into the artery from a remote access site that is created either percutaneously or through open exposure of the artery. The catheter is passed along the inside of the blood vessel over a wire that guides the way of the catheter. The portion of the catheter with the balloon attached is placed at the location of the atherosclerotic plaque that requires treatment. The balloon is generally inflated to a size that is consistent with the original diameter of the artery prior to developing occlusive disease.
- When the balloon is inflated, the plaque is stretched, compressed, fractured, or broken, depending on its composition, location, and the amount of pressure exerted by the balloon. The plaque is heterogeneous and may be soft in some areas or hard in others causing unpredictable cleavage planes to form under standard balloon angioplasty. Balloon angioplasty can cause plaque disruption and sometimes even arterial injury at the angioplasty site.
-
EP 1,809,361A discloses a cutting balloon catheter and method of making and using the same. The cutting balloon catheter may include a catheter shaft having a balloon coupled thereto. One or more cutting members or blades may be coupled to the balloon. The cutting members may include two or more sections that are connected via a fracturable or yielding bridge section that increases flexibility when passing through or being utilized in tortuous anatomy. -
US 2012/172901 discloses a medical balloon catheter including a catheter shaft and an inflatable balloon secured to a distal portion of the catheter shaft. One or more cutting blades are secured to the inflatable balloon by a first polymeric adhesive material forming a mounting pad encasing a base portion of the cutting blade therein, and a second polymeric adhesive material adhesively bonding the mounting pad to a surface of the balloon. The first polymeric adhesive material has a first ductility and the second polymeric adhesive material has a second ductility greater than the first ductility. -
US 2002/010489 discloses a stiffened balloon which can be used in angioplasty, endovascular, and valvuloplasty procedures or as a delivery balloon to deliver a stent or a stent-graft. Longitudinally discontinuous stiffening members connected to the expandable balloon stiffen the balloon but allow it to be navigated through curved passages. Projections on the stiffening members may engage, incise, crush, fracture, or pierce occlusions or retain a stent or stent-graft. Radio-opaque portions may be referenced to determine orientation. Longitudinally continuous stiffening members bearing projections and connected to the balloon perform in a similar manner. -
US 2004/098014 discloses a balloon angioplasty device which provides a combination of cutting elements to enhance dilation of an artery together with controlled drug delivery directed towards the regions of cutting. The invention is preferably implemented using rows of hollow microneedles to serve both as the cutting elements and the drug delivery conduits. The invention also provides a corresponding method in which a drug is delivered via conduits located within cutting elements around the exterior of a balloon angioplasty device during and/or immediately subsequent to inflation of the balloon within a blood vessel. -
US 2005/149082 discloses a microsurgical balloon, with at least one incising component mounted to the surface of the balloon, including a protective pad to prevent the outer surface of the incising component from coming into contact with and damaging the balloon surface. In particular, the protective pad is positioned on the outer surface of the balloon substantially parallel to and juxtaposed with the incising component. When the balloon is in a deflated configuration, either for insertion into the vasculature system or removal from the patient, the protective pad engages the outer surface of the incising component thereby protecting the balloon from being punctured or damaged by the incising component. The protective pad may be bonded to the outer surface of the balloon, or it may be an integral part of a homogeneous balloon structure. - The invention is defined in the claims. There is a continuing need to improve the methods for treating occlusive disease, including balloon angioplasty and other related treatment systems. In some embodiments a cage can be positioned around a medical balloon, such as an angioplasty balloon, to assist in a medical procedure. The cage can include at least first and second rings and a plurality of strips. Each strip can extend longitudinally between the first and second rings. Moving the cage to an expanded position can move the first and second rings closer together while expanding the strips. In some examples, the cage may further include spikes on the strips that can be used as wedge dissectors to dissect plaque in a vessel, among other things.
- In some embodiments, disclosed herein is a medical balloon catheter, and wedge dissectors and strips that can be configured to be attached to a medical balloon catheter or other expandable member. The balloon catheter can include any number of the following: an elongate member having an inner lumen, the elongate member defining a longitudinal axis; an expandable balloon connected to the elongate member at a distal end of the elongate member; and a plurality of strips, each strip of the plurality of strips including a plurality of wedge dissectors spaced apart along a surface of each strip, each strip extending longitudinally along an outer surface of the balloon. The wedge dissectors can include a strip-facing base surface directly adjacent a surface of each of the strips and an unhoned radially outward facing surface having a length between a proximal edge of the radially outward facing surface and a distal edge of the radially outward facing surface and defining a height of each wedge dissector. The radially outward facing surface has a first width at the proximal edge, a second width smaller than the first width between the proximal edge and the distal edge, and a third width at the distal edge larger than the second width. In some embodiments, the second width corresponds to a single point along the length of the radially outward facing surface. The second width can correspond to a central segment having a central length in between the proximal edge and the distal edge. The length of each strip can be less than a length of the outer surface of the balloon coaxial to the length of each strip. The length of each strip can also be between about 3% and about 6% less than the length of the outer surface of the balloon coaxial to the length of each strip. The total length of the radially outward facing surface of each wedge dissector can be less than a total length of the strip-facing base surface of each wedge dissector. The radially outward facing surface can be, for example, one or more curved and/or chamfered surfaces. The radially outward facing surface can have a first height at the proximal edge and a second height between the proximal edge and the distal edge, wherein the second height is greater than the first height. In some cases, a maximal height of the radially outward facing surface is at a midpoint between the first unbounded edge and the second unbounded edge. In some cases, a maximal height of the unbounded surface can be offset from a midpoint between the proximal edge and the distal edge. In some embodiments, a lateral surface segment of the wedge dissector from the strip-facing base surface to the proximal edge has a first segment with a first slope and a second segment with a second slope different from the first slope. The strip can include a textured surface. In some embodiments, the strip can include a plurality of tabs on an inferior-facing surface of the strip opposite the wedge dissectors. A plurality of reliefs on the strip can also be included. The strips can in some cases include an elongate length and first and second lateral edges. The first and second lateral edges of the plurality of strips can be circumscribed by an adhesive. In some embodiments, a hydrophilic slip layer can surround the outer surface of the balloon, the strips, and the wedge dissectors. In some embodiments, at least one polymer retention layer surrounds the outer surface of the balloon, the strips, and the wedge dissectors. The balloon can also include cones about the lateral ends of the balloon. The cones can have a maximal outer diameter that is greater than about 5% of the maximal outer diameter of the balloon. In some cases, the cones comprise rails oriented with longitudinal axes of the strips.
- The cage can be assembled and/or manufactured in many ways, including, in some examples, an extrusion process, material removal from a tube, or by splitting a wire to form the strips.
- The cage can assist a medical procedure in many ways. For example, the cage may cover a drug coating on the balloon pre-deployment. In some variants, when the cage is expanded, the cage may allow access to the drug coating on the surface of the balloon. In this way, the cage can prevent or reduce the chances that the drug will become diluted during delivery or will treat areas of the body not intended for treatment.
- As another example, the cage can prevent or reduce dog boning of the balloon by increasing the resistance to expansion of the combined balloon and cage at the ends of the cage as compared to the center of the cage.
- In some embodiments, a balloon catheter can comprise an elongate member, a balloon, and a cage. The elongate member can have an inner lumen, the elongate member defining a longitudinal axis. The balloon can be connected to the elongate member at a distal end of the elongate member. The cage can be for positioning about the balloon. The cage can comprise a plurality of strips and a plurality of rings. The plurality of rings can be configured to secure the plurality of strips to the balloon catheter. Each strip of the plurality of strips can have a first ring of the plurality of rings at a distal end, a second ring of the plurality of rings at a proximal end. At least a portion of the strip between the distal and proximal ends remains uncovered by and/or unconnected to any ring. The balloon and cage are configured to have an initial state and an expanded state, the plurality of strips configured to move with the balloon as it moves toward the expanded state.
- According to some embodiments of the balloon catheter, at least some of the rings of the plurality of rings comprise a heat shrink material. Further each strip of the plurality of strips can include a plurality of wedge dissectors spaced along a surface of the strip, each strip extending longitudinally along an outer surface of the balloon. The plurality of rings can secure the plurality of strips to distal and proximal ends of the balloon. At least some of the strips of the plurality of strips can be secured with rings at intermediate points of the balloon. The strip may be secured at intermediate points and/or at the ends.
- In some embodiments, at least some of the rings of the plurality of rings comprise a part ring having a top layer of heat sink material and a bottom layer, an end of a strip of the plurality of strips sandwiched between the top layer and the bottom layer. Some embodiments can include hooks on the strips, grooves on the strips or rings, springs, and other features.
- In some embodiments, a plurality of polyurethane coatings in combination with a series of strips collectively produce a cage. In one such embodiment the cage is comprised as a full or partial single top layer or multiple layers of urethane, polyurethane, or other polymer material and a bottom layer of urethane, polyurethane, or other polymer material, and a plurality of strips sandwiched between the top layer/s and the bottom layer. Some embodiments can include hooks on the edges of strips, grooves on the strips or rings, springs, and other features.
- A method of retrofitting a balloon catheter with a cage can comprise any of the below steps. Positioning a plurality of strips around an inflated balloon of a balloon catheter, the strips being positioned equally spaced around the inflated balloon. Advancing rings of heat shrink material over the balloon so that each end of the strips of the plurality of strips is covered by a ring heat shrink material. Heating the rings of heat shrink material to shrink the rings of heat shrink material to thereby secure the plurality of strips to the balloon, at least a portion of each strip of the plurality of strip between distal and proximal ends of the strip remaining uncovered by and/or unconnected to any ring of heat shrink material.
- A method may further include positioning the strips to extend primarily longitudinally, and/or positioning the strips serially in rows around the balloon with 4 rows, each having between 2-6 strips per row. The strips can be attached either permanently or temporarily to the balloon with an adhesive.
- Advancing rings of heat shrink material over the balloon further may comprise covering a distal end of distal-most strips of the plurality of strips with a single ring of heat shrink material. Further, advancing rings of heat shrink material may include covering a proximal end of proximal-most strips of the plurality of strips with a single ring of heat shrink material. Still further, it can include covering a proximal end of distal-most strips of the plurality of strips and a distal end of proximal-most strips with a single ring of heat shrink material.
- In some embodiments, a cage can be positioned around an angioplasty balloon. The cage can include first and second rings and a plurality of strips. Each strip of the plurality of strips can extend longitudinally between the first and second rings. The cage can have a pre-expansion position and an expanded position, wherein moving to the expanded position moves the first and second rings closer together while expanding the strips.
- A method of making a cage for an angioplasty balloon can comprise extruding a plastic tube with a plurality of spaced apart splines positioned longitudinally along the tube; cutting at least one of the splines of the plurality of splines to form a plurality of spikes positioned circumferentially around the tube; and cutting the tube to form a plurality of longitudinally extending strips, each strip including at least one spike of the plurality of spikes.
- A method of making a cage for an angioplasty balloon can comprise splitting a wire into a plurality of longitudinally extending strips; cutting at least two longitudinally extending strips of the plurality of longitudinally extending strips to form a plurality of spikes spaced apart along the longitudinally extending strip; and connecting the at least two longitudinally extending strips to a first ring and a second ring such that each strip of the plurality of longitudinally extending strips extends between the first and second rings.
- A method of protecting an angioplasty balloon with a drug coating can comprise providing an angioplasty balloon with a drug coating; providing a cage having a pre-expansion position and an expanded position, the cage comprising: first and second rings; and a plurality of strips, each strip of the plurality of strips extending between the first and second rings; wherein the cage is positioned over the angioplasty balloon such that in the pre-expansion position the cage covers the angioplasty balloon radially such that none, or substantially none, of the surface of the angioplasty balloon with the drug coating is exposed, and moving to the expanded position moves the first and second rings closer together while expanding the strips and exposing the angioplasty balloon surface.
- A method of treating a diseased blood vessel can comprise advancing an angioplasty balloon, optionally with a drug coating, to a treatment site in a diseased blood vessel, the angioplasty balloon having a cage positioned over the angioplasty balloon, the cage having a pre-expansion position and an expanded position, the cage comprising: first and second rings; and a plurality of strips, each strip of the plurality of strips extending between the first and second rings; expanding the angioplasty balloon at the treatment site, where expanding the angioplasty balloon further comprises moving the first and second rings closer together while expanding the strips, the cage preventing or reducing dog boning of the angioplasty balloon by increasing the resistance to expansion of the combined angioplasty balloon and cage at the ends of the cage as compared to the center of the cage.
- In some embodiments, a cage for positioning about an angioplasty balloon can include a plurality of rings and a plurality of strips. The plurality of rings can be non-expandable. At least one of the plurality of rings can be configured to be disposed about a first end of an angioplasty balloon, and at least one of the plurality of rings can be configured to be disposed about a second end of the angioplasty balloon. Each of the plurality of strips can include a plurality of protrusions positioned on the surface of each of the plurality of strips. Each of the plurality of rings can be configured to attach to each end of the plurality of strips. The plurality of strips can be attached to the plurality of rings through a coupling. In some embodiments, the cage can have a first length and a second length. The second length is shorter than the first length, and the plurality of rings are closer in proximity with each other such that each of the plurality of strips bends away from each of the plurality of strips.
- These and other features, aspects and advantages are described below with reference to the drawings, which are intended to illustrate but not to limit the invention. In the drawings, like reference characters denote corresponding features consistently throughout similar embodiments.
-
Figure 1A illustrates a cage positioned on an angioplasty balloon in an expanded position. -
Figure 1B shows an exploded view of an angioplasty balloon that can be positioned within a cage, both being shown in a pre-expanded position. -
Figure 2 shows a schematic representation of a cage laid flat showing both long and short slits. -
Figure 3 shows an angioplasty balloon within a vessel at a treatment site that is experiencing dog boning. -
Figure 4A shows an unfinished cage during manufacturing being cut from a tube. -
Figure 4B is a cross-section of the unfinished cage ofFigure 4A taken along line B-B. -
Figure 4C shows the cross-section ofFigure 4B after an additional manufacturing step. -
Figure 4D illustrates a cross-section of another embodiment with a larger interior lumen. -
Figure 4E shows a detail view of a portion of another embodiment of cage. -
Figure 5A shows another embodiment of an unfinished cage during manufacturing. -
Figure 5B shows a cross-section of the unfinished cage ofFigure 5A taken along line B-B. -
Figure 6A shows a wire cut to form strips and wedge dissectors for an embodiment of a cage. -
Figure 6B shows a section of the cut wire ofFigure 6A . -
Figure 7 shows a schematic view of a plurality of strips that are connected by two rings to form a cage. -
Figure 8 illustrates a two-part ring that can be used to capture strips to form part of a cage. -
Figure 9A is another embodiment of cage with a conical ring. -
Figure 9B is a perspective view of a ring with a tapered outer diameter wherein the ring includes a screw-like feature on its outer surface. -
Figure 10 shows the end of a strip configured to accommodate and be secured by a multi-layer ring to form an end of the cage. -
Figure 11 illustrates another embodiment of the end of a strip configured to accommodate and be secured by a multi-layer ring to form an end of the cage. -
Figure 12 is a perspective view of a ring. -
Figure 13A shows a strip with a hook feature and ring. -
Figure 13B is an end view of strip with a ridged hook feature. -
Figure 13C shows a perspective view of a portion of a cage. -
Figure 13D illustrates a view of a conical distal ring retaining a plurality of strips. -
Figures 13E-F show a view of one end of a balloon with a cage disposed about the balloon and the forces applied to the balloon during inflation and deflation. -
Figure 14A illustrates a side view of an embodiment of a cage having strips with hooks that can attach to the inside of a balloon neck. -
Figure 14B shows an end view of a cage attached to a balloon as illustrated inFigure 14A . -
Figure 14C is a cross sectional schematic view of the strip with hook locked into the balloon neck. -
Figure 14D is an alternative embodiment of the end of a strip with a multi-layer ring to form an end of the cage. -
Figures 14E shows an embodiment of a strip retained by a plurality of rings with the wedge dissectors protruding from the plurality of rings. -
Figure 15A illustrates a partial view of an embodiment of an angioplasty balloon with an embodiment of a strip bound to the angioplasty balloon with a plurality of ringed material to form a cage. -
Figure 15B is an angioplasty balloon with a cage having a plurality of segmented strips that are bound to the surface of the balloon by a plurality of rings. -
Figure 15C shows an example of the placement of the segmented strips on the surface of the balloon. -
Figure 15D is another example of the placement of a plurality of segmented strips onto the surface of an angioplasty balloon. -
Figure 15E illustrates an example of a plurality of segmented strips bound to the surface of a balloon by a plurality of rings. -
Figures 16A-C show a plurality of embodiments of strips secured by a ring. -
Figure 17 illustrates a schematic view showing a detail of an embodiment of a cage with a spring. -
Figure 18 illustrates various an embodiments of a cage utilizing aspects of the spring detail ofFigure 18 . -
Figure 19 shows a portion of a cage including a spring strip and spike configuration. -
Figure 20 is a close-up detail view of an embodiment of a wedge dissector on its associated strip. -
Figure 21 illustrates a schematic perspective view of various dimensions and terminology of a wedge dissector, according to some embodiments. -
Figures 21A-G illustrate various embodiments of wedge dissector geometries. -
Figures 22A-22F illustrate respective end and isometric views of various wedge dissector geometries, according to some embodiments. -
Figures 23A-23D illustrate respective end and isometric views of various asymmetric wedge dissector geometries, according to some embodiments. -
Figure 24 illustrates an embodiment illustrating how theunbounded surface 204 may have a varying height, according to some embodiments. -
Figures 25A-25K illustrate various embodiments of strips with reliefs in various locations. -
Figures 25L and25M illustrate embodiments of method of stabilizing strips during the laser cutting manufacturing process and involving temporary tabs, according to some embodiments. -
Figure 25N illustrates embodiments of an adhesive ramp for bonding lateral ends of a strip to the balloon surface, according to some embodiments. -
Figure 25O illustrates a cone ramp for a balloon, according to some embodiments. -
Figure 25P illustrates a series of cone rails or struts, according to some embodiments. -
Figure 26 illustrate another embodiment of strips having reliefs, according to some embodiments. -
Figure 27 illustrate a schematic cross-section of a balloon with wedge dissector and intervening layers. -
Figure 28 illustrate an embodiment of a pleated balloon with strips and wedge dissectors in between pleats. -
Figures 1A and 1B illustrate an embodiment of acage 10 positioned on anangioplasty balloon 20.Figure 1A shows an expanded position andFigure 1B shows how the angioplasty balloon can be advanced into the cage. Thecage 10 is described herein primarily with respect to anangioplasty balloon 20 and an angioplasty procedure. It is to be understood that thecage 10 can be used with other types of medical balloons and in other procedures. - The
cage 10 can include afirst ring 12 andsecond ring 14, and a plurality ofstrips 16. Each strip can extend longitudinally between thefirst ring 12 and thesecond ring 14. The strips and rings can be made of a monolithic part formed from a single piece of material. Thus, the first and second rings can be the ends of a cut tube, for example. The strips and rings can also be made of separate materials and be connected together. As shown the illustrated cage ofFigures 1A and 1B has fivestrips 16, though other numbers of strips can be used such as 2, 3, 4, 5, 6, 7, 8, 9, 10, etc. -
Figure 2 shows a plan view of a cut tube embodiment of cage, though some embodiments of cage can alternatively be made of a single flat piece of material. The material can be elastic or semi-elastic and made from a polymer, copolymer, a metal, alloy or combination of these. The strips are typically designed to enable theballoon 20 to be inflated multiple times. As well, thestrips 16 can be configured such that thecage 10 can apply forces both longitudinally and axially or in orientations that enable thestrips 16 to return to this original position. - In some embodiments the
cage 10 is prefabricated, packaged, and sterilized separately from theballoon 20, allowing the physician to position thecage 10 around amedical balloon 20, such as an angioplasty balloon, to assist in a medical procedure at the time of the procedure.Figure 1B shows theballoon 20 in a folded state prior to deployment and prior to placement within thecage 10. The foldedballoon 20 can be advanced into thecage 10 without requiring expansion or change in shape of thecage 10. Thecage 10 can completely surround and enclose theballoon 20 prior to balloon deployment or expansion. Thecage 10 in the pre-expanded state can be longer than theballoon 20. This can allow for movement of one or both ends of thecage 10 towards each other while the device (e.g. balloon 20) expands. Thecage 10 can be free floating over theballoon 20. One or both ends 12, 14 of thecage 10 may be fixed to theballoon 20 or another part of the delivery device. In some embodiments thecage 10 is not attached to any portion of theballoon 20 that expands. This can prevent thecage 10 from interfering with theballoon 20 as it expands. - In some examples, a
cage 10 can be used with anangioplasty balloon 20 with a drug coating to can protect the drug coating. Thecage 10 can prevent or reduce the premature exposure of the drug to the blood vessel. As will be understood with reference toFigure 1B , thecage 10 can be positioned over a drug coatedangioplasty balloon 20 in the pre-expansion state to prevent premature exposure of the drug to the blood vessel. Thecage 10 can cover theballoon 20 radially such that a minimal amount, or substantially none, of the surface of theangioplasty balloon 20 with the drug coating is exposed. Theballoon 20 andcage 10 can be advanced to a treatment location in this configuration. Though not shown, the system may be advanced over a guidewire within the vasculature. - As illustrated in
Figure 1A , thecage 10 can be moved to an expanded position. In the expanded position the first 12 andsecond rings 14 are closer together and the strips are expanded thereby exposing the angioplasty balloon surface. In this position, the drug can be placed into contact with diseased tissue in the blood vessel. - In currently available systems, it is generally difficult to predict how much drug will reach the diseased tissue. There are many factors that limit the ability to accurately predict how much drug will be transferred to the diseased tissue. For example, blood flow can dilute the drug on the
balloon 20 as it is advanced to the treatment site. Furthermore, navigating the device through the blood vessel can cause theballoon 20 to rub against the endoluminal surface thereby removing some of the drug as theballoon 20 is being advanced to the treatment location. Therefore, in some examples, thecage 10 can offer a physical barrier to protect the drug covering of theballoon 20 during advancement to the treatment location. In this way thecage 10 can be used such thatballoon 20 and drug covering are exposed to blood flow in a vessel only during expansion of theballoon 20 as the space between the strips increases. In this way, thecage 10 can prevent or reduce the chances that the drug will become diluted or that the drug will treat areas of the body that are not meant for treatment. In some variants, this can allow for more controlled delivery of the drug with a reduction in the amount of drug necessary to be coated on theballoon 20. - In some embodiments, the folded
balloon 20 can be positioned entirely within thecage 10. As is illustrated inFigure 1A , thecage 10 can have slits between each of thestrips 16. In some variants, the slits can be formed by cutting between each of thestrips 16 to separate them from a single piece of material. In other embodiments, the slits are really just the space between adjacent strips. The space between strips can be a minuscule amount, such as would formed by a laser cut, or much larger, such as equal to or greater than a width of the strip itself. Depending on the size of the slits, the exposed surface of theballoon 20 in the pre-expansion position is not more than 50% and can be as low as 25%, 10%, 5%, 1%, or less. - As has been described previously, expansion of the
balloon 20 moves the first 12 andsecond rings 14 closer together while moving thestrips 16 further apart radially. With thestrips 16 in an expanded position, theballoon 20 is more exposed to and can interact with the vessel wall. In the expanded position, theballoon 20 can deliver a drug, stem cells, or other treatment to the vessel wall or to a diseased area of the vessel wall. When theballoon 20 is fully expanded, the exposed surface of theballoon 20 not covered by thestrips 16 can be between 65% and 99%, 75% and 99%, more commonly 80% and 99%, or most commonly 90% and 99%, among other ranges. - Drug delivery using the
cage 10 can be employed before, during, or after an angioplasty procedure. At the same time, it is not required that the cage cover the entire balloon, or be used to control or assist with drug delivery. - In some embodiments, a
cage 10 can be used to prevent or reduce dog boning of theballoon 20 in an angioplasty procedure. This may be in addition to, or instead of assisting with drug delivery.Figure 3 shows anangioplasty balloon 20 within a blood vessel 2 at a treatment site. As illustrated, theangioplasty balloon 20 is experiencing dog boning as it is expanding. The plaque buildup 4 resists expansion of theballoon 20, forcing both ends of theballoon 20 to expand first, rather than focusing the expansion energy in the center of theballoon 20 at the plaque 4 where it is needed most. - To prevent dog boning, the
cage 10 as shown inFigure 1A , can constrain theballoon 20 upon expansion to encourage the middle ofballoon 20 to expand first. This is because the middle area of thecage 10 can be designed to have the least resistance to expansion, being farthest away from the ends where the strips are confined by rings. This can prevent or reduce dog boning of theballoon 20 independent of the disease morphology or arterial topography theballoon 20 is expanding within. - Dog boning usually occurs where a
balloon 20 expands in a vessel with plaque where the plaque resists expansion, forcing the ends of theballoon 20 to expand first (due to lack of resistance) such that theballoon 20 takes the shape of a dog bone. By enveloping aballoon 20 with acage 10 and configuring the rings to display different expansion resistance, the ends of theballoon 20 can have the highest resistance and the center of theballoon 20 have the lowest resistance. Therefore, thecage 10 can help control and limit expansion of theballoon 20, as theballoon 20 will tend to expand more readily in the center which is typically the area of disease. - The pattern and orientation of the
strips 16 can influence expansion and dog boning. Returning toFigure 2 , theshort slits 22 positioned in the center of thestrips 16 can reduce rigidity in the center of each of thestrips 16. This can help reduce the likelihood of dog boning by further reducing resistance to expansion in the center of thecage 10. - The cage may further include spikes or wedge dissectors on the strips. The spikes can be used as a vessel preparation tool before a secondary treatment, or during a primary treatment. For example, the spikes can assist with cutting and/or perforating plaque before or during an angioplasty procedure. This may be in addition to, or instead of assisting with drug delivery and/or preventing dog boning. It will be understood that any of the embodiments described herein can provide any of these benefits and/or be used in any of these procedures, as well as the other benefits and procedures described herein.
- Spikes can be positioned on the strips in any number of different orientations and configurations as will be described further below. The spikes can be any of the spikes discussed in
U.S. Patent No. 8,323,243 to Schneider et al. , issued 12/04/12. The spikes and cage can also be used in accordance with the plaque serration methods and other methods also described therein. - The
cage 10 can be made in many ways. For example, an extrusion process may be used, a tube may be cut, and/or a wire split as will be described in more detail below. Beginning withFigures 4A-5B , various embodiments of cages will be described.Figures 4A and5A show embodiments ofcages 10 during the manufacturing process. Thecages 10 are each in the form of a tube with a plurality ofsplines 24 spaced apart on the tube. In some embodiments, the tube can be pre-formed and then machined to the illustrated shape. The tube can be made of metal or plastic among other materials. In other embodiments, the tube is extruded to form the illustrated shape. For example, a method of making the tube can include extruding a plastic tube with a plurality of spaced apart splines 24 positioned longitudinally along the tube. Cross-sections of the cages are shown inFigures 4B-D and5A . - After forming the tube with the
splines 24, material from the tube can be removed to form the slits and strips 16. Either as part of removal process, or before creating the slits, the splines may be shaped to form different shaped spikes orwedge dissectors 26. For example, thesplines 24 illustrated inFigure 4B can be machined to form thesharp wedge dissectors 26 as shown inFigures 4C and 4D . In some embodiments, thesplines 24 can be manufactured with an additive process and shaped initially like the illustratedwedge dissectors 26 without requiring additional machining or other work. - Looking now to
Figure 4E , an enlarged detail view of a portion of a cage is shown. In this embodiment, thestrip 16 has been formed with a plurality of spikes orwedge dissectors 26. In some embodiments, from the base of the unfinished cage ofFigures 4A and4B , a slit can be cut in the tube to form adjacent strips. The wedge dissectors 26 can be shaped like a tent or axe head with an elongated tip and base, both of which extend longitudinally, along the longitudinal axis of the tube. The wedge dissectors 26 can assist with cutting and/or perforating plaque before or during an angioplasty procedure. The space between thewedge dissectors 26 can be machined or otherwise formed to remove material and increase the flexibility of the strip. The space between thewedge dissectors 26 is shown as being twice the length of thewedge dissector 26, though other spacing can also be used. Typically spacing length can be 4:1 to 3:1 space to length and more commonly 3:1 to 1:1 space to length. - Turning to manufacturing of the splines, in some embodiments, the
splines 26 are fabricated from a tube of material, where thecage 10 is a plastic extruded tube with splines that are cut, ground, electrical discharge machined, or molded to form thewedge dissectors 26. The tube can be manufactured with slits along its length. In some examples, the ends of the tube remain intact in order to forming rings. In some variants, thestrips 16 are spaced apart with some or all thestrips 16 having spikes orwedge dissectors 26. As will be understood from the above discussion, in the embodiments shown inFigures 4A-5B five slits would be made to form outward points. - In some embodiments, a method of making a
cage 10 for anangioplasty balloon 20 can comprise first extruding a plastic tube with a plurality of spaced apart splines positioned longitudinally along the tube. In some examples, the method can then include cutting at least one of the splines of the plurality of splines to form a plurality of spikes orwedge dissectors 26 positioned circumferentially around the tube. In some variants, the method can further include cutting the tube to form a plurality of longitudinally extendingstrips 16, each strip including at least one spike of the plurality ofwedge dissectors 26. - Looking now to
Figures 6A-6B , another method of manufacturing acage 10 will be described. Awire 28 can be split or cut to form three ormore strips 16 that can be used as part of forming acage 10. In some examples, thewire 28 is constructed of an alloy, or polymeric material. Any number of different manufacturing methods can be used including laser cutting and electrical discharge machining. In some variants, thewire 28 can be divided into sections, such as four quarters. In some embodiments, square or other shapedholes 30 can be cut into thewire 28 to form spaces between thewedge dissectors 26. Each of the sections of wire can then be separated to form thestrips 16 of thecage 10. Acage 10 can be assembled with a plurality of rings and include any number ofstrips 16. In some examples, acage 10 can be assembled from 1, 2, 3, 4, 5, 6, 7, 8 or more strips 16. -
Strips 16 can be attached in many ways to form thecage 10. In addition, to forming the strips from a wire, they can also be extruded and/or formed from a flat piece of material and/or a tube. For example, it will be understood that the embodiments described with reference toFigures 2 ,4A-5B can be modified to provide individual strips that can then be connected to form a cage. - In some embodiments, strips can be connected with two or
more rings cage 10. For instance, the individual strips of thecage 10 may be bonded to rings on either end. As illustrated inFigure 7 , eachindividual strip 16 is secured on either end byrings cage 10, thestrips 16 can be attached to therings balloon 20 before connecting to the rings. Thecage 10 may be permanently fixed to one or both ends of theballoon 20 or to the balloon catheter. In some embodiments, therings strips 16 can also help to keep theballoon 20 in a compressed state prior to deployment and can assist in deflating the balloon after expansion. - The
rings rings - In some examples, the
rings strips 16 and prevents or limits thestrips 16 from moving, sliding, tilting or twisting at any point along the length of the strips but especially at either end of theballoon 20. When the rings are elastic, super elastic, or thermally active, the rings can be placed about the strips and allowed to shrink onto the strips such that thestrips 16 are retained against the outer diameter of theballoon 20. Preferably, the rings and strips are positioned around a balloon in a fully expanded state and then heat is applied to the heat shrink type rings. In other embodiments, the heat shrink types rings are applied with the balloon in a deflated state. - As discussed with respect to
Figures 1A and 1B the cage can be performed and slid onto the balloon. But, in some embodiments, assembling the cage around the balloon can allow for a smaller cage design. In retrofitting theballoon 20, the rings can be advanced onto the balloon catheter from either side which may allow for a smaller ring inner dimension as compared to a cage with one ring that is advanced over a balloon. - The
rings cage 10 can be configured to accommodate theballoon 20 as it transitions from a deflated to an inflated shape. Not unlike the configuration of the cage with balloon illustrated inFigure 1B , thestrips 16 of thecage 10 can be in contact with theballoon 20 when theballoon 20 is in a deflated configuration. As theballoon 20 inflates, eachstrip 16 bows in a concave orientation with the balloon 20 (Figure 1A ). In some examples, thestrips 16 are free-floating and not bound to the balloon surface. - As the
balloon 20 begins deflating, the material properties of thestrips 16 can allow it to begin to return to their original position. This may be a completely flat position. As thestrips 16 return to their original position, this can provide an additional force to assist the deflation of theballoon 20. As the strips move from the concave position to a flat linear position, thestrips 16 move from an expanded length ("Le") to a deflated length ("Ld") where Ld is longer than Le. The straightening of thestrips 16 from Le to Ld in the axial direction elongates theballoon 20 and assists in morecomplete balloon 20 deflation. - The
rings strips 16. The following discussion of certain illustrated embodiments, are but a few such examples. - The
rings strips 16 in a number of different ways. The rings can be mechanically attached to thestrips 16 through a friction fit for example, or can be connected with an ultrasonic weld, adhesive, etc. Turning toFigure 8 , eachring more strips 16 of thecage 10 by rotating the rings in opposite directions (e.g. clockwise and counterclockwise). Therings strips 16 can be advanced to connect to the ring. In particular, the asymmetrical shape of the holes 32 can be configured to accommodate astrip 16 with periodically spacedwedge dissectors 26 such as that illustrated inFigure 6B . - As illustrated, the holes 32 can have a narrowed
portion 33 and awider portion 34. Thewider portion 34 can be configured to accommodate thewedge dissector 26 while the narrowedportion 33 can be configured to accommodate the width of the strip 16 (i.e. the space between wedge dissectors). Thestrips 16 can be advanced through the holes 32 by fitting awedge dissector 26 through thewider portion 34. In some examples, thestrip 16 can then be secured by turning therings strip 16 is moved into the narrowedportion 33. This can secure thestrips 16 to therings wedge dissector 26 cannot move past the narrowedportion 33. As described above, bothrings cage 10. Additionally, as illustrated inFigure 8 , because the holes 32 of thering 12 and the holes 32 of thering 14 are opposed, by rotating the two parts of the ring in opposite directions, this further prevents movement of thestrips 16. - The
strips 16 can be secured byrings Figure 9A illustrates an embodiment of thecage 10 where thestrips 16 are secured with aconical ring 12 at the distal end. The conical end can be the distal end of the balloon catheter and can provide an atraumatic end of the device. - Similarly,
Figure 9B shows aring 12 with a tapered outer diameter with ascrew feature 101 on its outer surface. This screw feature 101 can provide either a negative or positive impression about the outer surface of the distal ring. - The
ring 12 illustrated inFigure 9B can serve a treatment purpose as well. In some examples, the tapered and screw features on the ring can assist theballoon 20 in navigating and entering a narrow lesion. The coiledouter surface 101 can be configured to provide a gripping or tunneling mechanism. This feature can allow the ring to aid the operator in navigating through occluded lesions (either totally or partially) and enable passage of theballoon 20 therein. The negative orpositive impression 101 can be circumferential or patterned like a cork screw. In some embodiments, the negative orpositive impression 101 can be macro in scale or have micro features that offer an enhanced surface to enable passage through a narrowing in a vessel. In some examples, the function of theouter surface 101 of the ring can be described as acting like a lubricant although the feature is mechanical in nature. This function can be further enhanced with hydrophilic, hydrophobic coating. The surface texture can also be modified to aid in passages with less penetration energy. In some embodiments, this can be accomplished by adding micro scales (as seen in porcupine quills) or enhanced surface roughness (as used in nature by mosquitos). - The
ring 12 illustrated inFigure 9B can be secured tostrips 16 that are disposed about the surface of the balloon circumferentially in a helical fashion. In contrast to thelinear strips 16 illustrated inFigure 9A , thestrips 16 attached to the taperedring 12 can be wound around the balloon. A tapered oruntampered ring 14 can be used at the proximal end of the balloon. In some examples, the configuration of the attached strips 16 can follow the same pattern as the negative orpositive impression 101 on thering 12. - Turning now to
Figures 10-11 , multiple layer rings will be discussed. A ring with multiple layers can be used to hold the strips between the layers. The ring can have at least abase layer 122 and atop layer 121. As seen inFigures 10-11 , thering bottom layer 122 and a compressible, thermally or electrostaticallycompressible layer 121. Thetop layer 121 can be configured of a compressible material while thebase layer 122 can be configured of a non-compressible material and thestrips 16 can be captured between them. In some examples, the top layer or the top and base layers can be made from a heat shrink material. In some embodiments, thering - The rings can be made of a layer of composite materials where the
base layer 122 is less compressible or elastic than thetop layer 121. Energy can be added to thetop layer 121 to produce a reduction in the top layer's diameter until the top layer compresses and captures the strips between thebase layer 122. For example, thetop layer 121 can be a heat shrink material. In this way, thetop layer 121,base layer 122 and strips 16 can form acage 10 as seen inFigures 10 and11 . In some embodiments, the strips can be attached to the balloon and/or balloon catheter with the rings that are made of a single layer of heat shrink material positioned over the strips similar to just the top layer. - The strips or rings can include indentations to facilitate attachment to the other. The
strip 16 can include anindentation 171 on either side of the strip 16 (as illustrated inFigure 10 ) or anindentation 171 on one surface of thestrip 16 that can form a groove (as illustrated inFigure 11 ). Though inFigure 11 , thetop layer 121 is shown as a heat shrink material, it will be understood that in other embodiments a rigid ring could be press fit into theindentation 171. Such a rigid ring could be part of a single or multiple layer ring, thus there may or may not be acorresponding base layer 122. -
Figure 12 , illustrates another embodiment of thering ring grooves 17. Thegrooves 17 can have a width that can accommodate the width of the distal end ofstrip 16. An end of a strip can be attached to thering grooves 17 through the use of adhesive, mechanical coupling, wrapping heat shrink material around the ring, etc. In some embodiments, thestrip 16 ofFigure 11 can be placed in thering Figure 12 so that the indentations are engaged with each other. -
Figures 13A-C illustrate examples of astrip 16 that includes ansecurement feature 181 that improves the hold of thestrips 16 to therings securement feature 181 forms a section of thestrip 16 with a higher surface roughness. This can be in the form of the illustrated ridges or other teeth-like elements that aid in the imbedding of thestrip 16 into or holding the strip on the ring. - When the
ring securement feature 181 can be formed as narrow sections of thestrip 16 at the ends (as illustrated inFigure 13A-B ), or placed strategically along the strip length (such as where three or more rings are used). Thesecurement feature 181 can be aligned with therings securement feature 181 can be pressed into the polymeric material as illustrated inFigure 13A at a high temperature where the polymeric material is near or greater than the glass transition temperature of the material. In so doing thesecurement feature 181 can be used to engage or connect thestrips 16 to therings Figure 13C . - In
Figure 13A thering securement feature 181 into the body of the ring material.Figure 13A shows thestrip 16 with a ridgedhook feature 181 before it is pressed into the ring material.Figure 13B shows a perspective view of another embodiment ofsecurement feature 181. In some examples, thesecurement feature 181 can be significantly longer than thering cage 10. - When the
ring ring cage 10 to enable thecage 10 to return to the relaxed,deflated balloon 20 position. Furthermore, the portion of thestrips 16 without a wedge dissector is the thinnest and the most flexible. This can allow thestrip 16 to be the most flexible at the edge of theballoon 20 where the forces are the highest. -
Figures 13D-F illustrate an example where the elastic material of a ring can provide tension on a cage during expansion and to then assist in deflating the balloon as the tension is released. Turning first toFigure 13D , thecage 10 is disposed about theballoon 20. Thecage 10 can be composed of a plurality ofstrips 16 that are secured to the balloon byrings rings strips 16 down into a linear position such that the wedge dissectors are perpendicular to the surface of theballoon 20. Callout "A" provides a schematic, see-through view of the proximal end ofring 14. As shown,ring 14 is secured about theouter catheter shaft 22 by an adhesive 23. As well, aninner guidewire shaft 21 can run concentric to theballoon 20. Theguidewire shaft 21 can be secured with relationship to thecatheter shaft 22. For example, theguidewire shaft 21 and thecatheter shaft 22 can both be connected to different ports on a hub, such as the illustrated bifurcated luer at the proximal end of the balloon catheter. The balloon can be inflated by injecting a fluid into the catheter shaft. It will be understood that in some embodiments thecatheter shaft 22 open directly inside theballoon 20, rather than opening at thering 14 as shown. The ring can be attached to thecatheter shaft 22 and/or theballoon 20. -
Figures 13E-F illustrate aballoon 20 andcage 10 as theballoon 20 is inflated and subsequently deflated. As noted above, in some examples, the elastic material of therings cage 10 to expand as theballoon 20 is inflated. In some embodiments such as the shown inFigures 13E-F , the rings can be made of an elastic polymer and the strips can be made of metal or an inelastic polymer. As shown inFigure 13E , as theballoon 20 is inflated, thestrips 16 of thecage 10 begin to move apart. In order to push each of thestrips 16 outward, force is exerted radially outwards (as illustrated by the arrows) on the balloon 20 - and by extension the cage 10 - as theballoon 20 is inflated. As theballoon 20 expands, therings strips 16 to maintain alignment while expanding with theballoon 20. - This tension can also help the
balloon 20 to deflate. During balloon deflation, as illustrated inFigure 13F , the tension on thestrips 16 exerts a force radially inward as thestrips 16 and therings strips 16 and allowing them to flatten, thereby providing a narrowed profile for catheter retraction. - Looking now to
Figures 14A-D another embodiment ofstrip 16 is shown with various types of rings. As illustrated inFigures 14A-B , in some examples, the ring can be fabricated from the lip on the neck of theballoon 20 and the portion of the catheter body used to bond the catheter to theballoon 20. The catheter can provide a pathway for gas or liquid inflation of theballoon 20. Additional components such as an over mold or heat shrink can be added to the bond joint, as can additive glue or polymeric material. In some examples, this can serve to prevent pressure from leaking out of theballoon 20 along the length of thestrips 16 forming thecage 10. - As illustrated in
Figures 14A-D , ahook 161 at the strip end can enable the strip to be easily aligned along the balloon surface and can aid in orienting the strip in a longitudinal orientation relative to the axis of theballoon 20. Thehook 161 can be integrated into each end of thestrip 16. Thehook 161 can be wrapped around the lip of the neck of theballoon 20 from the outer diameter ("OD") of theballoon 20 neck around the opening and into the neck where the end of thehook 161 rests within the inner diameter ("ID") of theballoon 20 neck. - Both ends of the
strip 16 can have ahook 161, or just one end can have the hook. In addition, the ends can be attached to the balloon catheter in the same or in different ways. For example, heat shrink can be wrapped around the ends of the strips and balloon. In some embodiment, heat shrink is wrapped around one end and a rigid ring, such as those discussed with respect toFigures 8-12 can be used at the other end, which may also include a heat shrink layer. - The strip may or may not be attached to the balloon at other locations. As shown, the
strip 16 can also have hinges or pre-bent regions that correspond with the shape of the balloon. Thus, the strip in the expanded state can have a main portion havingwedge dissectors 26 that is parallel with the axis of the balloon. Angled sections can extend from the main portion to thehooks 161. The angled sections can form an angle when the balloon is expanded as shown, but can be flat when the balloon is deflated. In some embodiments, hinges between the sections can be formed with thinner sections of material. - As shown in
Figure 14A the strip can attach to the balloon without a separate ring by use of thehooks 161. The balloon can be glued to a catheter (for example an elongated tube with one or more lumen) which can also secure the hook in place.Figure 14A shows one strip for simplicity, though it will be understood that 2, 3, 4 (Figure 14B ), 5, or more strips could be used. -
Figure 14C shows a detail view of thehook 161 attaching to aballoon 20. As can be seen the balloon can serve as abase layer 122 of the ring and atop layer 122 is also shown.Adhesive 123 is also shown securing thetop layer 121 to the balloon. In some embodiments, thetop layer 121 can be the tube of the catheter. -
Figure 14D shows a twolayer Figures 10-11 , the ring illustrated inFigure 14D can be a multi-layer ring where thebase layer 122 is less compressible or elastic than thetop layer 121 and where energy is added to the top layer producing a reduction in the top layer's diameter until the top layer compresses and captures the strips between thebase layer 122 and thetop layer 121 to produce thecage 10. -
Figure 14E illustrates another embodiment of therings strips 16 on the surface of theballoon 20. As shown in callout "A," therings balloon 20 such that the wedge dissectors protrude through the surface of therings ring strip 16 below. The wedge dissectors can protrude through therings rings rings strips 16. This can form ahole 27. Therings holes 27 pre-cut into therings - It can also be seen that the
rings balloon 20. For example,cutouts 29 of material in the rings can help a ring made of heat shrink material to shrink to the shape of the balloon. - As discussed above, each of the
strips 16 can extend between one or two rings, though additional rings can be used as needed. For example, three, four, five, six, seven, eight, nine, or ten, or more rings can be used, especially with longer balloons. As one example, anangioplasty balloon 20 having a length of 300 mm can be fitted with acage 10 having tworings rings cage 10 can includerings 13 or other similar controlling elements that can aid thestrips 16 in maintaining alignment and orientation as theballoon 20 expands towards the artery wall. - As illustrated in
Figure 15A , therings 13 can be a fraction of the overall length of theballoon 20. Somering 13 designs are less than one and a half times the length of theballoon 20. In other examples, the rings are between 1.0-0.5 times theballoon 20 length. More commonly the length of therings 13 are between 2.5 and 1.5 times theballoon 20 diameter and typically between 1.5 and 0.5 times theballoon 20 diameter. Eachring rings - The
rings 13 can be placed on the outer surface of the body of theballoon 20. In some examples, therings 13 can be designed to retain the body of thestrips 16 such that the position and orientation of thestrips 16 are maintained. It can also be seen, that thestrip 16 does not extend along the shoulders of the balloon. Thus, the strip can be elongated and can extend parallel with the axis of the balloon.Figure 15A shows onestrip 16 for simplicity, though it will be understood that 2, 3, 4, 5, or more strips could be used. - These
rings 13 can be positioned over the expandedballoon 20 area and may have different properties than therings balloon 20. As illustrated inFigure 15A , in some embodiments, therings 13 positioned over theballoon 20 surface may be more elastic in property than those located on the ends of theballoon 20. This can allow the rings to accommodate the expansion and refolding of theballoon 20. In some examples, the rings used on the outer diameter of theballoon 20 are placed over the two ends of each separated strip. Thestrips 16 may also be glued, welded, restrained by friction fit, or otherwise attached to any of the rings described above. - In some embodiments, rows of strips and/or strip segments can be placed around the
balloon 20. Some rows may extend over the entire length of theballoon 20 and other rows may not. In some examples, a row may include a plurality of strips in series that are separated by gaps. Placing strips in a series on the balloon can provide greater flexibility which can improve deliverability through tortuous anatomy. - As described previously, rings 12, 14, 13 can be used to retain the strip on the surface of the
balloon 20. The rings can be connected to the strips in any number of different ways, as described in the various embodiments herein. In some embodiments, the ends of thestrips 16 with no wedge dissectors can be used to attach to the rings. In other embodiments, the ends with wedge dissectors can attach to the rings. -
Figure 15B illustrates another embodiment of balloon catheter. Aballoon 20 is shown with acage 10 with four equally spaced rows ofstrips 16. Each row has twostrips 16 that are laid in series. Aring 13 attaches theadjacent strips 16 to properly secure and orient thestrips 16 across the surface of theballoon 20.Rings - The callout "A" provides an enlarged view of the distal end of the
balloon 20 withcage 10. The hatching illustrated in callout "A" is provided to help visualize and delineate the different parts of the device. As shown, the end of theballoon 20 includes aring 12 that secures a plurality ofstrips 16 to the surface of theballoon 20. Theballoon 20 is disposed about acatheter 19. Thering 12 can be a heat shrink material. A wedge dissector is also shown extending through the ring. The placement of the strips is further clarified inFigure 15C which shows how a pair ofstrips 16 which are laid in series such that thestrips 16 span the length of theballoon 20. - To improve flexibility, the
cage 10 can have rows that are made up of a greater number ofstrips 16 than illustrated inFigures 15B and15C .Figures 15D-15E illustrate an example where fivestrips 16 are laid across the surface of theballoon 20 in series. As noted previously, each of thesestrips 16 can be secured on the surface of theballoon 20 by a plurality ofrings 13. Callout "A" provides a cut away of thering 13 to show the gap between the twostrips 16 that are in series. As described above with reference toFigure 14E , the wedge dissector can protrude through thering 13 in a variety of ways. For example, the shape of the wedge dissector can cause the wedge dissector to poke through the material of thering 13. As well, thering 13 can have a plurality of holes cut into therings 13 to allow the wedge dissectors to poke through. - In addition to having multiple strips in rows, the gap between the strips in a row can also be adjusted to increase flexibility. To ease manufacturing the linear alignment in the theta direction around the radius (angle drift) and the spacing alignment between the strips 16 (gap) can have a relatively broad tolerance creating greater options in developing the manufacturing process and choosing tools. In some cases, the gap tolerance can be ±5 mm and the angle drift ± 25 degrees; ±3 mm and the angle drift ± 10 degrees; and ±2 mm and the angle drift ± 5 degrees. Cage designs that require greater tortuosity can utilize the periodic strip placements in a linear sequence with spaced apart strips. This can enable the balloon to manage bends and turns in anatomical spaces with less stress on the strips and more effective pushability of the entire system.
- As shown herein many of the
strips 16 have a flat bottom. This can help thestrips 16 sit on the surface of the balloon and to maintain the orientation of the wedge dissectors. This can prevent rotational movement of thestrips 16 on the surface of theballoon 20. - Three unique features that all strip and ring configurations can work to achieve are 1) perpendicularity of the wedge dissectors to the balloon surface, 2) maintaining flat and low profile of the strips on the balloon, aiding in limiting the wedge dissectors from damaging tissue on its journey, and 3) either assisting in deflation of the balloon or producing a minimal burden on the typical balloon deflation characteristics. To achieve these features strips typically have a flat bottom, are bounding to the balloon with rings on either end of the strip, are folded to limit wedge dissector interaction with tissue on its journey, and when a ring lays over the wedge dissectors the wedge dissectors poke through the rings and the majority of the wedge dissector height is still available for penetration into the vessel. Although some designs utilize rings to produce forces on the balloon enabling more effective balloon deflation by either pulling on the strips end to end or by applying radial compression, in most designs the rings can support the strips by limiting strip movement, aiding in wedge dissector orientation, and preventing the strips from separating from the balloon. Design features that contribute to these functional characteristics include: strips that have flat bottoms enabling stable orientation of the wedge dissectors but are thin enough to be laid down tangential to the balloon or contained in a fold of the balloon during folding, spacing between the wedge dissectors does not have a cutting edge enabling rings to lay in the spacing and support strip retention, and the ends of the strips can be thinnest with no wedge dissectors enabling greater surface area for rings to bond to the strip and enabling the strip to be most flexible at the edge of the balloon where forces are highest during catheter migration to and from site of deployment. It will be understood that other benefits and advantages can also be provided.
- The
rings strips 16 in a variety of ways.Figures 16A-C shows examples of therings strips 16.Figure 16A shows a material wrapped around the balloon to formrings Figure 16B , thering Figure 10 , where each of the rings can have an upper layer and bottom layer that wraps around a portion of thestrip 16.Figure 16C illustrates asolid ring - As discussed herein, many of the embodiments can use a heat shrink material for part of, or the
entire ring - Heat shrink material can be manufactured from a thermoplastic material, such as polyolefin, fluoropolymer (including fluorinated ethylene-propylene (FEP), polytetrafluoroethylene (PTFE) or polyvinylidene fluoride (PVDF)(e.g. KYNAR)), polyvinyl chloride (PVC), neoprene, silicone, elastomer or synthetic rubber and fluoropolymer elastomer (e.g. VITON). When a flexible material is desired, such as one that expands with a balloon, the heat shrink material can include one or more of polyolefin, silicone, elastomer or VITON (synthetic rubber and fluoropolymer elastomer).
- Heat shrink material in the form of a tube can be used to slide onto or over the
strips 16. The tube can have a shrink ratio of 3:1 or higher (e.g. 3.5:1, 4:1, 4.5:1, 5:1, 6:1) and allow for gentle heat shrinking to prevent any balloon deformation or other changing of the balloon's properties. The material can be flexible enough to conform to the balloon through a range of balloon diameters (such as typical with semi-compliant balloon technology ∼.5mm diameter range), and may have an adhesive or other coating to support the bonding of the heat shrink material and balloon. The heat shrink material can be a thin film. The heat shrink material may also be in the form of a sheet or multiple sheets instead of a tube. - A method of retrofitting a balloon catheter with a cage can include any of the following steps. Positioning strips around an inflated balloon. The strips may include wedge dissectors. The strips can be positioned equally spaced around the inflated balloon. The strips can extend primarily longitudinally. The strips may be positioned serially in rows, such as 2-6 rows, each with 2-6 strips. The strips can be attached either permanently or temporarily to the balloon with an adhesive. Heat shrink material can be positioned around the ends of the strips as a ring. Individual rings of heat shrink material can connect to or cover ends of multiple strips positioned circumferentially around the balloon. Individual rings of heat shrink material can also connect to or cover ends of adjacent strips positioned serially in a row. Heat can then be applied to shrink the heat shrink material. The balloon can be deflated and then sterilized in preparation for use.
- Turning now to
Figure 17 , a schematic view is illustrated showing a detail of acage 10. In some embodiments, thestrip 16 is shown having asection 34 composed of a spring zone. The spring section of thestrip 16 can provide a plurality of benefits. For example, thespring section 34 can increase the flexibility of thecage 10. Increasing the flexibility of thecage 10 can allow thecage 10 to more easily pass through the tortuous geometry of a blood vessel. Thespring section 34 can also provide a wider base for thewedge dissectors 26, to help thewedge dissectors 26 remain in the desired orientation. - In some embodiments, the
spring section 34 can interface with a surface of theballoon 20. The spring section can help thestrip 16 to remain in the correct position with thewedge dissectors 26 in an outwardly projecting orientation. In some examples, the spring section can counteract a sideways bending moment on the spike such that thewedge dissectors 26 do not bend, flex, or change position an undesirable amount. In some embodiments, thespring section 34 can also provide the benefit of assisting theballoon 20 in refolding post inflation. The spring can add mechanical tension on theballoon 20 to return it to a compressed state and further aid the rings in compressing theballoon 20 during deflation cycles. - The
spring section 34 can have an undulating configuration and be connected to astraight section 36. In some examples, thewedge dissectors 26 can be located on the straight section. In other embodiments, the spring section can be sinusoidal. As illustrated inFigure 18 , the spring section is shown having a larger amplitude at the proximal end as compared to the distal end. The amplitude can decrease while the period increases along the spring section towards the straight section in a distal direction. In some embodiments, one side of the spring section can have a larger amplitude than the opposite side. In some embodiments, the spring section can be symmetrical. -
Figure 18 illustrates various embodiments of thecage 10 utilizing thespring section 34 andstraight section 36. Any number of different patterns can be used.Figure 19 shows a detail ofwedge dissectors 26 onstraight sections 36. - Systems and methods as disclosed herein can deploy the cages and wedge dissectors in any body lumen, including vascular lumens such as arteries and veins. The arteries could be coronary arteries, peripheral arteries, or carotid or other cerebral arteries, for example, or iliac, femoral, superficial femoral, iliac, or other peripheral vasculature, for example. The device may also be used in any lumen or transportation vessel found in any of the respiratory, digestive, urinary, reproductive, lymphatic, auditory, optical, or endocrine systems. It is understood that a device for generating serrations in any one, two, or more of these systems may take slightly different forms. Independent of the location the device might be used, some embodiments of devices include spikes (also herein referred to as wedge dissectors, or serrating elements on a spline and an expandable mechanism to increase and decrease the diameter of the spike features (such as a balloon) with both attached to a base catheter-like device.
- In some embodiments, as illustrated for example in
Figure 20 which is a close-up detail view of an embodiment of awedge dissector 200 on its associatedstrip 300, awedge dissector 200 can include a strip-facing base surface 202 (which may also be referred to herein as a bounded surface). The strip-facingbase surface 202 of thewedge dissector 200 can be defined by the base where thewedges 200 protrude outward and directly continuous with a surface of the strip at the interface between the wedge dissectors and the balloon. The strip could be aspline 300 or other strip-like structure. In some embodiments, this strip-facingbase surface 202 has a relatively narrow width made of a hard material capable of holding a sharp edge. In some embodiments, the preferred material is martensitic stainless steel, with a hardness of 52 to 64 on the Rockwell C-scale (HRC) although other materials including a polymer or co-polymer including but not limited to polyolefin, fluoropolymer (including fluorinated ethylene-propylene (FEP), polytetrafluoroethylene (PTFE) or polyvinylidene fluoride (PVDF)(e.g. KYNAR)), polyvinyl chloride (PVC), neoprene, silicone, elastomer or synthetic rubber and fluoropolymer elastomer (e.g. VITON), or a combination thereof can be utilized. In some embodiments, the strip is about or no more than about .008", .010", or .012" (0.203mm, 2.54mm, 3.048mm) wide (oriented circumferentially). In some cases, the width can be between about .006" and about .020" (0.152mm and about 0.508mm) or between about .004" and about .030" (0.102mm and about 0.762mm) . In some embodiments, thestrip 300 typically runs longitudinally the length of the working balloon edge, but can also be oriented in angles up to and including 90 degrees from the longitudinal axis of the balloon (or other expandable structure), or in a helical fashion at varying pitches. In some embodiments, the height of thebase strip 300 can be between about .004" and about .01 " (0.102mm and about 0.254mm), or between about .002". and about .020" (0.051mm and about 0.508mm) in some embodiments. - Still referring to
Figure 20 , awedge dissector 200 can also include a radially outwardly facing surface 204 (which may be referred to herein as an unbounded surface) that can define a top surface of thewedge dissector 200 from first (e.g., proximal)edge 206 to second (e.g., distal)edge 208 and be configured to contact tissue, plaques, or other structures within the body. Also shown are anterior surface 210,posterior surface 212, and opposinglateral surfaces 214 and 216. In some embodiments, the lateral surfaces 214, 216 extend upward generally perpendicular to the longitudinal axes of the strips, and the radially outward facing surface extends between the lateral surfaces as a linear, curved, or other geometry as described elsewhere herein at an angle to the lateral surface/lateral surface axis. Also illustrates are strips orsplines 300 having an unbounded (e.g., superior-facing)surface 302 that can be coextensive with the strip-facing surface orboundary 202 of thewedge dissector 200, as well as side surfaces (e.g., 304), and inferior-facingsurface 303. -
Figure 21 is a schematic illustrating several possible non-limiting embodiments of a wedge dissector. In some embodiments, the length of the radially outwardly facing surface LU (e.g., radially outwardly facingsurface 204 betweenfirst edge 206 andsecond edge 208 ofFigure 20 ) is between about 30%, 20%, or 10% less than the total length of the strip-facing surface LB (of strip-facingsurface 202 inFigure 20 ). In some embodiments, the radially outwardly facing surface length LU can be from about 50% to about 20% less than the strip-facing surface length LB, and sometimes as large as the strip-facing surface length LB. The radially outwardly facing surface width WU is in some cases equal to or less than the strip-facing surface width WB,, and typically between or less than about 10%, 20%, 30%, 40%, or 50% of the strip-facing surface width WB, or between about 20% and about to 50% less than the strip-facing surface width WB, and sometimes about or up to about 50%, 60%, 70%, 75%, or 80% of the strip-facing surface width WB. Therefore, in some embodiments there is an angle θ that is equal to or less than about 90 degrees that defines the slope from the strip-facing surface width WB to the radially outwardly facing surface width WU on at least one of the strip-facing surface width WB edges. While in some embodiments the radially outwardly facing surface width WU is constant from edge to edge, in some embodiments the radially outwardly facing surface width WU varies along the radially outwardly facing surface length LU as described elsewhere herein, such as decreasing from a first lateral edge to a point or segment in between the first lateral edge and the second lateral edge of the radially outwardly facing surface segment, and then increasing, from the point or segment in between the proximal edge and the distal edge, to the distal edge. In some embodiments, the relatively central segment in between the proximal edge and the distal edge has a constant width, while the lateral segments surrounding relatively central segment have variable, such as tapered widths. - Although the radially outward facing width WU can come to a point, sloping from the strip-facing base width WB of the strip-facing
base surface 202 to the radially outward facing width WU of the radially outward facingsurface 204 in a single, constant sloped angle θ or bevel such as shown inFigure 22A (end view resembling an isosceles triangle) andFigure 22B (isometric view), it can also in some embodiments include a plurality of different angles, such as more than a single slope angle such as a double, triple or more bevel (e.g., a first angle for a first segment of the height, a second angle for a second part of the height that can be less than or greater than the first angle, and in some cases a third angle for a third part of the height that can be less than or greater than the first angle, and less than or greater than the second angle).Figure 22C illustrates an end view andFigure 22D illustrates an isometric view of a wedge dissector with a plurality of differing slopes and associated angles from the strip-facing base surface to the radially outward facing surface, where the angle θ2 between horizontal and an upward slope after a transition point is greater than an angle θ1 between the horizontal strip-facing base edge and the intersecting upward slope (in other words, the first slope S1 from the strip-facing base edge base is less steep than a second slope S2 higher up after a transition point).Figures 22E and22F illustrate an embodiment similar toFigures 22C and22D except the angle θ2 is less than the angle θ1 (in other words, the first slope S1 from the strip-facing base edge base is steeper than a second slope S2 higher up after a transition point). - Alternately, some embodiments may also include a series of steps at different heights where the width transitions to a narrower width and then continues to climb in height. When a series of steps is used in place of the bevel it can sometimes be due to fabrication limitation when methods other than a reel of stainless steel is honed to an edge.
- The shapes of the radially outward facing edge or surface (e.g., radially outward facing
surface 204 ofFigure 20 ) can in some embodiments be the same height from oneedge 206 of the radially outward facing length or width to theother edge 208. In some embodiments, the height along the radially outward facingsurface 204 can vary from oneedge 206 to theother edge 208. When the radially outward facing edge orsurface 204 varies, typically the radially outward facing edge has a series of raised features herein referred to as wedge dissectors, spikes, orserrating elements 200. In some embodiments, the midpoint of these raised features along the radially outward facinglength 204 betweenedges base surface 202. The maximal variation of height betweenedges surface 204 of thewedge dissectors 200 and the radially outward facingsurface 302 of thebase strip 300 between thewedge dissectors 200 can in some embodiments be less than about 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, or less than the total height of thewedge dissector 200. - In some embodiments, the
base strip 300 has a roughened or otherwise textured inferior surface to aid in adhesion to an outer surface of the underlying balloon. The base strip can have any desired geometry such as square, rectangular, or in some embodiments trapezoidal with the bottom surface having a greater width, such as about or at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more of the top surface. In some embodiments between about 1/3 and ½ of the top surface of thestrip 300 is covered bywedge dissectors 200, while between about ½ and 2/3 of the top surface are free ofwedge dissectors 200. - Referring to
Figure 21 , in some embodiments, the radially outward facing surface viewed from the top can be seen as a line extending from one edge of the radially outward facing length to the other edge of the radially outward facing length (e.g., where Wu is a point assuming 210A is the radially outward facing surface of the device). This would be analogous to a honed or "razor-sharpened" edge with no apparent width. In other embodiments, the top view appears as an unhoned surface that is slightly blunt resembling a rectangle (e.g., if 210B or 210C is the top of the device, and assuming everything above those lines were cut off) with the width of the radially outward facing surface Wu being less than the strip-facing base surface WB but directly correlated with the slope or slopes between the width edge and height from the strip-facing base surface to the radially outward facing surface. In some embodiments, the top or the radially outward facing surface can be a line, a flat rectangle, a rounded or mounded surface (that might appear to be a rectangle or square in a 2-dimension point of view), or take a pyramidal, wedge, trapezoidal, or other polygonal shape. - In some embodiments, an unhoned width can be a width, for example, that is about or greater than about 1nm, 5nm, 10nm, 50nm, 100nm, 500nm, 1µm, 2µm, 5µm, or 10µm. In some embodiments, unhoned radially outward facing surfaces of wedge dissectors can be advantageous as being slightly blunt/relatively less sharp than honed edges, in situations for example where creating serrations, indentations, and/or microperforations in a wedge dissector target, for example, is desirable rather than making cuts through the entire luminal wall. In some embodiments, the entire radially outward facing wedge dissector surface has an unhoned width.
- The shape of the wedge dissectors can take many forms, including further non-limiting embodiments as those shown in
Figures 21A-G . For example,Figure 21A illustrateswedge dissectors 200 rising from abase strip 300 with a honed/sharp radially outward facingsurface 204 fromedge 206 to edge 208.Figure 21B-21C illustrates wedge dissectors withchamfered segments 780 of a radially outward facing surface on both lateral edges that slope or otherwise ramp upward to a honed centralsingle point 782 or edge having alength 781. The slope could be a straight line ramp, or follow a curve as seen inFigure 21D below. As illustrated inFigure 21B , the wedge dissector includeslateral segments 780 of radially outward facing surface that increases in height, but decreases in width from a first edge to acentral mid-portion 781 having a length with minimal/negligible width, and then increases in width and decreases in width from the midpoint to the second edge.Figure 21C illustrates a wedge dissector similar toFigure 21B except that the mid-portion is a single honedapex point 782. -
Figure 21D illustrates a wedge dissector with a radiused radially outward facingsurface 785 that increases in height from an edge along a first curved length but decreases in width from a first edge to a central zone such as amidpoint 786, then decreases in height and increases in width along a second curved length to another edge. -
Figures 21E-21G illustrate embodiments of wedge dissectors with an unhoned, radially outward facing surface that do not include a sharp honed point or edge (e.g., having a width that is larger than that of a honed edge).Figure 21E illustrates an embodiment of a wedge dissector somewhat similar to that ofFigure 21B , except the radially outward facing surface is completely unhoned along its length.Figure 21F illustrates an embodiment of a wedge dissector somewhat similar to that ofFigure 21C , except the radially outward facing surface is completely unhoned along its length.Figure 21G illustrates an embodiment of a wedge dissector somewhat similar to that ofFigure 21D , except the radially outward facing surface is completely unhoned along its length. - One commonality of the embodiments of
Figures 21B-21G is that the widths of the radially outward facing surfaces are greater (wider) at the lateral edges, and narrower/less wide more centrally, either at a central point or longer central segment. The height of the radially outward facing surface from one edge to the other edge can be arched or otherwise variable, e.g., with a highest point more centrally and the shortest height at one or more edges when viewed from the side. In these embodiments, the orientation of the narrowest or thinnest (least wide) section of the radially outward facing surface can be along the longitudinal axis of the strip, which may or may not be aligned with the longitudinal axis of the balloon. - In other embodiments, the narrower point or segment need not be symmetric about the midpoint of the length of the radially outward facing surface, but can be asymmetrical/offset from the midpoint of the length in some cases.
- Independent of the geometry of the wedge dissectors, some embodiments are characterized by having a
bounded end 202 or base (e.g., the spikes have a base the spikes are "attached" to, whether it is a spline (or strip), a balloon, or a molded element of some sort) with a length and width and an radially outward facingsurface 204, end or tip with a length and width. In some embodiments, the width of the radially outward facing end is about, or less than about 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, or less than the width of the strip-facing base end, or ranges incorporating any of two of the foregoing values. The width of the strip-facing base end of the wedge dissector (as well as the spline/strip) can be fixed/constant, or alternatively variable in some embodiments. - The wedge dissectors can be a number of different sizes and shapes. In some embodiments, the wedge dissectors are about or less than about, for example, 0.10", 0.09", 0.08", 0.07", 0.06", 0.05", 0.04", 0.03", 0.02", or 0.01" (2.54mm, 2.286mm, 2.032mm, 1.78mm, 1.52mm, 1.27mm, 1.02mm, 0.762mm, 0.508mm or 0.254mm) in length at the strip-facing base end or ranges incorporating any of two of the foregoing values, or between about 0.01" and about 0.06", or between about 0.01" and about 0.04' (0.254mm and about 1.52mm, or between about 0.254mm and about 1.02mm) ' in length. In some embodiments, the wedge dissectors can be about or less than about 0.05", 0.04", 0.03", 0.025", 0.02", 0.015", 0.01", or 0.005" (1.27mm, 1.02mm, 0.762mm, 0.52mm, 0.508mm, 0.284mm, 0.254mm or 0.127mm) in height as measured from the unbonded edge of the base strip, or between about 0.005" and about 0.025" or between about 0.01" and about 0.025", or between about 0.005" and about 0.015' (between about 0.127mm and about 0.52mm or between about 0.254mm and about 0.52mm or between about 0.127mm and about 0.284mm) ' in some embodiments.
- The wedge dissectors can, in some embodiments, have a wedge strip-facing base length of about, or less than about 25mm, 20mm, 15mm, 14mm, 13mm, 12mm, 11mm, 10mm, 9mm, 8mm, 7mm, 6mm, 5mm, 4mm, 3mm, 2mm, or 1mm long, or ranges incorporating any two or more of the foregoing values. In some embodiments the wedge dissectors have a wedge strip-facing base length of 2mm, 2.5mm, or 3mm long, or between about 1mm and about 5mm long, or between about 1.5mm and about 3.5mm long. The wedge dissectors can be spaced apart in a regular or irregular fashion to increase the flexibility of the device. For example, the space between adjacent wedge dissectors can be, for example, between about 2 times to about 10 times the wedge strip-facing base length of the wedge dissectors, with the wedge dissectors positioned lengthwise. For example, in some embodiments, wedge dissectors with a wedge strip-facing base length about 2.5mm long can have about 5mm spaces between them, or about 25mm spaces between them. In some embodiments, groups of wedge dissectors can be spaced apart with a first smaller ratio of, for example, about 1-4 times the strip-facing base length of the wedge dissectors and then a group can be spaced apart by a second larger ratio, for example, about 8-10 times the strip-facing base length of the wedge dissectors. For example, a first group of wedge dissectors with a strip-facing base length of 2.5mm can have 5mm spaces between them and then a second group of wedge dissectors can be spaced 20mm from first group. The second group can have the same or a different size, shape, and or spacing as the first group.
- The location of the radially outward facing surface relative to the strip-facing base surface is not always centered or symmetric in some embodiments. In other words, the midpoint of the radially outward facing surface can be offset from the midpoint of the strip-facing base surface.
Figures 23A-B and24 illustrate an asymmetric radially outward facing surface as an alternate embodiment of the spikes. An asymmetric radially outward facing surface can be off center with respect to the alignment of a radially outward facing width edge directly over the strip-facing base width edge. In this configuration only one of the strip-facing base width edges has a tiltededge 440 climbing in height off of the radially outward facing surface while theother height edge 442 is perpendicular, at a 90 degree (right) angle RA to the strip-facingbase surface 444, seen best inFigure 23A . In addition, the edges of the radially outward facing surface in one or both of the width ends and/or in one or both of the length ends can be chamfered or beveled or have a radius. In some variations, the radially outward facing surface location is limited to the area projected upward over the strip-facing base surface. The radially outward facing surface can be a sharp line (e.g., honed edge) or any of the described unhoned edge variations for example.Figure 23C-D illustrates an embodiment where the total volume or substantially the total volume of the wedge dissector rises/is present over less than the entire width (or surface area) of the base of the strip, such as about or less than about 70%, 60%, 50%, 40%, or 30% of the width or surface area of the strip, for example, and are thus the wedge dissectors are asymmetrically offset either anteriorly or posteriorly from the longitudinal axis of the strip. -
Figure 24 illustrates an embodiment illustrating how the radially outward facingsurface 204 may have a varying height (increasing from first height 24H1 atfirst edge 206 to second height 24H2 at second edge 208) from the strip-facingbase surface 202 and may include edge profiles that are rounded with a radius of curvature of the radially outward facing length edges 206, 208. Here we see a wider radius of curvature at oneedge 206 that has a shallow height 24H1 measured from the strip-facingbase surface 202 while the radius of curvature of theopposite edge 208 is narrower and has a longer height 24H2 measured from the strip-facingbase surface 202. - In some embodiments, the various wedge dissector features described herein can offer unique advantages to aid in delivery of the device, including but not limited to reducing vessel trauma if the radially outward facing surface is positioned outside of the delivery apparatus and/or can contact the luminal wall and has the potential to scrape the vessel wall during movement through the artery. This can be the case, for example, in embodiments with wedge dissectors with unhoned, radially outward facing surfaces.
- In addition, not to be limited by theory, certain shapes may offer more effective penetration into the tissue. For instance, wedge dissectors that include chamfered or rounded radially outward facing edges can potentially enter the vessel wall with less force (requires less pressure to penetrate tissue) while still maintaining an effective micro channel to weaken the tissue and enable tissue expansion with minimal vessel trauma and cellular injury.
- Furthermore, while there have been prior proposals for providing blades or sharp edges or scoring wire on a balloon during angioplasty or other procedure for cutting or scoring the plaque in conjunction with balloon expansion, these prior methods are deemed to have problems or disadvantages which are eliminated or avoided by systems and methods as disclosed herein. Cutting or scoring a luminal wall, such as, for example, the plaque during angioplasty can be performed at high pressures that can result in high injury to the blood vessel. The cutting blades, edges or scoring wire can be forced into the wall of the blood vessel at the same time that the angioplasty balloon is expanded to dilate the plaque. During this process the cutting blades, edges, or scoring wire can be forced into the vessel wall at oblique angles and can plow up the plaque potentially increasing the tendency for dissections. In contrast, in some embodiments, wedge dissectors employ can be expanded into the plaque at low pressures so as to form precise microperforations, serrations, and/or indentations in a radially outward direction that form precise indentations, cleavage lines or planes in the plaque or other location in the luminal wall, or other target. The radially outward facing surface of the wedge dissector can push into the plaque or other luminal surface in small surface areas, thereby being much less likely to plow up the plaque or luminal surface.
- Wedge dissectors can be designed, in some embodiments, to provide a series of oriented punctures or serrations into (but not completely through in some cases) a diseased vessel wall. The wedge dissectors produce a linear line of weakness or perforations that enable more effective and gentler vessel lumen expansion. The perforations can also serve as a pathway for pharmaceutical agents. The pharmaceutical agents could be delivered using a drug coated balloon, either incorporated with the device disclosed herein, or on a separate device that is used following the usage of the disclosed device. In some embodiments, the wedge dissectors can be detachable from the base strip, and/or be coated or otherwise impregnated with one or more pharmaceutical agents for drug delivery.
- To reduce potential rigidity of the spline, or base strip, it is envisioned that a series of reliefs on the spline can be added in some embodiments, as illustrated in
Figures 25 and26 . The relief elements can be produced in many different ways with the intent to have material removed and offer a more pliable spline for the wedges to be strip-facing base to. Relief can be made in the base of the spline opposite the wedge dissector strip-facing base surface, at the top of the spline directly adjacent the wedge dissector strip-facing base surface, or in both locations, e.g., a combination of top and bottom. The relief can also be made on the side of the spline, or apertures strip-facing base by other areas of the spline can be added to the spline. Any combination of top, bottom, side or through apertures can be added to the spline to offer relief. - In some embodiments, as illustrated in
Figures 25 and26 , thestrip 300 can have relief holes or slits located at the top, bottom, centered or off center that are either circular, rectangular, linear, triangular, or elliptical or combinations thereof (Seefigures 25 and26 ). The strips offer a supporting base infrastructure, intended to be flexible and follow the movement of the balloon, for the wedges to be oriented correctly. - The relief holes illustrations as shown in
Figures 25 and26 can be specifically designed to offer a pathway for balloon-based pharmacological agents to migrate through; in addition, they offer strain relief in the surface to enhance the deliverability of the device in tortuous anatomy.Figures 25A-C illustrate embodiments of wedge dissectors withreliefs 502 on the inferior surface 500 of thestrips 300 opposite the bounded surface of thewedge dissectors 200.Figure 25A illustrates an embodiment where thereliefs 502 are regularly spaced apart approximately a length of the bounded surface of eachwedge dissector 200.Figure 25B illustrates an embodiment where thereliefs 502 are regularly spaced apart 50% or less of the length of the bounded surface of eachwedge dissector 200.Figure 25C illustrates an embodiment where eachrelief 502 is spaced apart 50% or less of the length of the bounded surface of eachwedge dissector 200, but thereliefs 502 are grouped only under the wedge dissectors and are not present under the strip sections in between the wedge dissectors. In other embodiments, thereliefs 502 are grouped only under the strip sections in between the wedge dissectors, but not under the strip sections directly below the wedge dissectors. -
Figures 25D-25E illustrates an embodiment where the reliefs 502' are present on the top (bounded or superior-facing surface 302) of the strip in between the wedge dissectors. InFigures 25D and25E , the reliefs form depressions in the superior-facingsurface 302 of the strips in between wedge dissectors with a generally curved based as illustrated inFigure 25D , and a relatively more square or rectangular base as illustrated inFigure 25E , with or without rounded edges.Figure 25F is an embodiment combining two different kinds ofreliefs 502 found in the embodiments ofFigures 25C and 25D . Other permutations of combinations are also possible, depending on the desired clinical result.Figures 25G and 25H illustrate other embodiments where thereliefs 502 are on an anterior 304 and/or posterior side surface of thestrip 300.Figure 25G illustrates generally pyramidal-shapedreliefs 502, whileFigure 25H illustrates generallyarcuate reliefs 502. The reliefs can be spaced axially apart from the wedge dissectors as shown, and/or spaced axially aligned with wedge dissectors in other embodiments.Figures 25I and 25J illustrate embodiments where thereliefs 502 take the form of vertically (Figure 25I ) or horizontally (Figure 25J ) oriented through-channels, which can be spaced axially apart from the wedge dissectors as shown, or in another configuration. In some embodiments, the reliefs can be oriented at an oblique angle to the longitudinal axis of the strip.Figure 25K illustrates an embodiment where thereliefs 502 take the form of slots on the anterior and/or posterior side surfaces, bounded base surface, and/or other locations. - To aid in removal of material fabrication from the initial blade, the strips can include tabs along the base or bonded surface in some embodiments. The tabs can aid in controlling long strips from vibration or movement during the material removal. Once fabrication is completed, the tabs are then removed. In some embodiments, the tabs have an inset that they sit at the base of the strip. In some embodiments, inset reliefs can serve as the tabs, and be advantageous during the manufacturing process, when several strips are, for example, laser cut from the same sheet of source material. In some embodiments, a complementary protrusion (e.g., a tab or related structure) on or connected to an adjacent area of the source material to be laser cut can fit into an inset relief of a strip adjacent to the source material to maintain proper alignment of the strips during laser cutting/manufacturing. This can keep the strips in place during laser cutting, and prevent undesired migration and misalignment of a strip relative to an adjacent material area due to, for example, laser vibrations, which can decrease product yields. In some embodiments, reliefs for manufacturing stability purposes need not be inset and can take the form of tabs that protrude outwardly from the base of the tab. In some embodiments, these tabs are later removed by laser cutting or other methods prior to bonding or other attachment to the outer surface of the balloon, to prevent inadvertent puncture of the balloon. Some embodiments are illustrated in
Figures 25L and25M , which schematically illustratestrips 300 withwedge dissectors 200 during the strip and manufacturing process. Also shown istab 580, which can be laser cut out of the source material, and be connected with one end at an adjacent area of the source material 581 and the other end inset in aninset relief 502 in, for example, an inferior surface of thestrip 300. Theinset relief 502 can be any pattern as previously described, for example, inFigures 25A-25K or others, and in some embodiments are shown underneath thewedge dissector 200.Figure 25M illustrates thetab 580 which can be cut into segments 588, 589 following the manufacturing process when it is no longer required to hold thestrip 300 in place with respect to adjacent source material 581, and thestrip 300 can then be separated for attachment to a balloon or other device. The inset can allow for the tab to be removed while minimizing that amount of material that could potentially hang below the base of the strip which might interfere with the bonding of the strip to the balloon or other expansion device. - In some embodiments, balloons can be pleated and crimped down to the very narrow profile allowing the device to be delivered through and introducer sheath with a narrow diameter. Once the balloon has been deployed and deflated, the post-inflated balloon profile can be larger than its original pleated and crimped down diameter. This new profile may have strips that sit proud of the balloon profile potentially scraping the arterial wall or snagging on the opening of an accessory device such as an introducer sheath. The following elements, which are in general described as ramps, can address this potential issue, according to some embodiments.
-
Figure 25N illustrates schematically an embodiment of aramp 680 of adhesive or other material is placed at (e.g., over) one, as shown, or both lateral ends 333 of some or all of thestrips 300. This can be, in some cases, in addition to adhesive placed at other locations such as under the strips (e.g., on the inferior surface of the strips 300) to attach thestrips 300 to the balloon. Theramp 680 can offer an effective flexible interface between the edge of the flexible balloon (not shown) and thesemi-rigid strip 300, as theramp 680 can be made of a material (e.g., an adhesive) that is relatively more flexible than that of thestrip 300. Theramp 680 can be designed in some embodiments to gently slope from the balloon surface (not shown) to the edge of strip. In some embodiments, theadhesive ramps 680 can advantageously both retain strips and offer protection fromundesired strip interaction 300 with ancillary devices during a procedure. - In some embodiments, a feature that can be incorporated into the balloon element is a cone ramp. The cone ramp feature can be implemented in several ways. In one embodiment, the cone ramp is fabricated by taking a cone configuration for a larger balloon, for example taking a cone for a 6 mm balloon, or 5.5 mm balloon and incorporating it using known methods to be attached to a 5 mm balloon. One such embodiment is shown schematically in
Figure 25O . Thecone 970 can have in some cases an outer diameter that is larger than that of the outer diameter of theballoon 960, such as about or at least about 5%, 10%, 15%, 20%, or more than that of the outer diameter of theballoon 960, or between about 5% and about 20% larger than that of the outer diameter of theballoon 960 in some embodiments. The relativelylarger cone 970 will sit proud of theballoon 960 generating alip 972 at the intersection of the balloon body. Thelip 972 can be beneficial in reducing the potential of the metal strip edges to be snagged or lifted off when the balloon is deflated and retracted through the introducer catheter. - In some embodiments, illustrated in
Figure 25P , included are a series of rails 980 along thecone 970 to serve as support or stiffening structures, and assist in collapsing theballoon 960 as it enters an introducer catheter (not shown). In some embodiments, the rails 980 are oriented/align with the longitudinal axes of the strips, furthering enhancing the function of pushing the strips toward the middle of the balloon as the cone is pulled through the introducer. - In some embodiments, also disclosed herein are balloons that can have depressions in the outer surface of the balloon for strip attachment. A series of depressions can be produced on the surface of the balloon. The depressions can, in some embodiments, configured to be wide enough and long enough to allow the strips to be placed within, such as entirely within the depression. The depths of the depressions can be sized to limit the likelihood that the strips could get caught on the distal opening of the introducer during balloon retraction.
- The use of the through-holes or microchannels either in the spline or on the spline sides can offer a mechanism for a therapeutic agent such as, for example, one or more drugs, nanoparticles, and/or stem cell transport from the balloon surface into the diseased luminal surface through capillary or diffusion action and/or utilization of the balloon pressure forcing the drug, nanoparticles, and/or stem cells through the micro channels on to the surface or into the diseased site. Alternatively, the microchannels or modified surfaces can provide a reservoir for drug, nanoparticles, or stem cells or other therapeutics to be placed and protected during transport to the diseased site. In some embodiments, the drug may be any drug known in the art. In some embodiments, examples of drugs that may be suitable for use in the methods and devices of this disclosure depending, on the specific disease being treated, and with consideration of the physical properties of the drug, include, without limitation, anti-restenosis, pro- or anti-proliferative, anti-inflammatory, antineoplastic, antimitotic, anti-platelet, anticoagulant, antifibrin, antithrombin, cytostatic, antibiotic, anti-enzymatic, anti-metabolic, angiogenic, cytoprotective, angiotensin converting enzyme (ACE) inhibiting, angiotensin II receptor antagonizing and/or cardioprotective drugs.
- Examples of antiproliferative drugs include, without limitation, actinomycins, taxol, docetaxel, paclitaxel, sirolimus (rapamycin), biolimus A9 (Biosensors International, Singapore), deforolimus, AP23572 (Ariad Pharmaceuticals), tacrolimus, temsirolimus, pimecrolimus, zotarolimus (ABT-578), 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-bydroxypropyl)rapamycin (a structural derivative of rapamycin), 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin (a structural derivative of rapamycin), 40-O-tetrazole-rapamycin (a structural derivative of rapamycin), 40-O-tetrazolylrapamycin, 40-epi-(N-1-tetrazole)-rapamycin, and pirfenidone.
- Examples of anti-inflammatory drugs include both steroidal and non-steroidal (NSAID) anti-inflammatories such as, without limitation, clobetasol, alclofenac, alclometasone dipropionate, algestone acetonide, alpha amylase, amcinafal, amcinafide, amfenac sodium, amiprilose hydrochloride, anakinra, anirolac, anitrazafen, apazone, balsalazide disodium, bendazac, benoxaprofen, benzydamine hydrochloride, bromelains, broperamole, budesonide, carprofen, cicloprofen, cintazone, cliprofen, clobetasol propionate, clobetasone butyrate, clopirac, cloticasone propionate, cormethasone acetate, cortodoxone, deflazacort, desonide, desoximetasone, dexamethasone, dexamethasone dipropionate, dexamethasone acetate, dexmethasone phosphate, momentasone, cortisone, cortisone acetate, hydrocortisone, prednisone, prednisone acetate, betamethasone, betamethasone acetate, diclofenac potassium, diclofenac sodium, diflorasone diacetate, diflumidone sodium, diflunisal, difluprednate, diftalone, dimethyl sulfoxide, drocinonide, endrysone, enlimomab, enolicam sodium, epirizole, etodolac, etofenamate, felbinac, fenamole, fenbufen, fenclofenac, fenclorac, fendosal, fenpipalone, fentiazac, flazalone, fluazacort, flufenamic acid, flumizole, flunisolide acetate, flunixin, flunixin meglumine, fluocortin butyl, fluorometholone acetate, fluquazone, flurbiprofen, fluretofen, fluticasone propionate, furaprofen, furobufen, halcinonide, halobetasol propionate, halopredone acetate, ibufenac, ibuprofen, ibuprofen aluminum, ibuprofen piconol, ilonidap, indomethacin, indomethacin sodium, indoprofen, indoxole, intrazole, isoflupredone acetate, isoxepac, isoxicam, ketoprofen, lofemizole hydrochloride, lomoxicam, loteprednol etabonate, meclofenamate sodium, meclofenamic acid, meclorisone dibutyrate, mefenamic acid, mesalamine, meseclazone, methylprednisolone suleptanate, momiflumate, nabumetone, naproxen, naproxen sodium, naproxol, nimazone, olsalazine sodium, orgotein, orpanoxin, oxaprozin, oxyphenbutazone, paranyline hydrochloride, pentosan polysulfate sodium, phenbutazone sodium glycerate, pirfenidone, piroxicam, piroxicam cinnamate, piroxicam olamine, pirprofen, prednazate, prifelone, prodolic acid, proquazone, proxazole, proxazole citrate, rimexolone, romazarit, salcolex, salnacedin, salsalate, sanguinarium chloride, seclazone, sermetacin, sudoxicam, sulindac, suprofen, talmetacin, talniflumate, talosalate, tebufelone, tenidap, tenidap sodium, tenoxicam, tesicam, tesimide, tetrydamine, tiopinac, tixocortol pivalate, tolmetin, tolmetin sodium, triclonide, triflumidate, zidometacin, zomepirac sodium, aspirin (acetylsalicylic acid), salicylic acid, corticosteroids, glucocorticoids, tacrolimus and pimecrolimus.
- Examples of antineoplastics and antimitotics include, without limitation, paclitaxel, docetaxel, methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride and mitomycin.
- Examples of anti-platelet, anticoagulant, antifibrin, and antithrombin drugs include, without limitation, heparin, sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin, prostacyclin dextran, D-phe-pro-arg-chloromethylketone, dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin and thrombin, thrombin inhibitors such as ANGIOMAX® (bivalirudin, from Biogen), calcium channel blockers such as nifedipine, colchicine, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin, monoclonal antibodies such as those specific for Platelet-Derived Growth Factor (PDGF) receptors, nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine, nitric oxide or nitric oxide donors, super oxide dismutases, super oxide dismutase mimetic and 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO).
- Examples of cytostatic or antiproliferative drugs include, without limitation, angiopeptin, angiotensin converting enzyme inhibitors such as captopril, cilazapril or lisinopril, calcium channel blockers such as nifedipine; colchicine, fibroblast growth factor (FGF) antagonists; fish oil (ω-3-fatty acid); histamine antagonists; lovastatin, monoclonal antibodies such as, without limitation, those specific for Platelet-Derived Growth Factor (PDGF) receptors; nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist) and nitric oxide.
- Examples of ACE inhibitors include, without limitation, quinapril, perindopril, ramipril, captopril, benazepril, trandolapril, fosinopril, lisinopril, moexipril and enalapril.
- Examples of angiotensin II receptor antagonists include, without limitation, irbesartan and losartan.
- Other therapeutic drugs that may find beneficial use herein include, again without limitation, alpha-interferon, genetically engineered endothelial cells, dexamethasone, antisense molecules which bind to complementary DNA to inhibit transcription, and ribozymes, antibodies, receptor ligands such as the nuclear receptor ligands estradiol and the retinoids, thiazolidinediones (glitazones), enzymes, adhesion peptides, blood clotting factors, inhibitors or clot dissolving drugs such as streptokinase and tissue plasminogen activator, antigens for immunization, hormones and growth factors, oligonucleotides such as antisense oligonucleotides and ribozymes and retroviral vectors for use in gene therapy, antiviral drugs and diuretics.
- In other embodiments, a combination of any two, three, or other number of the foregoing drugs or other therapeutic agents can be utilized depending on the desired clinical result.
- One method for laying down drugs, nanoparticles, stem cells or other therapeutics in specific regions such as the relief holes is the use of a direct write process, e.g., MICRO-PENNING (MICROPEN Technologies, Honeoye Falls, NY), to deposit material onto a surface. In general, the term "direct write" describes a printing or patterning method that employs a computerized, motion-controlled stage with a motionless pattern generating device to dispense flowable materials in a designed pattern onto a surface. MICRO-PENNING is a flow-based micro-dispensing technique in which printed materials are extruded with a high degree of control through a syringe and a precision pen tip. The pen tip "rides" on the surface of the material, not touching the substrate surface and is capable of place precise amount of materials in precise locations.
-
Figure 26 illustrates an embodiment of a strip 500 withreliefs 502 on the inferior surface of thestrips 300 opposite the bounded surface of thewedge dissectors 200, with additional relativelylarger apertures 503 in betweenwedge dissectors 200 which can be configured to facilitate bonding of thestrip 300 to the underlying balloon, which can be as disclosed, for example inPCT Pub. No. WO 2016/073490 published on May 12, 2016 . Theapertures 503 can be relatively oval shaped, circular, or any other shape depending on the desired clinical result. - In some embodiments, the longitudinal axis of the strips are longitudinally oriented along the balloon and spaced apart from each other. In some embodiments, the strips do not completely cover the length of the balloon. For example, in one embodiment an 80mm long balloon can have strips that measure 76.6mm. While the length of the strip can be the same as the defined working balloon length, in some embodiments the length of the strip is shorter than the defined working balloon length to allow for balloon contraction that is typically observed when a balloon goes to rated burst pressure. The length of each strip can in some cases be no more than about 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1%, or between about 2% and about 8%, between about 3% and about 6%, or between about 4% and about 5% shorter than the overall working balloon length. In some embodiments, the working balloon length does not include the lengths of the cones.
- In some embodiments, part of the strip, e.g., the base of the strip (e.g., the inferiormost surface configured to be attached to the outer surface of the balloon) can be roughened to aid in adhesion.
- Spikes (e.g., serrating elements or wedge dissectors) can be fabricated in many different manufacturing methods and in a large range of shapes. Regarding the manufacturing processes, the devices may be fabricated using one or more additive or subtractive processes. Additive processes such as high energy vapor deposition, for instance laser chemical vapor deposition, self-assembly techniques, polymer/metal 3D printing, selective laser sintering, powder printers, or other stereo lithographic are a few such options but other additive processes may be used. Alternatively, subtractive processes such as etching, CNC milling, laser cutting, water jet, or electrical discharge machining are just a few examples but other subtractive processes may be used.
- In some embodiments, a method of fabrication includes the use of a reel of martensitic stainless steel, such as for example a 300 or 400 series stainless steel with a hardness of about 52 to about 64 on the Rockwell C-scale (HRC) although other materials can be used. The reel is then honed on one or both edges of the steel. In some embodiments, the steel is in the form of a thin reel strip about 0.007" to about 0.015" (0.178mm to about 0.381mm) thick and between about 0.25" to about 0.75" (6.35mm to about 19.05mm) wide, but can range between 0.005" (0.127mm) and about 0.005". and 0.020" (0.508mm) and between 0.15" (3.81mm) and 1" (25,4mm) wide. In some embodiments, the tolerance of the thickness and width of the reel is greater on the higher end and can have a thickness greater than about .020" (0.508mm) and a width greater than about 1" (25.4mm) . The honed edge can be a single hone or two or more honed angles (as illustrated, for example in
Figures 21 and22 ). In some embodiments, when the angle of the honed edges are measured as the slope from the bounded end to the height of the unbounded end shown inFigure 21 , the angle of the honed edge can be, for example, greater than about 75 degrees. But when more than one honed angle is used, then the tip angle is can be less than, for example, about 75 degrees. In some embodiments, the honed edge has an angle of about or at least about 70, 75, 80, 85, 90 degrees or greater as it moves toward the honed edge in a series of bevels. In addition to the honed edge, independent of the number of honed angles, in some embodiments a separate and additional edge is generated at the very tip of the unbound edge of the strips. When added, the additional tip edge height from the honed edge to the unbounded edge is often very short and typically has a much larger angle than the overall honed edge. Independent of the number of honed angles used, the unbounded tip width, Wu, can be described as the radius of the tip. The unbounded tip width, Wu is the penetrating edge into the lesion, when the width is, in some cases, less than about 0.01" or 0.005" (0.254mm or 0.127mm) , the surface area is minimized to have a less pronounced contact surface with the vessel enabling a reduced amount of energy requirement for penetration. When the tip is configured for penetration into harder surfaces such as calcium beds, in some cases either a more obtuse angle or the removal of the unbound tip at a greater distance from the unbounded surface can produce a wider tip edge (seeFigure 21 , Wu). Not to be limited by theory, this wider edge distributes the load across the larger surface area generating a more effective resistance to tip deformation when the tip is pressured into rigid tissue surfaces. Once the reel is sharpened it is stamped to a desired length of blades. In some embodiments, the reel is hardened and then stamped to the desired length. Independent of when the stamping occurs, the blades can in some cases be passivated and hardened above, e.g., about HRC 45. but more typically in a range of from about HRC 58 to about HRC 62. The hardened blade can then be laser cut, stamped, EDM'ed or another precise metal shaping technology with spikes, serrating elements or wedge dissectors utilized. In some cases, the serrated elements are processed on the reel and then hardened and passivated. In some embodiments of strips where the tip is not a sharpened honed edge, the tip of the blade, that was produced during the reel sharpening step, is removed during the wedge dissector and strip manufacturing step. In some cases, the material removal is design to start a distance, such as from about 0.0001" to about 0.003" (0.0025mm to about 0.076mm) below the honed edge, or from about .0001" to about .0005" (0.0025mm to about 0.0127mm) is removed from the honed edge, producing a flat top as illustrated inFigure 21 . The thinnest edge remaining (now a flat top in some cases) on the previously honed edge side is what will become the unbounded surface of the strip. - In some embodiments, disclosed are methods for attaching the strips. The methods can include any number of processing steps that provides effective strip retention, perpendicular orientation, and structural stability during the fabrication and use. In one embodiment the bounded surface is typically coated with a base coat of an appropriate material, such as a polymer, e.g., polyurethane through a controlled dipping process producing a uniform layer of polyurethane. The coating is dried and typically 3 or 4 strips are aligned with a strip alignment mechanism or jig and glued with a medical grade cyanoacrylate into place at predetermined orientations. The number of strips and the periodicity can vary from, for example, 1 to 8 and is typically associated with the same number of balloon folds but can be less than the number of folds and the periodicity can be non-sequential. Once the strips are bonded to the balloon surface, a single or series of multiple top coats or retention layers, are placed over the metal interrupted scoring elements or wedge dissectors to retain the strips and protect the balloon from the thin tips of the scoring elements. In some embodiments, these layers follow a similar process as the base or pre coat using a controlled dipping process producing one or more uniform layers of urethane or polyurethane. Once the retention layer or layers are cured a layer of hydrophilic or other coating may be apply to decrease balloon friction and increase the balloons deliverability and retrievability. When incorporated, the outer slip coating as can increase the functionality of the balloon by reducing the force to insert and retract the device.
-
Figure 27 illustrates a schematic cross-sectional view of a strip and wedge dissector operably attached to the outer surface of a balloon A polymer layer, typically thin (e.g., from 0.0001" to 0.0009' (0.0025mm to 0.0229mm)), or about or less than about 0.001" (0.0254mm) in some embodiments, such as to limit increasing the balloon diameter profile, can be used as a base coat (layer 270A) covering the outer balloon surface. Thisbase coat 270A offers an interface bonding layer for the interrupted scoring element to the balloon surface. Thislayer 270A can be made of the same or similar polymer chemistry as other layers while offering a chemical, mechanical, or electromagnetic bond to the balloon surface. Thisbase coat layer 270A can be configured to and potentially capable of reducing the interface strain between the balloon outer surface and the bonding surface of the metal scoring element. Strain between the two surfaces is reduced by allowing anadhesive layer 270E and thescoring element 200 to be sandwiched within a polymer matrix independent and somewhat isolated from the balloon strain during balloon expansion and pressure. Althoughtypical base coats 270A are polymers, e.g., urethane or polyurethane this layer can be a variety of other materials. In some embodiments, the coating could include silicone and hydrophilic coatings involving hydrogel polymers or the like, such as polymer networks of a vinyl polymer and an uncrosslinked hydrogel, for example. Polyethylene oxide (PEO) is an example of a hydrogel. An example of a vinyl polymer is neopentyl glycol diacrylate (NPG). The deposition of the layer can be done by single or a series of dips of a balloon or matrix of balloons into a polymer bath under controlled insertion and extraction conditions at controlled rates in both or in one direction. Alternately, layers can be deposited at Angstrom layers through self-assembly of monolayers using known and practiced self-assembly techniques, typically employing surface ionic charging. - Still referring to
Figure 27 , abonding layer 270E between the metal scoring element and the basecoat can typically be thin (0.0001" to 0.0005" (0.0025mm to 0.0127mm)) but can be as thick as 0.001" (0.0254mm) in some embodiments and thin enough such as to limit increasing the balloon diameter profile. Theadhesive layer 270E can be a cyanoacrylate but can be made from other bonding materials that offer a chemical, mechanical, or electromagnetic bond between thebasecoat 270A and the bonding surface of the metal scoring element. Thislayer 270E can be seen as the functional layer at joining the bonding surface of the metal scoring element to the balloon and sometimes is the only layer between the bonding surface of the metal scoring element and the outer balloon surface. Thislayer 270E can be one or more adhesive products. In one preferred embodiment theadhesive layer 270E is a single adhesive with the low viscosity allowing a wicking of the adhesive along the interface of the bonded surface of the metal scoring element and the base coat. In some embodiments, an adhesive dries quickly, allowing successive layers to be applied on the top of the adhesive layer with minimal curing delay. In other methods of fabrication, a more viscous adhesive layer can be placed at both ends of the bottom of the strips or periodically between the bonding surface of the metal scoring element and the base layer allowing non-glued sections to be free or unbonded. In still another method more than one adhesive can be used. For instance, a more viscous adhesive can be used on either end of the bonding surface of the metal interrupted scoring elements and then followed by wicking adhesive on some or all of the unbonded sections. In some embodiments, one (e.g., a single layer) two, or more retention layers (two layers shown inFigure 27 ) 270B, 270C can be present over thebase layer 270A as well as the scoring element. A polymer retention layer can in some embodiments be similar to, and have dimensions as described above for the base layer with enough properties such that thebase 270A andretention 270B, 270C layers produce an effective bond between the layers. In some cases, the retention layer(s) can be designed to offer a similar thickness as the base layer while other times it may be useful to have the retention layers slightly thicker than the base layer. Thicker base and/or retention layers can in some circumstances offer greater puncture resistance and increased durability of the balloon against potential puncturing from the metal interrupted scoring elements, any sharp edges from implants left in the body, or from sharp edges found in severely calcified disease vessels for example. In some embodiments, an outer slip layer 270D can also be present, above the retention layer(s) over the balloon and/or scoring elements. A variety of hydrophilic coatings are commercially available to reduce friction and offer increased navigation of balloons through tortuous and narrow anatomical features. In some embodiments, the balloon surface can be fully encased in a hydrophilic coating while in other embodiments the balloon can be coated after pleating or after pleating and crimping and therefore only surfaces that will typically be exposed during delivery are coated with the hydrophilic coat. Typical hydrophilic coats are a few microns thick and can be as thin as about 10 Angstroms in some embodiments. - In some embodiments, the adhesive can be applied separately to the balloon and to the strips and then both components are then bonded together. A template can be used to ensure proper positioning of the scoring elements along the surface of the balloon.
- A
retention polymer layer 270B, 270C can be typically similar to the base layer with enough properties such that the base and retention layers produce an effective bond between the layers. Sometimes the retention layer(s) can be designed to offer a similar thickness as the base layer while other times it may be useful to have the retention layers slightly thicker than the base layer, such as about or no more than about 20%, 15%, 10%, or 5% thicker in some cases. Thicker base and/or retention layers offer greater puncture resistance and increased durability of the balloon against potential puncturing from the metal interrupted scoring elements, any sharp edges from implants left in the body, or from sharp edges found in severely calcified disease vessels. In some embodiments with a plurality of retention layers 270B, 270C, the layers can be made of the same or differing materials. - A variety of hydrophilic coatings are commercially available to reduce friction and offer increased navigation of balloons through tortuous and narrow anatomical features. In some embodiments, layer 270D of
Figure 27 can be a hydrophilic slip layer. In one preferred embodiment the balloon surface can be fully incased in a hydrophilic coating while in other embodiments the balloon can be coated after pleating or after pleating and crimping and therefore only surfaces that will typically be exposed during delivery are coated with the hydrophilic coat. Typical hydrophilic coats are a few microns thick and can be as thin as, for example 10 Angstroms. - The height of the wedge dissectors, strips, and layers of the outer balloon encapsulation process can be viewed as a cage for use with an expandable member such as a medical balloon, such as an angioplasty balloon or as part of a medical procedure involving a medical balloon or other expandable member. In order to effectively perform key hole or catheter based surgery, the ability to fold the balloon to a fraction of the diameter of the intended inflation diameter can be of value. Therefore the balloon and in some cases the cage are typically folded where the profile of the folded balloon can be effectively used. In one such embodiment the cage is folded in a manner that offers orientation of the spikes such as to avoid puncturing the balloon or scraping the intima of the lumen during delivery and removal, as illustrated in
Figure 28. Figure 28 illustrates the balloon 1000 with a plurality of pleats 1002, and strips 300 and associatedwedge dissectors 200 in between the pleats , thus allowing asingle strip 300 with its plurality ofwedge dissectors 200 to lie between two pleats 1002. A pleating tool was designed that offers effective orientation of the spikes and splines. The pleating tool can have a series of pleating wedges where each wedge offers the ability of the crimp the balloon between the wedges as the wedge elements are closed down onto the balloon. Due to the bulk of the spline elements and desire to minimize contact, and potential damage to the wedge heads, the wedges are designed with a series of pockets that run the length of the wedge heads. The pockets in the wedge heads offer the ability of the spline features to rest within said pockets and limits the spline to wedge contact. The pockets can also offer the ability to aid in orientation of the spline and spike features such that the orientation of the features limits contact with the balloon, such as over folding, and limits orientation, such as perpendicular orientation to the balloon, that might produce scraping of the intima of the vessel during transport of the device on said balloon. One such orientation of the spikes might be at a tangential orientation, an apparent lying down, to the balloon surface as illustrated inFigure 28 . - Various other modifications, adaptations, and alternative designs are of course possible in light of the above teachings. Therefore, it should be understood at this time that within the scope of the appended claims the invention may be practiced otherwise than as specifically described herein. It is contemplated that various combinations or subcombinations of the specific features and aspects of the embodiments disclosed above may be made and still fall within one or more of the inventions. Further, the disclosure herein of any particular feature, aspect, method, property, characteristic, quality, attribute, element, or the like in connection with an embodiment can be used in all other embodiments set forth herein. Accordingly, it should be understood that various features and aspects of the disclosed embodiments can be combined with or substituted for one another in order to form varying modes of the disclosed inventions. Thus, it is intended that the scope of the present inventions herein disclosed should not be limited by the particular disclosed embodiments described above. Moreover, while the invention is susceptible to various modifications, and alternative forms, specific examples thereof have been shown in the drawings and are herein described in detail. It should be understood, however, that the invention is not to be limited to the particular forms or methods disclosed, but to the contrary, the invention is to cover all modifications, equivalents, and alternatives falling within the scope of the various embodiments described and the appended claims. Any methods disclosed herein need not be performed in the order recited. The methods disclosed herein include certain actions taken by a practitioner; however, they can also include any third-party instruction of those actions, either expressly or by implication. For example, actions such as "creating microperforations in an arterial plaque" includes "instructing the creating of microperforations in an arterial plaque." The ranges disclosed herein also encompass any and all overlap, sub-ranges, and combinations thereof. Language such as "up to," "at least," "greater than," "less than," "between," and the like includes the number recited. Numbers preceded by a term such as "approximately", "about", and "substantially" as used herein include the recited numbers (e.g., about 10% = 10%), and also represent an amount close to the stated amount that still performs a desired function or achieves a desired result. For example, the terms "approximately", "about", and "substantially" may refer to an amount that is within less than 10% of, within less than 5% of, within less than 1% of, within less than 0.1% of, and within less than 0.01% of the stated amount.
Claims (14)
- A medical balloon catheter, comprising:an elongate member (10) having an inner lumen, the elongate member defining a longitudinal axis;an expandable balloon (20) connected to the elongate member at a distal end of the elongate member;a plurality of strips (16, 300), each strip of the plurality of strips including a plurality of wedge dissectors (26, 200) spaced apart along a surface of each strip, each strip extending longitudinally along an outer surface of the balloon,wherein the wedge dissectors (26, 200) comprise a strip-facing base surface (202) directly adjacent a surface of each of the strips, an unhoned radially outward facing surface (204) having a length (LU) between a proximal edge (206) of the radially outward facing surface and a distal edge (208) of the radially outward facing surface and defining a height of each wedge dissector, and lateral surfaces (214) between the strip-facing base surface and the radially outward facing surface, wherein the radially outward facing surface has a first width at the proximal edge, a second width smaller than the first width between the proximal edge and the distal edge, and a third width at the distal edge larger than the second width.
- The medical balloon catheter of Claim 1, wherein the second width corresponds to a single point along the length of the radially outward facing surface (204).
- The medical balloon catheter of Claim 1, wherein the second width corresponds to a central segment having a central length in between the proximal edge (206) and the distal edge (208).
- The medical balloon catheter of Claim 1, wherein the length of each strip (16, 300) is less than a length of the outer surface of the balloon (20) coaxial to the length of each strip.
- The medical balloon catheter of Claim 1, wherein a total length of the radially outward facing surface (204) of each wedge dissector (200) is less than a total length of the strip-facing base surface (202) of each wedge dissector.
- The medical balloon catheter of Claim 1, wherein the strip (16, 300) comprises a textured surface.
- The medical balloon catheter of Claim 6, wherein the plurality of strips (16, 300) comprise an elongate length and first and second lateral edges, wherein the first and second lateral edges of the plurality of strips are circumscribed by an adhesive.
- The medical balloon catheter of Claim 1, further comprising a hydrophilic slip layer surrounding the outer surface of the balloon (20), the strips (16, 300), and the wedge dissectors (26, 200).
- The medical balloon catheter of Claim 1, further comprising at least one polymer retention layer (270B, 270C) surrounding the outer surface of the balloon, the strips, and the wedge dissectors.
- The medical balloon catheter of Claim 1, wherein the balloon comprises cones about the lateral ends of the balloon, wherein the cones have a maximal outer diameter that is greater than about 5% of the maximal outer diameter of the balloon.
- The medical balloon catheter of Claim 10, wherein the cones comprise rails oriented with longitudinal axes of the strips.
- The medical balloon catheter of Claim 1, further comprising a ramp (680) of material covering lateral ends of each of the strips (16, 300), the material being relatively more flexible than that of each of the strips.
- The medical balloon catheter of Claim 12, wherein the ramp (680) of material gently slopes from the outer surface of the balloon to the edge of each of the strips.
- The medical balloon catheter of Claim 1, further comprising:a base layer (270A) on the outer surface of the expandable balloon (20);a bonding layer on top of the base layer and on an underside of each of the plurality of strips (16, 300);a first retention bonding layer (270B) surrounding the outer surface of the expandable balloon and the plurality of wedge dissectors (26, 200);at least a second retention bonding layer (270C) on top of the first retention bonding layer, wherein the first retention bonding layer and the second retention bonding layer comprise the same material; anda slip layer (270D) over the first retention bonding layer and the second retention bonding layer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20194806.4A EP3799919A1 (en) | 2015-09-17 | 2016-09-16 | Wedge dissectors for a medical ballon |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562220195P | 2015-09-17 | 2015-09-17 | |
PCT/US2016/052332 WO2017049227A2 (en) | 2015-09-17 | 2016-09-16 | Wedge dissectors for a medical ballon |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20194806.4A Division-Into EP3799919A1 (en) | 2015-09-17 | 2016-09-16 | Wedge dissectors for a medical ballon |
EP20194806.4A Division EP3799919A1 (en) | 2015-09-17 | 2016-09-16 | Wedge dissectors for a medical ballon |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3349837A2 EP3349837A2 (en) | 2018-07-25 |
EP3349837A4 EP3349837A4 (en) | 2019-05-29 |
EP3349837B1 true EP3349837B1 (en) | 2020-10-21 |
Family
ID=58276184
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16847495.5A Active EP3349837B1 (en) | 2015-09-17 | 2016-09-16 | Wedge dissectors for a medical ballon |
EP20194806.4A Pending EP3799919A1 (en) | 2015-09-17 | 2016-09-16 | Wedge dissectors for a medical ballon |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20194806.4A Pending EP3799919A1 (en) | 2015-09-17 | 2016-09-16 | Wedge dissectors for a medical ballon |
Country Status (7)
Country | Link |
---|---|
US (8) | US10166374B2 (en) |
EP (2) | EP3349837B1 (en) |
JP (2) | JP6817310B2 (en) |
CN (3) | CN113907834A (en) |
AU (3) | AU2016324292B2 (en) |
CA (1) | CA2998162A1 (en) |
WO (1) | WO2017049227A2 (en) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9480826B2 (en) | 2008-03-21 | 2016-11-01 | Cagent Vascular, Llc | Intravascular device |
EP2254641B1 (en) | 2008-03-21 | 2016-09-21 | Cagent Vascular, LLC | Device for pre-angioplasty serration and dilatation |
US11229777B2 (en) | 2008-03-21 | 2022-01-25 | Cagent Vascular, Inc. | System and method for plaque serration |
WO2015187872A1 (en) | 2014-06-04 | 2015-12-10 | Cagent Vascular, Llc | Cage for medical balloon |
CN107405475B (en) | 2014-11-03 | 2020-09-15 | 开金血管有限公司 | Sawtooth air bag |
EP3349837B1 (en) | 2015-09-17 | 2020-10-21 | Cagent Vascular, LLC | Wedge dissectors for a medical ballon |
JP2018537199A (en) | 2015-12-05 | 2018-12-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate | Endoscopic apparatus and method of using the same |
US10905329B2 (en) | 2016-06-09 | 2021-02-02 | Biosense Webster (Israel) Ltd. | Multi-function conducting elements for a catheter |
EP3518796A1 (en) * | 2016-09-30 | 2019-08-07 | Merit Medical Ireland Limited | Finned angioplasty balloon |
KR20200003776A (en) | 2016-11-02 | 2020-01-10 | 스템플랜트 엘엘씨 | Methods and Devices for Delivery of Cell Therapy |
CA3044046A1 (en) | 2016-11-16 | 2018-05-24 | Cagent Vascular, Llc | Systems and methods of depositing drug into tissue through serrations |
US11400205B2 (en) | 2016-11-23 | 2022-08-02 | Biosense Webster (Israel) Ltd. | Balloon-in-balloon irrigation balloon catheter |
US12029545B2 (en) | 2017-05-30 | 2024-07-09 | Biosense Webster (Israel) Ltd. | Catheter splines as location sensors |
US11577056B2 (en) | 2018-01-16 | 2023-02-14 | Aspero Medical, Inc. | Medical devices including textured inflatable balloons |
US11730928B2 (en) | 2018-01-16 | 2023-08-22 | Aspero Medical, Inc. | Split overtube assembly |
JP7194459B2 (en) | 2018-01-16 | 2022-12-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイト | A medical device containing a textured inflatable balloon |
EP3773268B1 (en) | 2018-04-09 | 2023-10-25 | Boston Scientific Scimed, Inc. | Cutting balloon catheter |
US12102781B2 (en) | 2018-06-29 | 2024-10-01 | Biosense Webster (Israel) Ltd. | Reinforcement for irrigated electrophysiology balloon catheter with flexible-circuit electrodes |
JP6975857B2 (en) * | 2018-07-09 | 2021-12-01 | 株式会社グッドマン | Balloon catheter |
AU2019310102A1 (en) | 2018-07-25 | 2021-01-28 | Cagent Vascular, Inc. | Medical balloon catheters with enhanced pushability |
JP2022500190A (en) * | 2018-09-22 | 2022-01-04 | トランジット サイエンティフィック,エルエルシー | Expandable exoskeleton device for delivering medicinal products |
JP7104185B2 (en) * | 2019-01-21 | 2022-07-20 | 日本ライフライン株式会社 | Scoring device and scoring system |
AU2020342393A1 (en) * | 2019-09-02 | 2022-03-24 | Stemplant Llc | Method and apparatus for delivery of cell therapies |
US11974803B2 (en) | 2020-10-12 | 2024-05-07 | Biosense Webster (Israel) Ltd. | Basket catheter with balloon |
CN112618922A (en) * | 2020-12-30 | 2021-04-09 | 上海心至医疗科技有限公司 | Preparation method of drug balloon, prepared drug balloon and application thereof |
CA3205481A1 (en) * | 2020-12-31 | 2022-07-07 | Cagent Vascular, Inc. | Balloon catheter and methods of use |
US11957852B2 (en) | 2021-01-14 | 2024-04-16 | Biosense Webster (Israel) Ltd. | Intravascular balloon with slidable central irrigation tube |
CN117015415A (en) * | 2021-08-16 | 2023-11-07 | 株式会社戈德曼 | Balloon for catheter and balloon catheter |
US12114905B2 (en) | 2021-08-27 | 2024-10-15 | Biosense Webster (Israel) Ltd. | Reinforcement and stress relief for an irrigated electrophysiology balloon catheter with flexible-circuit electrodes |
WO2023087455A1 (en) * | 2021-11-17 | 2023-05-25 | 上海腾复医疗科技有限公司 | Vascular recanalization device |
WO2023250378A2 (en) * | 2022-06-24 | 2023-12-28 | Cagent Vascular, Inc. | Balloon catheter and methods of use to reduce residual stenosis |
WO2024214553A1 (en) * | 2023-04-13 | 2024-10-17 | 株式会社カネカ | Balloon for balloon catheter, and balloon catheter |
Family Cites Families (186)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3221746A (en) | 1963-01-25 | 1965-12-07 | Noble John William | Surgical connecting device |
US3635223A (en) | 1969-12-02 | 1972-01-18 | Us Catheter & Instr Corp | Embolectomy catheter |
US4287892A (en) | 1980-03-03 | 1981-09-08 | Peter Schiff | Cannula for intra-aortic balloon devices and the like |
US4465072A (en) | 1983-02-22 | 1984-08-14 | Taheri Syde A | Needle catheter |
US4665906A (en) | 1983-10-14 | 1987-05-19 | Raychem Corporation | Medical devices incorporating sim alloy elements |
US6221102B1 (en) | 1983-12-09 | 2001-04-24 | Endovascular Technologies, Inc. | Intraluminal grafting system |
US4699611A (en) | 1985-04-19 | 1987-10-13 | C. R. Bard, Inc. | Biliary stent introducer |
US4795458A (en) | 1987-07-02 | 1989-01-03 | Regan Barrie F | Stent for use following balloon angioplasty |
US4856516A (en) | 1989-01-09 | 1989-08-15 | Cordis Corporation | Endovascular stent apparatus and method |
US5009659A (en) | 1989-10-30 | 1991-04-23 | Schneider (Usa) Inc. | Fiber tip atherectomy catheter |
US5078736A (en) | 1990-05-04 | 1992-01-07 | Interventional Thermodynamics, Inc. | Method and apparatus for maintaining patency in the body passages |
US5320634A (en) | 1990-07-03 | 1994-06-14 | Interventional Technologies, Inc. | Balloon catheter with seated cutting edges |
US5196024A (en) | 1990-07-03 | 1993-03-23 | Cedars-Sinai Medical Center | Balloon catheter with cutting edge |
US5042707A (en) | 1990-10-16 | 1991-08-27 | Taheri Syde A | Intravascular stapler, and method of operating same |
US5312456A (en) | 1991-01-31 | 1994-05-17 | Carnegie Mellon University | Micromechanical barb and method for making the same |
CA2380683C (en) | 1991-10-28 | 2006-08-08 | Advanced Cardiovascular Systems, Inc. | Expandable stents and method for making same |
US5192291A (en) | 1992-01-13 | 1993-03-09 | Interventional Technologies, Inc. | Rotationally expandable atherectomy cutter assembly |
CA2087132A1 (en) | 1992-01-31 | 1993-08-01 | Michael S. Williams | Stent capable of attachment within a body lumen |
US5209799A (en) | 1992-04-17 | 1993-05-11 | Inverventional Technologies, Inc. | Method for manufacturing a folding balloon catheter |
US5336178A (en) | 1992-11-02 | 1994-08-09 | Localmed, Inc. | Intravascular catheter with infusion array |
US5487730A (en) | 1992-12-30 | 1996-01-30 | Medtronic, Inc. | Balloon catheter with balloon surface retention means |
WO1994023787A1 (en) * | 1993-04-22 | 1994-10-27 | Rammler David H | Sampling balloon catheter |
CA2118886C (en) | 1993-05-07 | 1998-12-08 | Dennis Vigil | Method and apparatus for dilatation of a stenotic vessel |
US5411478A (en) | 1993-07-12 | 1995-05-02 | Michael E. Stillabower | Angioplasty apparatus and process |
US5417707A (en) | 1993-10-29 | 1995-05-23 | Medtronic, Inc. | Dilatation balloon protector with raised ribs |
US5484411A (en) | 1994-01-14 | 1996-01-16 | Cordis Corporation | Spiral shaped perfusion balloon and method of use and manufacture |
US5501689A (en) | 1994-02-03 | 1996-03-26 | United States Surgical Corporation | Plaque stapler |
US5423851A (en) | 1994-03-06 | 1995-06-13 | Samuels; Shaun L. W. | Method and apparatus for affixing an endoluminal device to the walls of tubular structures within the body |
US5824041A (en) | 1994-06-08 | 1998-10-20 | Medtronic, Inc. | Apparatus and methods for placement and repositioning of intraluminal prostheses |
US5397355A (en) | 1994-07-19 | 1995-03-14 | Stentco, Inc. | Intraluminal stent |
US5904697A (en) | 1995-02-24 | 1999-05-18 | Heartport, Inc. | Devices and methods for performing a vascular anastomosis |
US6053943A (en) | 1995-12-08 | 2000-04-25 | Impra, Inc. | Endoluminal graft with integral structural support and method for making same |
US5591197A (en) | 1995-03-14 | 1997-01-07 | Advanced Cardiovascular Systems, Inc. | Expandable stent forming projecting barbs and method for deploying |
CA2171896C (en) | 1995-03-17 | 2007-05-15 | Scott C. Anderson | Multi-anchor stent |
US6102904A (en) | 1995-07-10 | 2000-08-15 | Interventional Technologies, Inc. | Device for injecting fluid into a wall of a blood vessel |
US5713863A (en) | 1996-01-11 | 1998-02-03 | Interventional Technologies Inc. | Catheter with fluid medication injectors |
US5797951A (en) | 1995-08-09 | 1998-08-25 | Mueller; Edward Gene | Expandable support member |
EP0768098B1 (en) | 1995-10-10 | 2000-09-27 | Interventional Technologies Inc | Catheter with fluid medication injectors |
US5665116A (en) | 1995-11-13 | 1997-09-09 | Chaisson; Gary A. | Method and apparatus for catheterization to dilate vascular blockage |
US5718684A (en) | 1996-05-24 | 1998-02-17 | Gupta; Mukesh | Multi-lobed balloon catheter |
US6007543A (en) | 1996-08-23 | 1999-12-28 | Scimed Life Systems, Inc. | Stent delivery system with stent securement means |
US5797935A (en) | 1996-09-26 | 1998-08-25 | Interventional Technologies Inc. | Balloon activated forced concentrators for incising stenotic segments |
US6197013B1 (en) | 1996-11-06 | 2001-03-06 | Setagon, Inc. | Method and apparatus for drug and gene delivery |
US5824053A (en) | 1997-03-18 | 1998-10-20 | Endotex Interventional Systems, Inc. | Helical mesh endoprosthesis and methods of use |
US5957949A (en) | 1997-05-01 | 1999-09-28 | World Medical Manufacturing Corp. | Percutaneous placement valve stent |
US5868779A (en) | 1997-08-15 | 1999-02-09 | Ruiz; Carlos E. | Apparatus and methods for dilating vessels and hollow-body organs |
NL1007349C2 (en) | 1997-10-24 | 1999-04-27 | Suyker Wilhelmus Joseph Leonardus | System for the mechanical production of anastomoses between hollow structures; as well as device and applicator for use therewith. |
US6254642B1 (en) | 1997-12-09 | 2001-07-03 | Thomas V. Taylor | Perorally insertable gastroesophageal anti-reflux valve prosthesis and tool for implantation thereof |
US6096054A (en) | 1998-03-05 | 2000-08-01 | Scimed Life Systems, Inc. | Expandable atherectomy burr and method of ablating an occlusion from a patient's blood vessel |
US6626861B1 (en) | 1998-04-22 | 2003-09-30 | Applied Medical Resources | Balloon catheter apparatus and method |
US6450989B2 (en) | 1998-04-27 | 2002-09-17 | Artemis Medical, Inc. | Dilating and support apparatus with disease inhibitors and methods for use |
US6036725A (en) | 1998-06-10 | 2000-03-14 | General Science And Technology | Expandable endovascular support device |
US6290728B1 (en) | 1998-09-10 | 2001-09-18 | Percardia, Inc. | Designs for left ventricular conduit |
US6280414B1 (en) | 1998-09-30 | 2001-08-28 | Medtronic Ave, Inc. | Method and apparatus for local delivery of therapeutic agent |
US6048332A (en) | 1998-10-09 | 2000-04-11 | Ave Connaught | Dimpled porous infusion balloon |
US6325820B1 (en) | 1998-11-16 | 2001-12-04 | Endotex Interventional Systems, Inc. | Coiled-sheet stent-graft with exo-skeleton |
US7947015B2 (en) | 1999-01-25 | 2011-05-24 | Atrium Medical Corporation | Application of a therapeutic substance to a tissue location using an expandable medical device |
US6245101B1 (en) | 1999-05-03 | 2001-06-12 | William J. Drasler | Intravascular hinge stent |
US6350271B1 (en) | 1999-05-17 | 2002-02-26 | Micrus Corporation | Clot retrieval device |
US6723113B1 (en) | 2000-01-19 | 2004-04-20 | Cordis Neurovascular, Inc. | Inflatable balloon catheter seal and method |
CA2416825C (en) * | 2000-07-24 | 2012-10-02 | Jeffrey Grayzel | Stiffened balloon catheter for dilatation and stenting |
US7204847B1 (en) | 2000-07-28 | 2007-04-17 | C. R. Bard, Inc. | Implant anchor systems |
US6638246B1 (en) | 2000-11-28 | 2003-10-28 | Scimed Life Systems, Inc. | Medical device for delivery of a biologically active material to a lumen |
US7211101B2 (en) | 2000-12-07 | 2007-05-01 | Abbott Vascular Devices | Methods for manufacturing a clip and clip |
US6623452B2 (en) | 2000-12-19 | 2003-09-23 | Scimed Life Systems, Inc. | Drug delivery catheter having a highly compliant balloon with infusion holes |
US6719775B2 (en) | 2001-01-22 | 2004-04-13 | Scimed Life Systems, Inc. | Percutaneous endarterectomy |
WO2002078511A2 (en) | 2001-03-30 | 2002-10-10 | Nanopass Ltd. | Inflatable medical device with combination cutting elements and drug delivery conduits |
US7087088B2 (en) | 2001-05-24 | 2006-08-08 | Torax Medical, Inc. | Methods and apparatus for regulating the flow of matter through body tubing |
US6562062B2 (en) | 2001-08-10 | 2003-05-13 | Scimed Life Systems, Inc. | Balloon anchoring system |
US6632231B2 (en) | 2001-08-23 | 2003-10-14 | Scimed Life Systems, Inc. | Segmented balloon catheter blade |
US6808518B2 (en) | 2001-09-28 | 2004-10-26 | Ethicon, Inc. | Methods and devices for treating diseased blood vessels |
US7691119B2 (en) | 2001-11-09 | 2010-04-06 | Angioscore, Inc. | Balloon catheter with non-deployable stent |
US20040111108A1 (en) | 2001-11-09 | 2004-06-10 | Farnan Robert C. | Balloon catheter with non-deployable stent |
US20040186551A1 (en) | 2003-01-17 | 2004-09-23 | Xtent, Inc. | Multiple independent nested stent structures and methods for their preparation and deployment |
US6656155B2 (en) | 2001-12-17 | 2003-12-02 | Scimed Life Systems, Inc. | Catheter for endoluminal delivery of therapeutic agents that minimizes loss of therapeutic |
US7326245B2 (en) | 2002-01-31 | 2008-02-05 | Boston Scientific Scimed, Inc. | Medical device for delivering biologically active material |
US7186237B2 (en) | 2002-02-14 | 2007-03-06 | Avantec Vascular Corporation | Ballon catheter for creating a longitudinal channel in a lesion and method |
US7331992B2 (en) | 2002-02-20 | 2008-02-19 | Bard Peripheral Vascular, Inc. | Anchoring device for an endoluminal prosthesis |
US7985234B2 (en) | 2002-02-27 | 2011-07-26 | Boston Scientific Scimed, Inc. | Medical device |
US7007698B2 (en) | 2002-04-03 | 2006-03-07 | Boston Scientific Corporation | Body lumen closure |
US7850709B2 (en) | 2002-06-04 | 2010-12-14 | Abbott Vascular Inc. | Blood vessel closure clip and delivery device |
US7153315B2 (en) * | 2002-06-11 | 2006-12-26 | Boston Scientific Scimed, Inc. | Catheter balloon with ultrasonic microscalpel blades |
AU2003256499A1 (en) | 2002-07-11 | 2004-02-02 | Setagon, Inc. | Expandable body having deployable microstructures and related methods |
AU2003277306A1 (en) | 2002-10-07 | 2004-05-04 | Biovalve Technologies, Inc. | Microneedle array patch |
US7494497B2 (en) * | 2003-01-02 | 2009-02-24 | Boston Scientific Scimed, Inc. | Medical devices |
US20050021070A1 (en) | 2003-01-21 | 2005-01-27 | Angioscore, Inc. | Methods and apparatus for manipulating vascular prostheses |
US7686824B2 (en) | 2003-01-21 | 2010-03-30 | Angioscore, Inc. | Apparatus and methods for treating hardened vascular lesions |
US7438712B2 (en) | 2003-03-05 | 2008-10-21 | Scimed Life Systems, Inc. | Multi-braid exterior tube |
US7279002B2 (en) | 2003-04-25 | 2007-10-09 | Boston Scientific Scimed, Inc. | Cutting stent and balloon |
US6932776B2 (en) | 2003-06-02 | 2005-08-23 | Meridian Medicalssystems, Llc | Method and apparatus for detecting and treating vulnerable plaques |
US7771447B2 (en) * | 2003-12-19 | 2010-08-10 | Boston Scientific Scimed, Inc. | Balloon refolding device |
US7413558B2 (en) | 2003-12-19 | 2008-08-19 | Boston Scientific Scimed, Inc. | Elastically distensible folding member |
US7270673B2 (en) * | 2003-12-31 | 2007-09-18 | Boston Scientific Scimed, Inc. | Microsurgical balloon with protective reinforcement |
EP1740122A2 (en) | 2004-01-20 | 2007-01-10 | Massachusetts General Hospital | Permanent thrombus filtering stent |
US20050177130A1 (en) | 2004-02-10 | 2005-08-11 | Angioscore, Inc. | Balloon catheter with spiral folds |
US7754047B2 (en) | 2004-04-08 | 2010-07-13 | Boston Scientific Scimed, Inc. | Cutting balloon catheter and method for blade mounting |
US7654997B2 (en) | 2004-04-21 | 2010-02-02 | Acclarent, Inc. | Devices, systems and methods for diagnosing and treating sinusitus and other disorders of the ears, nose and/or throat |
US20050273049A1 (en) | 2004-06-08 | 2005-12-08 | Peter Krulevitch | Drug delivery device using microprojections |
US7976557B2 (en) | 2004-06-23 | 2011-07-12 | Boston Scientific Scimed, Inc. | Cutting balloon and process |
US20050288766A1 (en) | 2004-06-28 | 2005-12-29 | Xtent, Inc. | Devices and methods for controlling expandable prostheses during deployment |
US7972351B2 (en) * | 2004-07-13 | 2011-07-05 | Boston Scientific Scimed, Inc. | Balloon folding design and method and apparatus for making balloons |
US7354419B2 (en) | 2004-10-15 | 2008-04-08 | Futuremed Interventional, Inc. | Medical balloon having strengthening rods |
US8038691B2 (en) | 2004-11-12 | 2011-10-18 | Boston Scientific Scimed, Inc. | Cutting balloon catheter having flexible atherotomes |
US7291158B2 (en) | 2004-11-12 | 2007-11-06 | Boston Scientific Scimed, Inc. | Cutting balloon catheter having a segmented blade |
US7658744B2 (en) | 2004-12-03 | 2010-02-09 | Boston Scientific Scimed, Inc. | Multiple balloon catheter |
DE602005010906D1 (en) | 2004-12-30 | 2008-12-18 | Cook Inc | CATHETER ASSEMBLY WITH PLAQUE CUTTING BALLOON |
US20060184191A1 (en) | 2005-02-11 | 2006-08-17 | Boston Scientific Scimed, Inc. | Cutting balloon catheter having increased flexibility regions |
US10076641B2 (en) | 2005-05-11 | 2018-09-18 | The Spectranetics Corporation | Methods and systems for delivering substances into luminal walls |
US8672990B2 (en) | 2005-05-27 | 2014-03-18 | Boston Scientific Scimed, Inc. | Fiber mesh controlled expansion balloon catheter |
US8052703B2 (en) * | 2005-06-29 | 2011-11-08 | Boston Scientific Scimed, Inc. | Medical devices with cutting elements |
US8002725B2 (en) | 2005-07-18 | 2011-08-23 | Novostent Corporation | Embolic protection and plaque removal system with closed circuit aspiration and filtering |
US8034066B2 (en) * | 2005-09-15 | 2011-10-11 | Boston Scientific Scimed, Inc. | Multi-layer medical balloons |
US20070191766A1 (en) | 2006-02-10 | 2007-08-16 | Boston Scientific Scimed, Inc. | Balloon catheter having nanotubes |
US20070191811A1 (en) | 2006-02-10 | 2007-08-16 | Joseph Berglund | System and Method for Treating a Vascular Condition |
ATE447370T1 (en) | 2006-02-24 | 2009-11-15 | Nat Univ Ireland | MINIMAL INVASIVE INTRAVASCULAR TREATMENT DEVICE |
US20080077164A1 (en) | 2006-02-24 | 2008-03-27 | National University Of Ireland, Galway | Minimally Invasive Intravascular Treatment Device |
US7691116B2 (en) | 2006-03-09 | 2010-04-06 | Boston Scientific Scimed, Inc. | Cutting blade for medical devices |
US8979886B2 (en) | 2006-08-07 | 2015-03-17 | W. L. Gore & Associates, Inc. | Medical balloon and method of making the same |
US7785290B2 (en) | 2006-08-07 | 2010-08-31 | Gore Enterprise Holdings, Inc. | Non-shortening high angle wrapped balloons |
US20080300610A1 (en) | 2007-05-31 | 2008-12-04 | Cook Incorporated | Device for treating hardened lesions and method of use thereof |
JP2011502016A (en) | 2007-11-06 | 2011-01-20 | コロプラスト アクティーゼルスカブ | Balloon catheter |
US7896911B2 (en) | 2007-12-12 | 2011-03-01 | Innovasc Llc | Device and method for tacking plaque to blood vessel wall |
US20100274188A1 (en) | 2007-12-20 | 2010-10-28 | Acclarent, Inc. | Method and System for Treating Target Tissue Within the Eustachian Tube |
US9603980B2 (en) | 2008-02-26 | 2017-03-28 | CARDINAL HEALTH SWITZERLAND 515 GmbH | Layer-by-layer stereocomplexed polymers as drug depot carriers or coatings in medical devices |
US20090226502A1 (en) | 2008-03-06 | 2009-09-10 | Boston Scientific Scimed, Inc. | Balloon catheter devices with solvent-swellable polymer |
EP2636422B1 (en) | 2008-03-13 | 2018-10-31 | Cook Medical Technologies LLC | Cutting balloon with connector and dilation element |
US9480826B2 (en) | 2008-03-21 | 2016-11-01 | Cagent Vascular, Llc | Intravascular device |
US11229777B2 (en) | 2008-03-21 | 2022-01-25 | Cagent Vascular, Inc. | System and method for plaque serration |
EP2254641B1 (en) | 2008-03-21 | 2016-09-21 | Cagent Vascular, LLC | Device for pre-angioplasty serration and dilatation |
US8034022B2 (en) | 2008-04-08 | 2011-10-11 | Cook Medical Technologies Llc | Weeping balloon catheter |
US9061119B2 (en) | 2008-05-09 | 2015-06-23 | Edwards Lifesciences Corporation | Low profile delivery system for transcatheter heart valve |
US8557271B2 (en) | 2008-07-16 | 2013-10-15 | Warsaw Orthopedic, Inc. | Drug depot implantable within a joint |
US20100087783A1 (en) | 2008-10-07 | 2010-04-08 | Boston Scientific Scimed, Inc. | Medical devices for delivery of therapeutic agents to body lumens |
JP5245842B2 (en) * | 2009-01-09 | 2013-07-24 | 株式会社カネカ | Balloon catheter having a detachable balloon inflation liquid injection tube |
WO2011028203A1 (en) | 2009-09-02 | 2011-03-10 | Reflow Medical Inc. | Systems, methods and devices for ablation, crossing, and cutting of occlusions |
US9339291B2 (en) | 2009-12-29 | 2016-05-17 | Cook Medical Technologies Llc | Cutting or scoring balloon, system and method of making a cutting or scoring balloon |
EP2915556A1 (en) | 2010-01-21 | 2015-09-09 | Boston Scientific Scimed, Inc. | Balloon catheters with therapeutic agent in balloon folds and methods of making the same |
JP5918700B2 (en) | 2010-01-29 | 2016-05-18 | アイコン メディカル コーポレーション | Biodegradable protrusions on inflatable devices |
US9199066B2 (en) | 2010-03-12 | 2015-12-01 | Quattro Vascular Pte Ltd. | Device and method for compartmental vessel treatment |
US8211354B2 (en) | 2010-05-18 | 2012-07-03 | Cook Medical Technologies Llc | Balloon with integral retention of a dilation element |
EP2593171B1 (en) | 2010-07-13 | 2019-08-28 | Loma Vista Medical, Inc. | Inflatable medical devices |
WO2012009412A1 (en) | 2010-07-16 | 2012-01-19 | Abbott Cardiovascular Systems Inc. | Medical device having tissue engaging member and method for delivery of a therapeutic agent |
US8491615B2 (en) | 2010-12-29 | 2013-07-23 | Boston Scientific Scimed, Inc. | Cutting balloon catheter |
US20120197194A1 (en) | 2011-01-04 | 2012-08-02 | Oscor Inc. | Folding balloon catheter |
GB2487400B (en) | 2011-01-20 | 2013-07-10 | Cook Medical Technologies Llc | Scoring balloon with offset scoring elements |
US9415193B2 (en) | 2011-03-04 | 2016-08-16 | W. L. Gore & Associates, Inc. | Eluting medical devices |
US20120277783A1 (en) | 2011-04-28 | 2012-11-01 | Medtronic Vascular, Inc. | Reinforced Dilatation Balloon and Methods |
US9061127B2 (en) | 2011-04-29 | 2015-06-23 | Boston Scientific Scimed, Inc. | Protective surfaces for drug-coated medical devices |
CA2836294C (en) | 2011-06-03 | 2021-01-19 | C.R. Bard, Inc. | Radiopaque medical balloon |
WO2012170501A1 (en) | 2011-06-07 | 2012-12-13 | Boston Scientific Scimed, Inc. | Drug delivery device with instable sheath and/or push element |
WO2013012714A1 (en) * | 2011-07-15 | 2013-01-24 | Boston Scientific Scimed, Inc. | Cutting balloon catheter with flexible cutting blades |
US20130030406A1 (en) | 2011-07-26 | 2013-01-31 | Medtronic Vascular, Inc. | Textured Dilatation Balloon and Methods |
GB2494395B (en) | 2011-09-02 | 2014-01-08 | Cook Medical Technologies Llc | Ultrasonically visible scoring balloon |
AU2012308610B2 (en) | 2011-09-13 | 2017-03-09 | Venturemed Group, Inc. | Intravascular catheter having an expandable incising portion |
US9730726B2 (en) | 2011-10-07 | 2017-08-15 | W. L. Gore & Associates, Inc. | Balloon assemblies having controllably variable topographies |
US8574248B2 (en) | 2011-12-12 | 2013-11-05 | Kassab Kughn Endovascular Devices | Catheter system with balloon-mounted plaque-modifying elements |
CN102512747A (en) | 2011-12-27 | 2012-06-27 | 微创医疗器械(上海)有限公司 | Medicine eluting balloon catheter |
WO2013114201A1 (en) | 2012-02-01 | 2013-08-08 | Tanhum Feld | Device for compartmental dilatation of blood vessels |
CN104168859B (en) | 2012-02-08 | 2016-06-29 | 夸超脉管私人有限公司 | There is the restraining structure of non-linear axial pillar |
US9216033B2 (en) | 2012-02-08 | 2015-12-22 | Quattro Vascular Pte Ltd. | System and method for treating biological vessels |
US10173038B2 (en) | 2012-09-05 | 2019-01-08 | W. L. Gore & Associates, Inc. | Retractable sheath devices, systems, and methods |
GB2506160B (en) | 2012-09-24 | 2014-08-13 | Cook Medical Technologies Llc | Cutting or scoring balloon and apparatus therefor |
US9186215B2 (en) | 2012-09-27 | 2015-11-17 | City Of Hope | Microwave coaptive surgical sealing tool |
US9320530B2 (en) | 2013-03-13 | 2016-04-26 | The Spectranetics Corporation | Assisted cutting balloon |
CN203379465U (en) | 2013-04-18 | 2014-01-08 | 雅伦生物科技(北京)有限公司 | Drug-carrying cutting balloon dilating catheter |
NZ717730A (en) | 2013-08-28 | 2020-02-28 | Clearstream Tech Ltd | Apparatuses and methods for providing radiopaque medical balloons |
CN203564643U (en) | 2013-09-11 | 2014-04-30 | 乐普(北京)医疗器械股份有限公司 | Cutting balloon |
CA2871300A1 (en) | 2013-11-29 | 2015-05-29 | Cook Medical Technologies Llc | Medical balloon |
CN103877672B (en) * | 2014-03-27 | 2016-08-17 | 北京工业大学 | A kind of double blade Cutting balloon of uneven gauge |
CN103948972B (en) | 2014-05-04 | 2016-06-29 | 广东博迈医疗器械有限公司 | A kind of surface is with the dilating sacculus of modified coating and preparation technology thereof |
WO2015187872A1 (en) | 2014-06-04 | 2015-12-10 | Cagent Vascular, Llc | Cage for medical balloon |
CA2969538A1 (en) | 2014-11-03 | 2016-05-12 | Cagent Vascular, Llc | Medical balloon |
CN107405475B (en) | 2014-11-03 | 2020-09-15 | 开金血管有限公司 | Sawtooth air bag |
KR101663805B1 (en) | 2014-12-03 | 2016-10-14 | 연세대학교 산학협력단 | Balloon Catheter Having Micro Needles and Manufacturing Method Thereof |
EP3247302A1 (en) | 2015-01-22 | 2017-11-29 | Koninklijke Philips N.V. | Robotic control of an endovascular deployment device with optical shape sensing feedback |
US10357631B2 (en) | 2015-05-29 | 2019-07-23 | Covidien Lp | Catheter with tapering outer diameter |
EP3349837B1 (en) | 2015-09-17 | 2020-10-21 | Cagent Vascular, LLC | Wedge dissectors for a medical ballon |
AU2016339033B2 (en) | 2015-10-12 | 2021-04-08 | Reflow Medical, Inc. | Stents having protruding drug-delivery features and associated systems and methods |
WO2017083112A1 (en) | 2015-11-10 | 2017-05-18 | Cook Medical Technologies Llc | Weeping balloon with flow channels for reduced infusion pressure |
CA3044046A1 (en) | 2016-11-16 | 2018-05-24 | Cagent Vascular, Llc | Systems and methods of depositing drug into tissue through serrations |
WO2018096572A1 (en) | 2016-11-22 | 2018-05-31 | 朝日インテック株式会社 | Balloon catheter |
JP6804370B2 (en) | 2017-03-31 | 2020-12-23 | テルモ株式会社 | Medical long body |
JP2020533154A (en) | 2017-09-12 | 2020-11-19 | アイエスエル,エルエルシー | Devices and methods for contact with living tissue |
US10918839B2 (en) | 2018-03-13 | 2021-02-16 | II Jaro Mayda | Balloon catheter |
AU2019310102A1 (en) | 2018-07-25 | 2021-01-28 | Cagent Vascular, Inc. | Medical balloon catheters with enhanced pushability |
CA3205481A1 (en) | 2020-12-31 | 2022-07-07 | Cagent Vascular, Inc. | Balloon catheter and methods of use |
-
2016
- 2016-09-16 EP EP16847495.5A patent/EP3349837B1/en active Active
- 2016-09-16 EP EP20194806.4A patent/EP3799919A1/en active Pending
- 2016-09-16 US US15/268,407 patent/US10166374B2/en active Active
- 2016-09-16 CN CN202111216420.XA patent/CN113907834A/en active Pending
- 2016-09-16 WO PCT/US2016/052332 patent/WO2017049227A2/en active Application Filing
- 2016-09-16 CN CN202111217588.2A patent/CN113907835A/en active Pending
- 2016-09-16 CN CN201680059509.0A patent/CN108348734B/en active Active
- 2016-09-16 AU AU2016324292A patent/AU2016324292B2/en active Active
- 2016-09-16 CA CA2998162A patent/CA2998162A1/en active Pending
- 2016-09-16 JP JP2018534466A patent/JP6817310B2/en active Active
-
2018
- 2018-12-27 US US16/234,422 patent/US11123527B2/en active Active
-
2019
- 2019-12-09 US US16/708,323 patent/US10689154B2/en active Active
-
2020
- 2020-12-24 JP JP2020214640A patent/JP7210529B2/en active Active
-
2021
- 2021-07-30 US US17/390,078 patent/US11266818B2/en active Active
- 2021-07-30 US US17/390,134 patent/US11266819B2/en active Active
- 2021-08-19 AU AU2021218145A patent/AU2021218145B2/en active Active
-
2022
- 2022-02-23 US US17/678,394 patent/US11491314B2/en active Active
- 2022-06-20 US US17/844,464 patent/US11717654B2/en active Active
-
2023
- 2023-06-12 US US18/333,371 patent/US20230398336A1/en active Pending
- 2023-08-16 AU AU2023216815A patent/AU2023216815A1/en active Pending
Non-Patent Citations (1)
Title |
---|
None * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11491314B2 (en) | Wedge dissectors for a medical balloon | |
AU2017361422B2 (en) | Systems and methods of depositing drug into tissue through serrations | |
US11369779B2 (en) | Medical balloon catheters with enhanced pushability | |
US20220211983A1 (en) | Balloon catheter and methods of use | |
JP7583073B2 (en) | Wedge dissector for medical balloons |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180312 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20190430 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61B 17/22 20060101ALI20190424BHEP Ipc: A61M 25/10 20130101AFI20190424BHEP Ipc: A61M 37/00 20060101ALI20190424BHEP |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61M 25/10 20130101AFI20191029BHEP Ipc: A61B 17/22 20060101ALI20191029BHEP Ipc: A61M 37/00 20060101ALI20191029BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20191220 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602016046443 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1325222 Country of ref document: AT Kind code of ref document: T Effective date: 20201115 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1325222 Country of ref document: AT Kind code of ref document: T Effective date: 20201021 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20201021 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210121 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210222 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210122 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210121 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210221 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602016046443 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 |
|
RAP4 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: CAGENT VASCULAR, INC. |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 |
|
26N | No opposition filed |
Effective date: 20210722 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R081 Ref document number: 602016046443 Country of ref document: DE Owner name: CAGENT VASCULAR, INC. (N.D.GES.D. STAATES DELA, US Free format text: FORMER OWNER: CAGENT VASCULAR, LLC, WAYNE, PA., US |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20210930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210221 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210916 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210930 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20160916 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230502 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240702 Year of fee payment: 9 Ref country code: IE Payment date: 20240702 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20240701 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20240702 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20240812 Year of fee payment: 9 |